Anti-CD70 antibodies, conjugates thereof, and methods of using the same

Abstract

To provide CD70 antibodies and CD70 antibody drug conjugates for use in treatment of cancer and autoimmune disease.SOLUTION: Provided herein are CD70 antibodies, antigen binding portions thereof and other binding agents as well as conjugates of such antibodies, antigen binding portions and other binding agents. Also provided are methods of using the CD70 antibodies, antigen binding portions and other binding agents and conjugates thereof for treatment of cancer and other diseases. The invention disclosed herein is based in part on CD70 antibodies, antigen-binding portions thereof and other binding agents, as well as conjugates thereof, that specifically bind to CD70 and that exhibit improved properties. CD70 is an important and advantageous therapeutic target for the treatment of certain cancers.SELECTED DRAWING: Figure 1

Description

[Technical Field]

[0001] Sequence Listing Description The sequence listing associated with this application is provided in text format in lieu of a paper copy and is incorporated herein by reference. The text file containing the sequence listing is named 760270_40101WO_SEQUENCE_LISTING.txt. The text file is 23.6 KB, was created on April 20, 2022, and has been submitted electronically via EFS-Web. [Background technology]

[0002] CD70 is a member of the tumor necrosis factor (TNF) family of membrane-bound and secreted molecules expressed by a variety of normal and malignant cell types. CD70 is a transmembrane type II protein whose carboxyl terminus is exposed to the outside of the cell and whose amino terminus is found on the cytosolic side of the plasma membrane (Bowman et al., 1994, J. Immunol. 152:1756-61; Goodwin et al., 1993, Cell, 73:447-56). Human CD70 contains a 20-amino acid cytoplasmic domain, an 18-amino acid transmembrane domain, and a 155-amino acid extracellular domain with two potential N-linked glycosylation sites (Bowman et al., supra; Goodwin et al., supra). Based on its homology to TNF-α and TNF-β, a trimeric structure of CD70 is predicted (Petsch et al., 1995, MoI. Immunol. 32:761-72).

[0003] CD70 has limited expression in normal human tissues, making it an attractive target for cancer therapy. CD70 expression has been identified in several cancers, including renal cell carcinoma, colon cancer, ovarian cancer, pancreatic cancer, certain types of non-Hodgkin's lymphoma, and multiple myeloma. Although CD70 is present on various types of cancer, clinical trials using CD70 antibodies and CD70 antibody-drug conjugates have met with limited success. The present invention addresses this and other needs. [Prior art documents] [Non-patent literature]

[0004] [Non-Patent Document 1] Bowman et al., 1994, J.Immunol.152:1756-61 [Non-patent document 2] Goodwin et al., 1993, Cell, 73:447-56 [Non-patent document 3] Petsch et al., 1995, Mol. Immunol. 32:761-72 Summary of the Invention [Means for solving the problem]

[0005] Provided herein are CD70 antibodies, antigen-binding portions thereof, and other binding agents, as well as conjugates of such antibodies, antigen-binding portions, and other binding agents. Methods of using CD70 antibodies, antigen-binding portions thereof, and other binding agents, as well as conjugates thereof, to treat cancer and other diseases are also provided. The inventions disclosed herein are based in part on CD70 antibodies, antigen-binding portions thereof, and other binding agents, as well as conjugates thereof, that specifically bind to CD70 and exhibit improved properties. CD70 is an important and advantageous therapeutic target for treating certain cancers. The CD70 antibodies, antigen-binding portions thereof, other binding agents, and conjugates thereof provide compositions and methods based on the use of such antibodies, antigen-binding portions, and related binding agents, as well as conjugates thereof, in the treatment of CD70+ cancers and other diseases.

[0006] In some embodiments, a binding agent is provided comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have an amino acid sequence selected from the set of amino acid sequences set forth in the group consisting of SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:18, respectively; and SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively.

[0007] In some embodiments, the VH and VL regions have amino acid sequences selected from the pair of amino acid sequences set forth in the group consisting of SEQ ID NOs: 3 and 4; SEQ ID NOs: 5 and 6; SEQ ID NOs: 7 and 8; SEQ ID NOs: 9 and 10; and SEQ ID NOs: 11 and 12, respectively. In some embodiments, the VH and VL regions have amino acid sequences selected from the pair of amino acid sequences set forth in the group consisting of SEQ ID NOs: 3 and 4; SEQ ID NOs: 5 and 6; SEQ ID NOs: 7 and 8; SEQ ID NOs: 9 and 10; and SEQ ID NOs: 11 and 12, respectively, and the heavy and light chain framework regions are optionally modified with substitutions, deletions, or insertions of 1 to 8 amino acids within the framework regions. In some embodiments, HCDR1, HCDR2, and HCDR3 and LCDR1, LCDR2, and LCDR3 have the amino acid sequences set forth in SEQ ID NOs: 21, 22, and 15, and SEQ ID NOs: 24, 25, and 26, respectively.

[0008] In some embodiments, the VH and VL framework regions are human framework regions. In some embodiments, the binding agent is an antibody or an antigen-binding portion thereof. In some embodiments, the binding agent is a monoclonal antibody, Fab, Fab', F(ab'), Fv, disulfide-linked Fc, scFv, single-domain antibody, diabody, bispecific antibody, or multispecific antibody.

[0009] In some embodiments, the binding agent has a heavy chain variable region that further comprises a heavy chain constant region. In some embodiments, the heavy chain constant region is of the IgG isotype. In some embodiments, the heavy chain constant region is an IgG1 constant region. In some embodiments, the heavy chain constant region is an IgG4 constant region. In some embodiments, the IgG1 constant region has the amino acid sequence set forth in SEQ ID NO: 28. In some embodiments, the binding agent has a light chain variable region that further comprises a light chain constant region. In some embodiments, the light chain constant region is of the kappa isotype. In some embodiments, the light chain constant region has the amino acid sequence set forth in SEQ ID NO: 29. In some embodiments, the heavy chain constant region further comprises an amino acid modification that reduces binding affinity to at least human Fc gamma RIII.

[0010] In some embodiments, the binding agent is monospecific. In some embodiments, the binding agent is bivalent. In some embodiments, the binding agent is bispecific.

[0011] In some embodiments, a pharmaceutical composition is provided comprising any of the binding agents described herein and a pharmaceutically acceptable carrier.

[0012] In some embodiments, a nucleic acid encoding any of the binding agents described herein is provided. In some embodiments, a vector comprising a nucleic acid encoding any of the binding agents described herein is provided. In some embodiments, a cell line comprising a vector comprising a nucleic acid encoding any of the binding agents described herein is provided.

[0013] In some embodiments, a conjugate is provided comprising any of the binding agents described herein, at least one linker attached to the binding agent, and at least one drug attached to each linker. In some embodiments, each drug is selected from a cytotoxic agent, an immunomodulator, a nucleic acid, a growth inhibitory agent, a PROTAC, a toxin, and a radioisotope. In some embodiments, each linker is attached to the binding agent via an interchain disulfide residue, a lysine residue, an engineered cysteine ​​residue, a glycan, a modified glycan, the N-terminal residue of the binding agent, or a polyhistidine residue attached to the binding agent. In some embodiments, the average drug loading of the conjugate is about 1 to about 8, about 2, about 4, about 6, about 8, about 10, about 12, about 14, about 16, about 3 to about 5, about 6 to about 8, or about 8 to about 16.

[0014] In some embodiments, the drug is a cytotoxic agent. In some embodiments, the cytotoxic agent is selected from the group consisting of an auristatin, a maytansinoid, a camptothecin, a duocarmycin, or a calicheamicin. In some embodiments, the cytotoxic agent is an auristatin. In some embodiments, the cytotoxic agent is MMAE or MMAF. In some embodiments, the cytotoxic agent is a camptothecin. In some embodiments, the cytotoxic agent is exatecan. In some embodiments, the cytotoxic agent is SN-38. In some embodiments, the cytotoxic agent is calicheamicin. In some embodiments, the cytotoxic agent is a maytansinoid. In some embodiments, the maytansinoid is maytansine, maytansinol, or the maytansine analogs DM1, DM3, and DM4, and ansamitocin-2.

[0015] In some embodiments, the linker is a cleavable linker. In some embodiments, the linker comprises mc-VC-PAB, CL2, CL2A, or (succinimide-3-yl-N)-(CH)C(=O)-Gly-Gly-Phe-Gly-NH-CH-O-CH-(C=O)-(SEQ ID NO: 34) (wherein n=1-5). In some embodiments, the linker comprises mc-VC-PAB. In some embodiments, the linker comprises CL2A. In some embodiments, the linker comprises CL2. In some embodiments, the linker comprises (succinimide-3-yl-N)-(CH)C(=O)-Gly-Gly-Phe-Gly-NH-CH-O-CH-(C=O)-(SEQ ID NO: 34). In some embodiments, the linker is attached to at least one molecule of exatecan.

[0016] In some embodiments, the drug is an immunomodulator.In some embodiments, the immunomodulator is selected from the group consisting of TRL7 agonist, TLR8 agonist, STING agonist or RIG-I agonist.In some embodiments, the immunomodulator is a TLR7 agonist.In some embodiments, the TLR7 agonist is imidazoquinoline, imidazoquinoline amine, thiazoquinoline, aminoquinoline, aminoquinazoline, pyrido[3,2-d]pyrimidine-2,4-diamine, pyrimidine-2,4-diamine, 2-aminoimidazole, 1-alkyl-1H-benzimidazol-2-amine, tetrahydropyridopyrimidine, heteroaromatic azido-2,2-dioxide, benzonaphthyridine, guanosine analog, adenosine analog, thymidine homopolymer, ssRNA, CpG-A, polyG10 and polyG3. In some embodiments, the immunomodulator is a TLR8 agonist. In some embodiments, the TLR8 agonist is selected from imidazoquinoline, thiazoloquinoline, aminoquinoline, aminoquinazoline, pyrido[3,2-d]pyrimidine-2,4-diamine, pyrimidine-2,4-diamine, 2-aminoimidazole, 1-alkyl-1H-benzimidazol-2-amine, tetrahydropyridopyrimidine or ssRNA. In some embodiments, the immunomodulator is a STING agonist. In some embodiments, the immunomodulator is a RIG-I agonist. In some embodiments, the RIG-I agonist is selected from KIN1148, SB-9200, KIN700, KIN600, KIN500, KIN100, KIN101, KIN400 and KIN2000. In some embodiments, the linker is selected from the group consisting of mc-VC-PAB, CL2, CL2A, and (succinimide-3-yl-N)-(CH)C(=O)-Gly-Gly-Phe-Gly-NH-CH-O-CH-(C=O)-(SEQ ID NO: 34) (wherein n=1 to 5).

[0017] In some embodiments, a pharmaceutical composition is provided comprising any of the conjugates described herein and a pharmaceutically acceptable carrier.

[0018] In some embodiments, a method of treating a CD70+ cancer is provided, comprising administering a therapeutically effective amount of any of the binding agents described herein, any of the conjugates described herein, or any of the pharmaceutical compositions described herein to a subject in need thereof. In some embodiments, the CD70+ cancer is a solid tumor or a hematological malignancy. In some embodiments, the CD70+ cancer is selected from hepatocellular carcinoma, colorectal cancer, pancreatic cancer, ovarian cancer, low-grade non-Hodgkin's lymphoma, non-Hodgkin's lymphoma, B-cell lineage cancer, multiple myeloma, renal cell carcinoma, nasopharyngeal carcinoma, thymic carcinoma, and glioma. In some embodiments, the CD70+ cancer is a solid tumor.

[0019] In some embodiments, the method further comprises administering an immunotherapy to the subject. In some embodiments, the immunotherapy comprises a checkpoint inhibitor. In some embodiments, the checkpoint inhibitor is selected from an antibody that specifically binds to human PD-1, human PD-L1, or human CTLA4. In some embodiments, the checkpoint inhibitor is pembrolizumab, nivolumab, cemiplimab, or ipilimumab. In some embodiments, the method further comprises administering a chemotherapy to the subject.

[0020] In some embodiments, a method of treating cancer comprises administering any of the conjugates described herein or any of the pharmaceutical compositions described herein. In some embodiments, the binding agent, conjugate, or pharmaceutical composition is administered intravenously. In some embodiments, the binding agent, conjugate, or pharmaceutical composition is administered at a dose of about 0.1 mg / kg to about 12 mg / kg.

[0021] In some embodiments, the subject's outcome is improved. In some embodiments, the improved outcome is an objective response selected from stable disease, partial response, or complete response. In some embodiments, the improved outcome is a reduction in tumor burden. In some embodiments, the improved outcome is progression-free survival or disease-free survival.

[0022] In some embodiments, there is provided a use of any of the binding agents described herein or any of the pharmaceutical compositions described herein for treating a CD70+ cancer in a subject. In some embodiments, there is provided a use of any of the conjugates described herein or any of the pharmaceutical compositions described herein for treating a CD70+ cancer in a subject.

[0023] In some embodiments, provided herein are methods for treating an autoimmune disease, the method comprising administering a therapeutically effective amount of any of the binding agents described herein, any of the conjugates described herein, or any of the pharmaceutical compositions described herein to a subject in need thereof. In some embodiments, the autoimmune disease is rheumatoid arthritis, multiple sclerosis, or systemic lupus erythematosus. In some embodiments, the method further comprises administering an immunosuppressive therapy to the subject. In some embodiments, the method comprises administering any of the conjugates described herein or any of the pharmaceutical compositions described herein.

[0024] In some embodiments, the binding agent, conjugate, or pharmaceutical composition is administered intravenously. In some embodiments, the binding agent, conjugate, or pharmaceutical composition is administered at a dose of about 0.1 mg / kg to about 12 mg / kg. In some embodiments, the subject's outcome is improved. In some embodiments, the improved outcome is a reduction in disease progression or a reduction in disease severity.

[0025] In some embodiments, there is provided a use of any of the binding agents described herein or any of the pharmaceutical compositions described herein for treating an autoimmune disease in a subject. In some embodiments, there is provided a use of any of the conjugates described herein or any of the pharmaceutical compositions described herein for treating an autoimmune disease in a subject.

[0026] These and other aspects of the present invention can be more fully understood by reference to the following detailed description, non-limiting examples of specific embodiments, and the accompanying drawings. [Brief explanation of the drawings]

[0027] [Figure 1] FIG. 1 shows a comparison of the relative binding affinities of lead CD70 scFvs to human CD70 protein. [Figure 2] FIG. 1 shows a comparison of lead CD70 antibody binding affinity to the CD70 protein. [Figure 3] FIG. 1 shows cross-linking of lead CD70 antibodies to cynomolgus CD70 protein. [Figure 4] FIG. 1 shows a comparison of anti-CD70 antibody binding to 786-O cells. [Figure 5] FIG. 1 shows a comparison of anti-CD70 antibody binding to Caki-1 cells. [Figure 6] FIG. 1 shows a comparison of anti-CD70 antibody binding to DBTRG-05MG cells. [Figure 7] FIG. 1 shows a comparison of anti-CD70 antibody binding to U251 cells. [Figure 8] FIG. 1 shows a comparison of anti-CD70 antibody internalization using 786-O cells. [Figure 9] FIG. 1 shows a comparison of anti-CD70 antibody internalization using Caki-1 cells. [Figure 10] FIG. 1 shows a comparison of the cytotoxicity of anti-CD70 conjugates against 786-O renal cell carcinoma cells. [Figure 11] FIG. 1 shows the binding activity of 2E7 or isotype control with Raji. [Figure 12] FIG. 1 shows the binding activity of 2E7 or an isotype control to MCF-7. [Figure 13] FIG. 2 shows 2E7 internalization in tumor cells. [Figure 14] FIG. 2E7 PK in rats. [Figure 15]FIG. 1 shows the in vitro cytotoxicity of 2E7 conjugates against 786-O. [Figure 16] FIG. 1 shows the in vitro cytotoxicity of 2E7 conjugates against Raji. [Figure 17] FIG. 1 shows the in vitro cytotoxicity of 2E7 conjugates against Caki-1. [Figure 18] FIG. 1 shows the in vitro cytotoxicity of 2E7 conjugates against A498. [Figure 19] FIG. 1 shows a multiple-dose study of the antitumor activity of 2E7 conjugates with Caki-1. [Figure 20] FIG. 1 shows a single-dose study of the antitumor activity of 2E7 conjugates with Caki-1. [Figure 21] FIG. 1 shows a multiple-dose study of the antitumor activity of 2E7 conjugates using Raji. [Figure 22] FIG. 1 shows a single-dose study of the antitumor activity of 2E7 conjugates using Raji. DETAILED DESCRIPTION OF THE INVENTION

[0028] definition For convenience, certain terms in the specification, examples, and claims are defined here. Unless otherwise specified or implied from context, the following terms and phrases have the meanings provided below. The definitions are provided to aid in the description of particular embodiments and are not intended to limit the claimed invention, as the scope of the invention is limited only by the claims. Unless otherwise defined, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.

[0029] As used herein, unless otherwise indicated, the terms "a" and "an" shall be construed to mean "one," "at least one," or "one or more." Unless otherwise required by context, singular terms used herein shall include pluralities and plural terms shall include the singular.

[0030] Unless the context clearly requires otherwise, throughout this specification and the claims, the words "comprise", "comprising", and the like are to be construed in an inclusive sense as opposed to an exclusive or exhaustive sense; that is, meaning "including, but not limited to".

[0031] The terms "reduced," "reducing," "reduced," "reduction," "reduce," and "inhibit" are all used generally herein to mean a statistically significant amount of reduction compared to a reference.

[0032] The terms "increased," "increase," or "enhance" or "activate" are all used herein to generally mean an increase in a statically significant amount relative to a reference.

[0033] As used herein, the terms "protein" and "polypeptide" are used interchangeably to refer to a series of amino acid residues connected to each other by peptide bonds between the α-amino and carboxyl groups of adjacent residues. The terms "protein" and "polypeptide" also refer to polymers of amino acids, including modified amino acids (e.g., phosphorylated, glycated, glycosylated, etc.) and amino acid analogs, regardless of their size or function. Although "protein" and "polypeptide" are often used in reference to relatively large polypeptides, while the term "peptide" is often used in reference to small polypeptides, the use of these terms in the art overlaps. The terms "protein" and "polypeptide" are used interchangeably herein to refer to encoded gene products and fragments thereof. Thus, exemplary polypeptides or proteins include gene products, naturally occurring proteins, homologs, orthologs, paralogs, fragments, and other equivalents, variants, fragments, and analogs of the foregoing.

[0034] CD70 is a cell surface antigen on activated T and B lymphocytes, but not on resting T and B lymphocytes. It is also known as CD27L, tumor necrosis factor (ligand) superfamily, member 7, TNFSF7, surface antigen CD70, and Ki-24 antigen. It has been reported to be overexpressed in certain cancers, as further described herein. Human CD70 polypeptides include, but are not limited to, those having the amino acid sequences set forth in UniProt identifiers P32970-1 and P32970-2 and reference sequences NP_001243.1 and NP_001317261.1; these sequences are incorporated herein by reference.

[0035] As used herein, "epitope" refers to amino acids conventionally bound by an immunoglobulin VH / VL pair, such as the antibodies, antigen-binding portions thereof, and other binding agents described herein. Epitopes can be formed on polypeptides of contiguous amino acids or noncontiguous amino acids juxtaposed by tertiary folding of the protein. Epitopes formed from contiguous amino acids are typically retained upon exposure to denaturing solvents, while epitopes formed by tertiary folding are typically lost upon treatment with denaturing solvents. An epitope typically comprises at least three, more usually at least five, about nine, or about eight to ten amino acids in a unique spatial arrangement. An epitope defines the minimal binding site of an antibody, its antigen-binding portion, and other binding agent and is thus the target of specificity for the antibody, its antigen-binding portion, or other immunoglobulin-based binding agent. In the case of single-domain antibodies, an epitope represents the structural unit bound by a single variable domain.

[0036] As used herein, "specifically binds" means that a binding agent (e.g., an antibody or antigen-binding portion thereof) described herein specifically binds to an antigen of interest. -5 M (10000nM) or less, e.g., 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12Specific binding refers to the ability to bind to a target, such as human CD70, with a KD of M or less. Specific binding can be influenced, for example, by the affinity and avidity of the antibody, antigen-binding portion, or other binding agent and the concentration of the target polypeptide. Those skilled in the art can determine appropriate conditions under which the antibodies, antigen-binding portions, and other binding agents described herein selectively bind to CD70 using any appropriate method, such as titrating the antibody or binding agent in an appropriate cell binding assay. A binding agent that specifically binds to CD70 is not displaced by a non-similar competitor. In certain embodiments, a CD70 antibody or antigen-binding portion thereof or other binding agent is said to specifically bind CD70 if it preferentially recognizes its target antigen, CD70, in a complex mixture of proteins and / or macromolecules.

[0037] In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent described herein is administered in a dose of 10 -5 M (10000nM) or less, e.g., 10 -6 M, 10 -7 M, 10 -8 M, 10 -9 M, 10 -10 M, 10 -11 M, 10 -12 The dissociation constant (KD or K D In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent described herein specifically binds to a CD70 polypeptide at about 10 -5 M~10 -6 In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent described herein specifically binds to a CD70 polypeptide with a dissociation constant (KD) of about 10 M. -6 M~10 -7 In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent described herein specifically binds to a CD70 polypeptide with a dissociation constant (KD) of about 10 M. -7 M~10 -8In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent described herein specifically binds to a CD70 polypeptide with a dissociation constant (KD) of about 10 M. -8 M~10 -9 In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent described herein specifically binds to a CD70 polypeptide with a dissociation constant (KD) of about 10 M. -9 M~10 -10 In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent described herein specifically binds to a CD70 polypeptide with a dissociation constant (KD) of about 10 M. -10 M~10 -11 In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent described herein specifically binds to a CD70 polypeptide with a dissociation constant (KD) of about 10 M. -11 M~10 -12 In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent described herein specifically binds to a CD70 polypeptide with a dissociation constant (KD) of 10 M. -12 It specifically binds to CD70 polypeptide with a dissociation constant (KD) of less than M.

[0038] As used herein, the term "consisting essentially of" refers to elements required for a given embodiment. The term permits the presence of elements that do not materially affect the basic and novel or functional characteristics of that embodiment.

[0039] As used herein, the term "consisting of" refers to the compositions, methods, and their respective components described herein, excluding any element not recited in that description of an embodiment.

[0040] Other than in the examples, or where otherwise indicated, all numbers expressing quantities of ingredients or reaction conditions used herein should be understood to be modified in all instances by the term "about." When used in connection with percentages, the term "about" can mean + / - 1%.

[0041] The term "statistically significant" or "significantly" refers to statistical significance, generally meaning a difference of 2 standard deviations (2SD) above or below a reference value.

[0042] Other terms are defined herein within the context of the description of various aspects of the invention.

[0043] Detailed Description Provided herein are CD70 binding antibodies (also referred to as CD70 antibodies) and antigen-binding portions thereof, as well as other binding agents, that specifically bind to human CD70. Also provided herein are conjugates of CD70 antibodies and antigen-binding portions (also referred to as CD70 conjugates) linked to drugs, such as cytotoxic agents or immunomodulatory agents. In some embodiments, the CD70 antibodies, antigen-binding portions, other binding agents, and / or CD70 conjugates specifically bind to and reduce the number of CD70+ cells in a subject. In some embodiments, the CD70 antibodies, antigen-binding portions, other binding agents, and / or CD70 conjugates specifically bind to and reduce the number of CD70+ cancer cells in a subject. In some embodiments, the CD70 antibodies, antigen-binding portions, other binding agents, and / or CD70 conjugates specifically bind to and reduce the number of CD70+ cells associated with a disease or condition of a subject, such as an autoimmune disease. In some embodiments, the CD70 antibodies, antigen-binding portions, other binding agents and / or CD70 conjugates specifically bind to and reduce the number of CD70+ cells associated with a disease or condition of interest.

[0044] In some embodiments, the CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively. In some embodiments, the CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 3 and 4, respectively. In some embodiments, the CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 5 and 6, respectively. In some embodiments, the CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO: 7 and SEQ ID NO: 8, respectively. In some embodiments, the CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO: 9 and SEQ ID NO: 10, respectively. In some embodiments, the CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO: 11 and SEQ ID NO: 12, respectively.

[0045] In some embodiments, the CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NO:3 and SEQ ID NO:4, respectively; SEQ ID NO:5 and SEQ ID NO:6, respectively; SEQ ID NO:7 and SEQ ID NO:8, respectively; SEQ ID NO:9 and SEQ ID NO:10, respectively; and SEQ ID NO:11 and SEQ ID NO:12, respectively; and the heavy chain variable framework region and light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or light chain variable region are unmodified. In some embodiments, the CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively; and the heavy and light chain variable framework regions are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and the CDRs of the heavy or light chain variable region are unmodified. The phrase "unmodified CDRs of the heavy or light chain variable region" refers to VH and VL CDRs that have no amino acid substitutions, deletions, or insertions.

[0046] In some embodiments, a CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, a CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acid substitutions, deletions, or insertions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0047] In some embodiments, a CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are not modified. In some embodiments, a CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acid substitutions, deletions, or insertions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are not modified.

[0048] In some embodiments, a CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 7 and 8, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, a CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 7 and 8, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acid substitutions, deletions, or insertions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0049] In some embodiments, a CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are not modified. In some embodiments, a CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acid substitutions, deletions, or insertions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are not modified.

[0050] In some embodiments, a CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO: 11 and SEQ ID NO: 12, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, a CD70 antibody, or antigen-binding portion thereof, comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO: 11 and SEQ ID NO: 12, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acid substitutions, deletions, or insertions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0051] In some embodiments, provided herein are binding agents that specifically bind to CD70, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively. In some embodiments, the binding agent comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively; and the binding agent specifically binds to CD70 with a higher binding affinity (lower Kd) than the binding affinity of antibody 69A7. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NO:3 and SEQ ID NO:4, respectively; SEQ ID NO:5 and SEQ ID NO:6, respectively; SEQ ID NO:7 and SEQ ID NO:8, respectively; SEQ ID NO:9 and SEQ ID NO:10, respectively; and SEQ ID NO:11 and SEQ ID NO:12, respectively; and wherein the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively; and the heavy chain variable framework region and light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and the CDRs of the heavy chain variable region or light chain variable region are unmodified. As described herein, the binding agent comprises a CD70 antibody or antigen-binding portion thereof and can optionally include other peptides or polypeptides covalently bound to the CD70 antibody or antigen-binding portion thereof. In any of these embodiments, the binding agent specifically binds to CD70.

[0052] In some embodiments, provided herein are binding agents that specifically bind to CD70, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 3 and 4, respectively. In some embodiments, the binding agent comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 3 and 4, respectively; and the binding agent specifically binds to CD70 with a higher binding affinity (lower Kd) than the binding affinity of antibody 69A7. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acid substitutions, deletions, or insertions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0053] In some embodiments, provided herein are binding agents that specifically bind to CD70, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO: 5 and SEQ ID NO: 6, respectively. In some embodiments, the binding agent comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO: 5 and SEQ ID NO: 6, respectively; and the binding agent specifically binds to CD70 with a higher binding affinity (lower Kd) than the binding affinity of antibody 69A7. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acid substitutions, deletions, or insertions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0054] In some embodiments, provided herein are binding agents that specifically bind to CD70, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 7 and 8, respectively. In some embodiments, the binding agent comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 7 and 8, respectively; and the binding agent specifically binds to CD70 with a higher binding affinity (lower Kd) than the binding affinity of antibody 69A7. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 7 and 8, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 7 and 8, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acid substitutions, deletions, or insertions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0055] In some embodiments, provided herein are binding agents that specifically bind to CD70, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO: 9 and SEQ ID NO: 10, respectively. In some embodiments, the binding agent comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO: 9 and SEQ ID NO: 10, respectively; and the binding agent specifically binds to CD70 with a higher binding affinity (lower Kd) than antibody 69A7. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 9 and 10, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 9 and 10, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acid substitutions, deletions, or insertions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0056] In some embodiments, provided herein are binding agents that specifically bind to CD70, comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively. In some embodiments, the binding agent comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively; and the binding agent specifically binds to CD70 with a higher binding affinity (lower Kd) than the binding affinity of antibody 69A7. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 11 and 12, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acid substitutions, deletions, or insertions within the framework regions, and the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0057] In some embodiments, the antibody or antigen-binding portion comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL Antibodies or antigen-binding portions are provided in which the CDRs have the amino acid sequences set forth in a set of amino acid sequences selected from: (i) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (ii) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (iii) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (iv) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:18, respectively; and (v) SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0058] In some embodiments, an antibody or antigen-binding portion is provided comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0059] In some embodiments, an antibody or antigen-binding portion is provided comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0060] In some embodiments, an antibody or antigen-binding portion is provided comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0061] In some embodiments, an antibody or antigen-binding portion is provided comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:18, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0062] In some embodiments, a binding agent is provided comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region. ... Binding agents are provided in which the CDRs have the amino acid sequences set forth in a set of amino acid sequences selected from: (i) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (ii) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (iii) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (iv) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:18, respectively; and (v) SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0063] In some embodiments, a binding agent is provided comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0064] In some embodiments, a binding agent is provided that comprises a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0065] In some embodiments, a binding agent is provided comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0066] In some embodiments, a binding agent is provided comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:18, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0067] In some embodiments, a binding agent is provided comprising a heavy chain variable (VH) region and a light chain variable (VL) region, wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0068] In some embodiments, the compositions and methods described herein relate to reducing CD70+ cells in a subject in vivo using a CD70 antibody, antigen-binding portion thereof, other binding agent, or conjugate thereof (e.g., reducing the number of CD70+ cells in a cancer or tumor, or CD70+ cells associated with an autoimmune disease or disorder). In some embodiments, the compositions and methods described herein relate to treating a CD70+ cancer in a subject by administering a CD70 antibody, antigen-binding portion thereof, other binding agent, or conjugate thereof. In some embodiments, the compositions and methods described herein relate to treating an autoimmune disorder in a subject by administering a CD70 antibody, antigen-binding portion thereof, other binding agent, or conjugate thereof. In some embodiments, the compositions and methods described herein relate to treating a disease or disorder associated with CD70+ cells in a subject by administering a CD70 antibody, antigen-binding portion thereof, other binding agent, or conjugate thereof. In any of these embodiments, the method further comprises reducing the number of CD70+ cells in a subject associated with a disease, condition, or cancer.

[0069] As used herein, the term "antibody" refers to immunoglobulin molecules and immunologically active portions of immunoglobulin molecules, i.e., molecules that contain an antigen-binding site that specifically binds to an antigen, such as human CD70. The term generally refers to antibodies that are composed of two immunoglobulin heavy chain variable regions and two immunoglobulin light chain variable regions, including full-length antibodies (having heavy and light chain constant regions).

[0070] Each heavy chain is composed of a variable region (abbreviated as VH) and a constant region. The heavy chain constant region may include three domains, CH1, CH2, and CH3, and optionally a fourth domain, CH4. Each light chain is composed of a variable region (abbreviated as VL) and a constant region. The light chain constant region is a CL domain. The VH and VL regions are further divided into hypervariable regions called complementarity-determining regions (CDRs), and may be interspersed with conserved regions called framework regions (FRs). Thus, each VH and VL region consists of three CDRs and four FRs arranged in the following order from N-terminus to C-terminus: FR1, CDR1, FR2, CDR2, FR3, CDR3, and FR4. This structure is well known to those skilled in the art.

[0071] As used herein, an "antigen-binding portion" of a CD70 antibody refers to a portion of a CD70 antibody described herein that has the VH and VL sequences or CDRs of the CD70 antibody and specifically binds to CD70. Examples of antigen-binding portions include Fab, Fab', F(ab')2, Fv, scFv, disulfide-linked Fv, single-domain antibodies (also called VHHs, VNARs, sdAbs, or nanobodies), or diabodies (see, e.g., Huston et al., Proc. Natl. Acad. Sci. USA, 85, 5879-5883 (1988) and Bird et al., Science 242, 423-426 (1988), which are incorporated herein by reference). As used herein, the terms Fab, F(ab')2, and Fv refer to: (i) a Fab fragment, i.e., a monovalent fragment composed of the VL, VH, CL, and CH1 domains; (ii) a F(ab')2 fragment, i.e., a bivalent fragment comprising two Fab fragments linked together in the hinge region via a disulfide bridge; and (iii) an Fv fragment, in each case composed of the VL and VH domains of a CD70 antibody. The two domains of the Fv fragment, VL and VH, are encoded by separate coding regions, which may be separated by a synthetic linker, such as the poly-G4S amino acid sequence ("(G4S)" disclosed as SEQ ID NO: 27). n(where n=1-5)) to allow them to be prepared as a single protein chain in which the VL and VH regions combine to form a monovalent molecule (known as a single-chain Fv or scFv). The term "antigen-binding portion" of an antibody is also intended to include such single-chain antibodies. Other forms of single-chain antibodies, such as "diabodies," are also included herein. Diabodies are bivalent, bispecific antibodies in which the VH and VL domains are expressed on a single polypeptide chain but use a linker connecting the VH and VL domains that is too short to allow the two domains to bind on the same chain, thereby allowing the VH and VL domains to pair with complementary domains (VL and VH, respectively) on different chains to form two antigen-binding sites (see, e.g., Holliger, R et al. (1993) Proc. Natl. Acad. Sci. USA 90:64446448; Poljak, RJ et al. (1994) Structure 2:1121-1123).

[0072] A single domain antibody is an antibody moiety consisting of a single monomeric variable antibody domain. Single domain antibodies can be derived from the variable domain of an antibody heavy chain from a camelid (e.g., a nanobody or VHH moiety). Additionally, the term single domain antibody includes autonomous human heavy chain variable domains (aVH) or VNAR moieties derived from sharks (see, e.g., Hasler et al., Mol. Immunol. 75:28-37, 2016).

[0073] Techniques for generating single-domain antibodies (e.g., DABs or VHHs) are known in the art, as disclosed, for example, in Cossins et al. (2006, Prot Express Purif 51:253-259) and Li et al. (Immunol. Lett. 188:89-95, 2017). Single-domain antibodies can be obtained, for example, from camels, alpacas, or llamas by standard immunization techniques (see, for example, Muyldermans et al., TIBS 26:230-235, 2001; Yau et al., J Immunol Methods 281:161-75, 2003; and Maass et al., J Immunol Methods 324:13-25, 2007). VHHs can have strong antigen-binding capabilities and can interact with novel epitopes inaccessible to conventional VH-VL pairs (see, for example, Muyldermans et al., 2001). Alpaca serum IgG contains approximately 50% camel heavy chain IgG antibodies (HCAbs) (see, e.g., Maass et al., 2007). Alpacas can be immunized with antigens, and VHHs that bind to and neutralize the target antigen can be isolated (see, e.g., Maass et al., 2007). PCR primers that amplify alpaca VHH coding sequences have been identified and can be used to construct alpaca VHH phage display libraries, which can be used to isolate antibody fragments by standard biopanning techniques well known in the art (see, e.g., Maass et al., 2007).

[0074] In some embodiments, the CD70 antibody, or antigen-binding portion thereof, is part of a bispecific or multispecific binding agent. Bispecific and multispecific antibodies include the following: scFv1-ScFv2, ScFv12-Fc-scFv22, IgG-scFv, DVD-Ig, triomab / quadroma, two-in-one IgG, scFv2-Fc, TandAb, and scFv-HSA-scFv. In some embodiments, the IgG-scFv is an IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, svFc-(L)IgG, 2scFV-IgG, or IgG-2scFv. See, for example, Brinkmann and Kontermann, MAbs 9(2):182-212 (2017); Wang et al., Antibodies, 2019, 8, 43; Dong et al., 2011, MAbs 3:273-88; Natsume et al., J. Biochem. 140(3):359-368, 2006; Cheal et al., Mol. Cancer Ther. 13(7):1803-1812, 2014; and Bates and Power, Antibodies, 2019, 8, 28.

[0075] VH and VL domain modifications With respect to VH and VL amino acid sequences, one of skill in the art will recognize that individual substitutions, deletions, or additions (insertions) to amino acids in a VH- or VL-encoding nucleic acid or polypeptide that alter a single amino acid or a small percentage of amino acids in the encoded sequence are "conservatively modified variants," in which the alterations result in the substitution of an amino acid with a chemically similar amino acid (conservative amino acid substitution), and the altered polypeptide retains the ability to specifically bind to CD70.

[0076] In some embodiments, conservatively modified variants of a CD70 antibody or antigen-binding portion thereof can have modifications in the framework regions (i.e., outside the CDRs), for example, conservatively modified variants of a CD70 antibody have the amino acid sequences of the VH and VL CDRs (set forth in the set of amino acid sequences SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26; SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26; SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26; SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:18; and SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26) and have at least one conservative amino acid substitution in the framework region (FR). In some embodiments, the VH and VL amino acid sequences collectively have no more than 8, 6, 4, 2, or 1 conservative amino acid substitutions in the FRs compared to the amino acid sequences of the unmodified VH and VL regions. In some embodiments, the VH and VL amino acid sequences have 8 to 1, 6 to 1, 4 to 1, or 2 to 1 conservative amino acid substitutions in the FRs compared to the amino acid sequences of the unmodified VH and VL regions. In a further aspect of any of these embodiments, conservatively modified variants of a CD70 antibody, antigen-binding portion thereof, or other binding agent exhibit specific binding to CD70.

[0077] For conservative amino acid substitutions, a given amino acid can be replaced by a residue with similar physicochemical properties, for example, by substituting one aliphatic residue for another (such as Ile, Val, Leu, or Ala for each other), or by substituting one polar residue for another (for example, Lys and Arg; Glu and Asp; or Gln and Asn). Other such conservative amino acid substitutions, such as the substitution of entire regions with similar hydrophobic properties, are well known. Polypeptides containing conservative amino acid substitutions can be tested in any one of the assays described herein to confirm that the desired activity of the native or reference polypeptide, i.e., activity against CD70, such as antigen-binding activity and specificity, is retained.

[0078] In some embodiments, a CD70 antibody or antigen-binding portion thereof or other binding agent can be further optimized to reduce potential immunogenicity or optimize other functional properties while maintaining functional activity, e.g., for human therapy. In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; 5 and 6, respectively; 7 and 8, respectively; 9 and 10, respectively; and 11 and 12, respectively; and the heavy and light chain variable framework regions are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and the CDRs of the heavy or light chain variable regions are unmodified. In some embodiments, the CD70 antibody or antigen-binding portion thereof or other binding agent comprises a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NO:3 and SEQ ID NO:4, respectively; SEQ ID NO:5 and SEQ ID NO:6, respectively; SEQ ID NO:7 and SEQ ID NO:8, respectively; SEQ ID NO:9 and SEQ ID NO:10, respectively; and SEQ ID NO:11 and SEQ ID NO:12, respectively; and the heavy chain variable framework region and light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and the CDRs of the heavy chain variable region or light chain variable region are unmodified.

[0079] In some embodiments, provided herein is a CD70 antibody, or antigen-binding portion thereof, or other binding agent comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, provided herein is a CD70 antibody, or antigen-binding portion thereof, or other binding agent comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0080] In some embodiments, provided herein is a CD70 antibody, or antigen-binding portion thereof, or other binding agent comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, provided herein is a CD70 antibody, or antigen-binding portion thereof, or other binding agent comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0081] In some embodiments, provided herein is a CD70 antibody, or antigen-binding portion thereof, or other binding agent comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:7 and SEQ ID NO:8, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, provided herein is a CD70 antibody, or antigen-binding portion thereof, or other binding agent comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:7 and SEQ ID NO:8, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0082] In some embodiments, provided herein is a CD70 antibody, or antigen-binding portion thereof, or other binding agent comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, provided herein is a CD70 antibody, or antigen-binding portion thereof, or other binding agent comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0083] In some embodiments, provided herein is a CD70 antibody, or antigen-binding portion thereof, or other binding agent comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:11 and SEQ ID NO:12, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, provided herein are binding agents comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:11 and SEQ ID NO:12, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0084] In any of these embodiments, the functional activity of a CD70-binding antibody or antigen-binding portion thereof or other binding agent comprises specific binding to CD70. Additional functional activities include depletion of CD70+ cells (e.g., cancer cells or autoimmune cells). Furthermore, a CD70-binding antibody or antigen-binding portion thereof or other binding agent having functional activity means that the polypeptide exhibits an activity, measured in a particular assay, e.g., a biological assay, similar to or better than the activity of a reference antibody or antigen-binding portion thereof described herein (e.g., a reference CD70-binding antibody or antigen-binding portion thereof described herein comprising (i) a heavy chain variable region having the amino acid sequence set forth in SEQ ID NO: 1 and (ii) a light chain variable region having the amino acid sequence set forth in SEQ ID NO: 2, or a variant thereof), regardless of whether or not there is dose dependency. If there is a dose dependency, it need not be identical to the dose dependency of the reference antibody or antigen-binding portion thereof, but rather will be substantially similar to or better than the dose dependency for a given activity compared to the reference antibody or antigen-binding portion thereof described herein (i.e., the candidate polypeptide will exhibit increased activity compared to the reference antibody).

[0085] For conservative substitutions, amino acids can be grouped according to the similarity of their side chain properties (A.L. Lehninger, Biochemistry, 2nd ed., pp. 73-75, Worth Publishers, New York (1975)): (1) nonpolar: Ala (A), Val (V), Leu (L), Ile (I), Pro (P), Phe (F), Trp (W), Met (M); (2) uncharged polar: Gly (G), Ser (S), Thr (T), Cys (C), Tyr (Y), Asn (N), Gln (Q); (3) acidic: Asp (D), Glu (E); and (4) basic: Lys (K), Arg (R), His (H).

[0086] Alternatively, for conservative substitutions, naturally occurring residues can be divided into groups based on common side chain properties: (1) hydrophobic: norleucine, Met, Ala, Val, Leu, Ile; (2) neutral hydrophilic: Cys, Ser, Thr, Asn, Gln; (3) acidic: Asp, Glu; (4) basic: His, Lys, Arg; (5) residues that affect chain orientation: Gly, Pro; and (6) aromatic: Trp, Tyr, Phe. Non-conservative substitutions involve exchanging members of one of these classes for another.

[0087] Particular conservative substitutions include, for example, Ala to Gly or Ser; Arg to Lys; Asn to Gln or His; Asp to Glu; Cys to Ser; Gln to Asn; Glu to Asp; Gly to Ala or Pro; His to Asn or Gln; Ile to Leu or Val; Leu to Ile or Val; Lys to Arg, Gln, or Glu; Met to Leu, Tyr, or Ile; Phe to Met, Leu, or Tyr; Ser to Thr; Thr to Ser; Trp to Tyr; Tyr to Trp; and / or Phe to Val, Ile, or Leu.

[0088] In some embodiments, conservatively modified variants of a CD70 antibody, or antigen-binding portion thereof, are preferably at least 90%, at least 91%, at least 92%, at least 93%, at least 94%, at least 95%, at least 96%, at least 97%, at least 98%, at least 99% or more identical to a reference VH or VL sequence, with the VH and VL CDRs unmodified. The degree of homology (percent identity) between a reference sequence and a modified sequence can be determined, for example, by comparing the two sequences using freely available computer programs commonly employed for this purpose on the World Wide Web (e.g., BLASTp or BLASTn with default settings).

[0089] In some embodiments, the VH and VL amino acid sequences collectively have no more than 8, 6, 4, 2, or 1 conservative amino acid substitutions in the framework regions compared to the amino acid sequences of the unmodified VH and VL regions. In some embodiments, the VH and VL amino acid sequences collectively have no more than 8, 6, 4, 1, or 2, or 1 conservative amino acid substitutions in the framework regions compared to the amino acid sequences of the unmodified VH and VL regions. In some embodiments, the VH and VL amino acid sequences collectively have no more than 8, 6, 4, 2, or 1 amino acid substitutions, deletions, or insertions in the framework regions compared to the amino acid sequences of the unmodified VH and VL regions. In some embodiments, the VH and VL amino acid sequences have no more than 8, 6, 4, 1, or 2, or 1 conservative amino acid substitutions in the framework regions compared to the amino acid sequences of the unmodified VH and VL regions. In some embodiments, the VH and VL amino acid sequences collectively have no more than 8, or 6, or 4, or 2, or 1 amino acid substitutions, deletions, or insertions compared to the amino acid sequences of the unmodified VH and VL regions.

[0090] Modification of a native (or reference) amino acid sequence can be achieved by any of several techniques known to those skilled in the art. Mutations can be introduced at specific loci, for example, by synthesizing oligonucleotides containing the desired mutant sequence flanked by restriction sites that allow ligation to fragments of the native sequence. After ligation, the resulting reconstructed sequence encodes a variant with the desired amino acid insertion, substitution, or deletion. Alternatively, oligonucleotide-directed site-specific mutagenesis procedures can be employed to provide modified nucleotide sequences with specific codons altered according to the desired substitution, deletion, or insertion. Techniques for making such modifications are very well established and include, for example, those disclosed by Walder et al. (Gene 42:133, 1986); Bauer et al. (Gene 37:73, 1985); Craik (BioTechniques, January 1985, 12-19); Smith et al. (Genetic Engineering: Principles and Methods, Plenum Press, 1981); and U.S. Pat. Nos. 4,518,584 and 4,737,462, which are incorporated herein by reference in their entireties.

[0091] constant region In some embodiments, a CD70 antibody or antigen-binding portion thereof or other binding agent has a fully human constant region. In some embodiments, a CD70 antibody or antigen-binding portion thereof or other binding agent has a humanized constant region. In some embodiments, a CD70 antibody or antigen-binding portion thereof or other binding agent has a non-human constant region. An immunoglobulin constant region refers to a heavy chain constant region or a light chain constant region. The amino acid sequences of human heavy and light chain constant regions are known in the art. The constant region can be of any suitable type selected from the immunoglobulin classes IgA, IgD, IgE, IgG, and IgM. Some immunoglobulin classes can be further divided into isotypes, such as IgG1, IgG2, IgG3, IgG4, or IgA1, and IgA2. The heavy chain constant regions (Fc) corresponding to different classes of immunoglobulins can be α, δ, ε, γ, and μ, respectively. The light chain can be either kappa (or κ) or lambda (or λ).

[0092] In some embodiments, the constant region can have an IgG1 isotype. In some embodiments, the constant region can have an IgG2 isotype. In some embodiments, the constant region can have an IgG3 isotype. In some embodiments, the constant region can have an IgG4 isotype. In some embodiments, the Fc domain can have a hybrid isotype comprising constant regions from more than one isotype. In some embodiments, the immunoglobulin constant region can be an IgG1 or IgG4 constant region. In some embodiments, the CD70 antibody heavy chain is of the IgG1 isotype and has the amino acid sequence set forth in SEQ ID NO:28. In some embodiments, the CD70 antibody light chain is of the kappa isotype and has the amino acid sequence set forth in SEQ ID NO:29.

[0093] Additionally, a CD70 antibody or antigen-binding portion thereof or other binding agent may be part of a larger binding agent formed by covalent or noncovalent association of the antibody or antigen-binding portion with one or more other proteins or peptides. Relevant to such binding agents is, for example, the use of streptavidin core regions to prepare tetrameric scFv molecules (Kipriyanov, SM et al. (1995) Human Antibodies and Hybridomas 6:93-101), and the use of cysteine ​​residues, marker peptides, and C-terminal polyhistidinyl peptides, such as a hexahistidinyl tag (the "hexahistidinyl tag" disclosed as SEQ ID NO: 30), to generate bivalent and biotinylated scFv molecules (Kipriyanov, SM et al. (1994) Mol. Immunol. 31:1047-1058).

[0094] Fc domain modifications to alter effector function In some embodiments, the Fc region or Fc domain of a CD70 antibody or antigen-binding portion thereof or other binding agent does not substantially bind to at least one Fc receptor selected from FcyRI (CD64), FcyRIIA (CD32a), FcyRIIB (CD32b), FcyRIIIA (CD16a), and FcyRIIIB (CD16b). In some embodiments, the Fc region or domain exhibits substantially no binding to any Fc receptor selected from FcyRI (CD64), FcyRIIA (CD32a), FcyRIIB (CD32b), FcyRIIIA (CD16a), and FcyRIIIB (CD16b). As used herein, "does not substantially bind" refers to weak to no binding to one or more selected Fc gamma receptors. In some embodiments, "does not substantially bind" refers to at least a 1000-fold decrease in binding affinity to an Fc gamma receptor (i.e., an increase in Kd). In some embodiments, the Fc domain or region is Fc null. As used herein, "Fc null" refers to an Fc region or Fc domain that exhibits weak to no binding to any of the Fc gamma receptors. In some embodiments, the Fc null domain or region exhibits at least a 1000-fold decrease in binding affinity (i.e., an increased Kd) to the Fc gamma receptors.

[0095] In some embodiments, the Fc domain has reduced effector function activity or is substantially free of effector function activity. As used herein, "effector function activity" refers to antibody-dependent cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), and / or complement-dependent cytotoxicity (CDC). In some embodiments, the Fc domain exhibits reduced ADCC, ADCP, or CDC activity compared to a wild-type Fc domain. In some embodiments, the Fc domain exhibits reduced ADCC, ADCP, and CDC compared to a wild-type Fc domain. In some embodiments, the Fc domain exhibits substantially no effector function (i.e., the ability to stimulate or effect ADCC, ADCP, or CDC). As used herein, "substantially no effector function" refers to at least a 1000-fold reduction in effector function activity compared to a wild-type or reference Fc domain.

[0096] In some embodiments, the Fc domain has reduced or no ADCC activity. As used herein, reduced or no ADCC activity refers to at least a 10-fold, at least a 20-fold, at least a 30-fold, at least a 50-fold, at least a 100-fold, or at least a 500-fold decrease in the ADCC activity of the Fc domain.

[0097] In some embodiments, the Fc domain has reduced or no CDC activity. As used herein, reduced or no CDC activity refers to a decrease in the CDC activity of the Fc domain by at least 10-fold, at least 20-fold, at least 30-fold, at least 50-fold, at least 100-fold, or at least 500-fold.

[0098] In vitro and / or in vivo cytotoxicity assays can be performed to confirm reduced / depleted ADCC and / or CDC activity. For example, Fc receptor (FcR) binding assays can be performed to ensure that the antibody lacks Fc gamma receptor binding (and therefore likely lacks ADCC activity). NK cells, the primary cells for mediating ADCC, express only Fc gamma RIII, whereas monocytes express Fc gamma RI, Fc gamma RII, and Fc gamma RIII. FcR expression on hematopoietic cells is summarized in Table 3 on page 464 of Ravetch and Kinet, Annu. Rev. Immunol. 9:457-492 (1991). Non-limiting examples of in vitro assays to assess ADCC activity of a molecule of interest are described in U.S. Pat. No. 5,500,362 (see, e.g., Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 83:7059-7063 (1986)) and Hellstrom, I. et al., Proc. Nat'l Acad. Sci. USA 82:1499-1502 (1985); U.S. Pat. No. 5,821,337 (see, Bruggemann, M. et al., J. Exp. Med. 166:1351-1361 (1987)). Alternatively, non-radioactive assay methods can be employed (see, e.g., ACTI™ Non-Radioactive Cytotoxicity Assay for Flow Cytometry (CellTechnology, Inc., Mountain View, CA) and CytoTox 96™ Non-Radioactive Cytotoxicity Assay (Promega, Madison, WI)). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMCs) and natural killer (NK) cells. Alternatively, or additionally, ADCC activity of the molecule of interest can be assessed in vivo, e.g., in an animal model such as that disclosed in Clynes et al., Proc. Nat'l Acad. Sci. USA 95:652-656 (1998).

[0099] C1q binding assays can also be performed to confirm that an antibody or Fc domain or region cannot bind to C1q and therefore lacks or has reduced CDC activity. See, for example, the C1q and C3c binding ELISAs in WO 2006 / 029879 and WO 2005 / 100402. To assess complement activation, CDC assays can be performed (see, for example, Gazzano-Santoro et al., J. Immunol. Methods 202:163 (1996); Cragg, MS et al., Blood 101:1045-1052 (2003); and Cragg, MS and MJ Glennie, Blood 103:2738-2743 (2004)).

[0100] In some embodiments, the Fc domain has reduced or no ADCP activity. As used herein, reduced or no ADCP activity refers to at least a 10-fold, at least a 20-fold, at least a 30-fold, at least a 50-fold, at least a 100-fold, or at least a 500-fold decrease in the ADCP activity of the Fc domain.

[0101] ADCP binding assays can also be performed to confirm that an antibody or Fc domain or region lacks or has reduced ADCP activity. See, e.g., U.S. Patent Application Publication Nos. 20190079077 and 20190048078 and references therein.

[0102] CD70 antibodies or antigen-binding portions thereof or other binding agents with reduced effector function activity include those with one or more substitutions of Fc region residues, such as, for example, 238, 265, 269, 270, 297, 327, and 329 according to Kabat EU numbering (see, e.g., U.S. Pat. No. 6,737,056). Such Fc variants include Fc variants with substitutions at two or more of amino acid positions 265, 269, 270, 297, and 327, including the so-called "DANA" Fc variant, which has substitutions of residues 265 and 297 with alanine according to Kabat EU numbering (see, U.S. Pat. No. 7,332,581). Certain antibody variants with reduced binding to FcRs are also known. (See, e.g., U.S. Pat. No. 6,737,056; WO 2004 / 056312; and Shields et al., J. Biol. Chem. 9(2):6591-6604 (2001).) CD70 antibodies or antigen-binding portions thereof or other binding agents containing such amino acid modifications can be prepared that have reduced binding to FcRs.

[0103] In some embodiments, the CD70 antibody, or antigen-binding portion thereof, or other binding agent comprises an Fc domain or region having one or more amino acid substitutions that reduce Fc gamma R binding, e.g., substitutions at positions 234 and 235 (EU numbering of residues) in the Fc region. In some embodiments, the substitutions are L234A and L235A (LALA) according to Kabat EU numbering. In some embodiments, the Fc domain comprises D265A and / or P329G in an Fc region derived from a human IgG1 Fc region, according to Kabat EU numbering. In some embodiments, the substitutions are L234A, L235A, and P329G (LALA-PG) in an Fc region derived from a human IgG1 Fc region, according to Kabat EU numbering (see, e.g., WO 2012 / 130831). In some embodiments, the substitutions are at L234A, L235A and D265A of the Fc region derived from a human IgG1 Fc region according to EU numbering of Kabat (LALA-DA).

[0104] In some embodiments, modifications are made in the Fc region that result in altered (i.e., decreased) C1q binding and / or complement-dependent cytotoxicity (CDC), e.g., as described in U.S. Pat. No. 6,194,551, WO 99 / 51642, and Idusogie et al., J. Immunol. 164:4178-4184 (2000).

[0105] Methods of Making Antibodies, Antigen-Binding Portions, and Other Binding Agents In various embodiments, CD70 antibodies, their antigen-binding portions, and other binding agents can be produced in human, mouse, or other animal-derived cell lines. Recombinant DNA expression can be used to produce CD70 antibodies, their antigen-binding portions, and other binding agents. This allows for the production of CD70 antibodies and a range of CD70 antigen-binding portions and other binding agents (including fusion proteins) in a selected host species. Production of CD70 antibodies, their antigen-binding portions, and other binding agents in bacteria, yeast, transgenic animals, and chicken eggs are also alternatives to cell-based production systems. The main advantage of transgenic animals is the potential high yield from renewable resources.

[0106] In some embodiments, the nucleic acid encodes a CD70 VH polypeptide having the amino acid sequence set forth in SEQ ID NO: 3, 5, 7, 9, or 11. In some embodiments, the nucleic acid encodes a CD70 VL polypeptide having the amino acid sequence set forth in SEQ ID NO: 4, 6, 8, 10, or 12. .... In some embodiments, the nucleic acid encodes a CD70 VH polypeptide having the amino acid sequence set forth in SEQ ID NO: 5. In some embodiments, the nucleic acid encodes a CD70 VH polypeptide having the amino acid sequence set forth in SEQ ID NO: 7. In some embodiments, the nucleic acid encodes a CD70 VH polypeptide having the amino acid sequence set forth in SEQ ID NO: 9. In some embodiments, the nucleic acid encodes a CD70 VL polypeptide having the amino acid sequence set forth in SEQ ID NO: 11. In some embodiments, the nucleic acid encodes a CD70 VH polypeptide having the amino acid sequence set forth in SEQ ID NO: 4. In some embodiments, the nucleic acid encodes a CD70 VH polypeptide having the amino acid sequence set forth in SEQ ID NO: 6. In some embodiments, the nucleic acid encodes a CD70 VH polypeptide having the amino acid sequence set forth in SEQ ID NO: 8. In some embodiments, the nucleic acid encodes a CD70 VH polypeptide having the amino acid sequence set forth in SEQ ID NO: 10. In some embodiments, the nucleic acid encodes a CD70 VH polypeptide having the amino acid sequence set forth in SEQ ID NO: 12.

[0107] In some embodiments, the nucleic acid encodes VH and VL polypeptides having the amino acid sequences set forth in SEQ ID NOs: 3 and 4. In some embodiments, the nucleic acid encodes VH and VL polypeptides having the amino acid sequences set forth in SEQ ID NOs: 5 and 6. In some embodiments, the nucleic acid encodes VH and VL polypeptides having the amino acid sequences set forth in SEQ ID NOs: 7 and 8. In some embodiments, the nucleic acid encodes VH and VL polypeptides having the amino acid sequences set forth in SEQ ID NOs: 9 and 10. In some embodiments, the nucleic acid encodes VH and VL polypeptides having the amino acid sequences set forth in SEQ ID NOs: 11 and 12.

[0108] As used herein, the terms "nucleic acid" or "nucleic acid sequence" or "polynucleotide sequence" or "nucleotide" refer to a polymeric molecule incorporating units of ribonucleic acid, deoxyribonucleic acid, or analogs thereof. Nucleic acids can be either single-stranded or double-stranded. A single-stranded nucleic acid can be a single-stranded nucleic acid of denatured double-stranded DNA. In some embodiments, a nucleic acid can be cDNA, e.g., a nucleic acid lacking introns.

[0109] Nucleic acid molecules encoding the amino acid sequences of CD70 antibodies, antigen-binding portions thereof, and other binding agents can be prepared by a variety of methods known in the art. These methods include, but are not limited to, the preparation of synthetic nucleotide sequences encoding CD70 antibodies, antigen-binding portions thereof, or other binding agents. Additionally, oligonucleotide-mediated (or site-directed) mutagenesis, PCR-mediated mutagenesis, and cassette mutagenesis can be used to prepare nucleotide sequences encoding CD70 antibodies or antigen-binding portions thereof, and other binding agents. Nucleic acid sequences encoding at least the CD70 antibodies, antigen-binding portions thereof, binding agents, or polypeptides thereof described herein can be recombined with vector DNA according to conventional techniques, such as, for example, restriction enzyme digestion to provide blunt or cohesive ends for ligation, suitable ends, filling-in of cohesive ends as needed, alkaline phosphatase treatment to avoid undesired ligation, and ligation with an appropriate ligase, or other techniques known in the art. Techniques for such manipulations are disclosed, for example, by Maniatis et al., Molecular Cloning, Lab. Manual (Cold Spring Harbor Lab. Press, NY, 1982 and 1989) and Ausubel et al., Current Protocols in Molecular Biology (John Wiley & Sons), 1987-1993, and can be used to construct nucleic acid sequences and vectors encoding CD70 antibodies or antigen-binding portions thereof or VH or VL polypeptides thereof, or other binding agents.

[0110] A nucleic acid molecule, such as DNA, is said to be "capable of expressing" a polypeptide if it contains a nucleotide sequence containing transcriptional and translational regulatory information, and such a sequence is "operably linked" to a nucleotide sequence encoding the polypeptide. An operable linkage is one in which the regulatory DNA sequence and the DNA sequence desired to be expressed (e.g., a CD70 antibody or antigen-binding portion thereof or other binding agent) are connected in a manner that allows for gene expression of recoverable quantities of the polypeptide or antigen-binding portion. The precise nature of the regulatory regions required for gene expression can vary from organism to organism, as is well known in the art. See, e.g., Sambrook et al., 1989; Ausubel et al., 1987-1993.

[0111] Thus, expression of the CD70 antibodies or antigen-binding portions thereof described herein can be carried out in either prokaryotic or eukaryotic cells. Suitable hosts include bacterial or eukaryotic hosts, including yeast, insect, fungal, avian, and mammalian cells, either in vivo or in situ, or host cells of mammalian, insect, avian, or yeast origin. Mammalian cells or tissues can be of human, primate, hamster, rabbit, rodent, bovine, porcine, ovine, equine, caprine, canine, or feline origin, although any other mammalian cell can be used. Furthermore, in vivo synthesis of ubiquitin-transmembrane polypeptide fusion proteins can be achieved, for example, by use of the yeast ubiquitin hydrolase system. The fusion proteins thus produced can be processed in vivo or purified and processed in vitro to allow synthesis of the CD70 antibodies or antigen-binding portions thereof or other binding agents described herein having a specified amino-terminal sequence. Furthermore, problems associated with retaining the methionine residue from the start codon in direct yeast (or bacterial) expression can be avoided (see, e.g., Sabin et al., 7 Bio / Technol. 705 (1989); Miller et al., 7 Bio / Technol. 698 (1989)). Recombinant CD70 antibodies or antigen-binding portions thereof, or other binding agents, can be produced using any of a range of yeast gene expression systems incorporating promoter and termination elements from actively expressed genes encoding glycolytic enzymes that are produced in large amounts when yeast is grown in glucose-rich medium. Known glycolytic genes can also provide highly efficient transcriptional control signals. For example, the promoter and terminator signals of the phosphoglycerate kinase gene can be utilized.

[0112] Production of CD70 antibodies or antigen-binding portions thereof or other binding agents in insects can be accomplished, for example, by infecting an insect host with a baculovirus engineered to express the polypeptide by methods known to those of skill in the art. See Ausubel et al., 1987-1993.

[0113] In some embodiments, the introduced nucleic acid sequence (encoding a CD70 antibody or antigen-binding portion thereof or other binding agent or polypeptide thereof) is incorporated into a plasmid or viral vector capable of autonomous replication in the recipient host cell. Any of a wide variety of vectors can be employed for this purpose, which are known and available to those of skill in the art. See, e.g., Ausubel et al., 1987-1993. Important factors in selecting a particular plasmid or viral vector include the ease with which recipient cells containing the vector can be recognized and selected from recipient cells that do not contain the vector; the copy number of the vector desired in a particular host; and whether it is desirable to be able to "shuttle" the vector between host cells of different species.

[0114] Exemplary prokaryotic vectors known in the art include plasmids, such as those capable of replication in E. coli. Other gene expression elements useful for expressing DNA encoding a CD70 antibody or antigen-binding portion thereof or other binding agent include, but are not limited to, (a) viral transcription promoters and their enhancer elements, such as the SV40 early promoter (Okayama et al., 3 Mol. Cell. Biol. 280 (1983)), Rous sarcoma virus LTR (Gorman et al., 79 PNAS, 6777 (1982)), and Moloney murine leukemia virus LTR (Grosschedl et al., 41 Cell, 885 (1985)); (b) splice regions and polyadenylation sites, such as those derived from the SV40 late region (Okayama et al., 1983), and (c) polyadenylation sites, such as those in SV40 (Okayama et al., 1983). DNA genes encoding immunoglobulins can be expressed using the SV40 early promoter and enhancer, the mouse immunoglobulin heavy chain promoter enhancer, the SV40 late region mRNA splicing sequence, the rabbit S globin intervening sequence, the immunoglobulin and rabbit S globin polyadenylation sites, and the SV40 polyadenylation element as expression elements, as described by Liu et al., infra, and Weidle et al., 51 Gene 21 (1987).

[0115] In the case of immunoglobulin encoding nucleotide sequences, the transcription promoter can be, for example, human cytomegalovirus and the promoter enhancer can be cytomegalovirus and mouse / human immunoglobulin.

[0116] In some embodiments, for the expression of the DNA coding region in rodent cells, the transcription promoter can be a viral LTR sequence, and the transcription promoter enhancer can be either or both of a mouse immunoglobulin heavy chain enhancer and a viral LTR enhancer, as well as polyadenylation and transcription termination regions. In other embodiments, DNA sequences encoding other proteins are combined with the above expression elements to achieve protein expression in mammalian cells.

[0117] Each coding region or gene fusion is assembled or inserted into an expression vector. Recipient cells capable of expressing the CD70 variable region or its antigen-binding portion or other binding agent are then transfected with nucleotides encoding the CD70 antibody or antibody polypeptide or its antigen-binding portion or other binding agent alone, or co-transfected with polynucleotides encoding the VH and VL chain coding regions or other binding agent. The transfected recipient cells are cultured under conditions that allow expression of the incorporated coding regions, and the expressed antibody chain or intact antibody or antigen-binding portion or other binding agent is recovered from the culture.

[0118] In some embodiments, nucleic acids containing coding regions encoding a CD70 antibody or antigen-binding portion thereof or other binding agent are assembled into separate expression vectors that are then used to cotransfect recipient host cells. Each vector can contain one or more selectable genes. For example, in some embodiments, two selectable genes are used, with one selectable gene designed for selection in a bacterial system and a second selectable gene designed for selection in a eukaryotic system, with each vector carrying a set of coding regions. This strategy initially results in a vector that directs the production of nucleotide sequences in a bacterial system and allows amplification. The DNA vector thus produced and amplified in the bacterial host is then used to cotransfect eukaryotic cells, allowing for the selection of cotransfected cells carrying the desired transfected nucleic acid (e.g., containing the heavy and light chains of a CD70 antibody). Non-limiting examples of selectable genes for use in bacterial systems are genes that confer resistance to ampicillin and genes that confer resistance to chloramphenicol. Selectable genes for use in eukaryotic transfectants include the xanthine guanine phosphoribosyltransferase gene (designated gpt) and the phosphotransferase gene from Tn5 (designated neo). Alternatively, fused nucleotide sequences encoding the VH and VL chains can be assembled on the same expression vector.

[0119] For transfection of the expression vector and production of the CD70 antibody or antigen-binding portion thereof or other binding agent, the recipient cell line can be a Chinese hamster ovary cell line (e.g., DG44) or a myeloma cell. Myeloma cells can synthesize, assemble, and secrete immunoglobulins encoded by the transfected immunoglobulin genes and have the machinery for immunoglobulin glycosylation. For example, in some embodiments, the recipient cells are recombinant Ig-producing myeloma cells SP2 / 0. SP2 / 0 cells produce only the immunoglobulins encoded by the transfected genes. Myeloma cells can be grown in culture or in the peritoneal cavity of mice, and secreted immunoglobulins can be obtained from the ascites fluid.

[0120] Expression vectors encoding CD70 antibodies or antigen-binding portions thereof or other binding agents can be introduced into suitable host cells by any of a variety of suitable means, including biochemical means such as transformation, transfection, protoplast fusion, calcium phosphate precipitation, and application of polycations such as diethylaminoethyl (DEAE) dextran, and mechanical means such as electroporation, direct microinjection, and particle bombardment. As known to those skilled in the art, see Johnston et al., 240 Science 1538 (1988).

[0121] Yeast offers certain advantages over bacteria for the production of immunoglobulin heavy and light chains. Yeast performs post-translational peptide modifications, including glycosylation. Several recombinant DNA strategies exist that utilize strong promoter sequences and high-copy-number plasmids that can be used to produce desired proteins in yeast. Yeast recognizes leader sequences in cloned mammalian gene products and secretes polypeptides (i.e., prepolypeptides) bearing leader sequences. See, e.g., Hitzman et al., 11th Intl. Conf. Yeast, Genetics & Molec. Biol. (Montpellier, France, 1982).

[0122] Yeast gene expression systems can be routinely evaluated for the production, secretion, and stability levels of antibodies, as well as assembled CD70 antibodies and their antigen-binding portions, and other binding agents. Various yeast gene expression systems incorporating promoter and termination elements from actively expressed genes encoding glycolytic enzymes that are produced in large amounts when yeast is grown in glucose-rich medium are available. Known glycolytic genes can also provide highly efficient transcriptional control signals. For example, the promoter and terminator signals of the phosphoglycerate kinase (PGK) gene can be utilized. Another example is the translation elongation factor 1α promoter, such as that from Chinese hamster cells. Several approaches can be taken to evaluate the optimal expression plasmid for immunoglobulin expression in yeast. II DNA Cloning 45, (Glover, ed., IRL Press, 1985) and, for example, U.S. Patent Application Publication No. 2006 / 0270045.

[0123] Bacterial strains can also be used as hosts for producing the antibody molecules or antigen-binding portions thereof or other binding agents described herein. E. coli K12 strains such as E. coli W3110, Bacillus species, enterobacteriaceae such as Salmonella typhimurium or Serratia marcescens, and various Pseudomonas species can be used. Plasmid vectors containing replicon and control sequences derived from species compatible with the host cell are used in conjunction with these bacterial hosts. The vectors contain replication sites and specific genes that can provide phenotypic selection in transformed cells. Several approaches can be used to evaluate expression plasmids for the production of CD70 antibodies and their antigen-binding portions, as well as other binding agents, in bacteria (see Glover, 1985; Ausubel, 1987, 1993; Sambrook, 1989; Colligan, 1992-1996).

[0124] Host mammalian cells can be grown in vitro or in vivo. Mammalian cells provide post-translational modifications to immunoglobulin molecules, including removal of leader peptides, folding and assembly of VH and VL chains, glycosylation of antibody molecules, and secretion of functional antibodies and / or antigen-binding portions thereof or other binding agents.

[0125] In addition to the cells of lymphoid origin described above, mammalian cells that can be useful as hosts for producing antibody proteins include cells of fibroblast origin, such as Vero cells or CHO-K1 cells. Exemplary eukaryotic cells that can be used to express immunoglobulin polypeptides include, but are not limited to, COS cells, including COS7 cells; 293 cells, including 293-6E cells; CHO cells, including CHO-S and DG44 cells; PERC6™ cells (Crucell); and NSO cells. In some embodiments, a particular eukaryotic host cell is selected based on its ability to make desired post-translational modifications to the heavy and / or light chains. For example, in some embodiments, CHO cells produce polypeptides with higher levels of sialylation than the same polypeptides produced in 293 cells.

[0126] In some embodiments, one or more CD70 antibodies or antigen-binding portions thereof or other binding agents may be produced in vivo in animals engineered or transfected with one or more nucleic acid molecules encoding the polypeptides, according to any suitable method.

[0127] In some embodiments, the antibody or antigen-binding portion thereof is produced in a cell-free system. Non-limiting exemplary cell-free systems are described, for example, in Sitaraman et al., Methods Mol. Biol. 498:229-44 (2009); Spirin, Trends Biotechnol. 22:538-45 (2004); and Endo et al., Biotechnol. Adv. 21:695-713 (2003).

[0128] Many vector systems are available for the expression of VH and VL chains in mammalian cells (see Glover, 1985). Various approaches can be followed to obtain intact antibodies. As described above, VH and VL chains, and optionally associated constant regions, can be coexpressed in the same cell to achieve intracellular association and linkage of the VH and VL chains into a complete tetrameric H2L2 antibody or its antigen-binding portion. Coexpression can be achieved by using either the same or different plasmids in the same host. Nucleic acids encoding VH and VL chains or their antigen-binding portions can be placed on the same plasmid, which is then transfected into cells, thereby directly selecting for cells expressing both chains. Alternatively, cells can be first transfected with a plasmid encoding one chain, e.g., the VL chain, and the resulting cell line subsequently transfected with a VH chain plasmid containing a second selection marker. Cell lines producing antibodies, antigen-binding portions thereof, via either route could be transfected with plasmids encoding additional copies of the peptide, VH, VL, or VH+VL chains, along with additional selectable markers, to generate cell lines with enhanced properties, such as higher production of assembled CD70 antibodies, or antigen-binding portions thereof, or other binding agents, or enhanced stability of the transfected cell line.

[0129] Furthermore, plants have emerged as a convenient, safe, and economical alternative expression system for recombinant antibody production based on the large-scale culture of microorganisms or animal cells. CD70-binding antibodies or their antigen-binding portions or other binding agents can be expressed in plant cell cultures or conventionally grown plants. Expression in plants can be systemic, restricted to intracellular plastids, or restricted to seeds (endosperm). See, for example, U.S. Patent Application Publication No. 2003 / 0167531; U.S. Patent No. 6,080,560; U.S. Patent No. 6,512,162; and WO 0129242. Several plant-derived antibodies have reached advanced stages of development, including clinical trials (see, for example, Biolex, NC).

[0130] In the case of intact antibodies, the variable regions (VH and VL regions) of CD70 antibodies are typically linked to at least a portion of an immunoglobulin constant region (Fc) or domain, typically at least a portion of the constant region or domain of a human immunoglobulin. Human constant region DNA sequences can be isolated from various human cells, such as immortalized B cells, according to well-known procedures (WO 87 / 02671). CD70-binding antibodies can contain both light and heavy chain constant regions. The heavy chain constant region can include CH1, hinge, CH2, CH3, and optionally CH4 regions. In some embodiments, the CH2 domain can be deleted or omitted.

[0131] Techniques described for the production of single-chain antibodies (see, e.g., U.S. Pat. No. 4,946,778; Bird, Science 242:423-42 (1988); Huston et al., Proc. Natl. Acad. Sci. USA 85:5879-5883 (1988); and Ward et al., Nature 334:544-54 (1989), which are incorporated herein by reference in their entirety) can be adapted to produce single-chain antibodies that specifically bind to CD70. Single-chain antibodies are formed by linking the heavy and light chain variable regions of the Fv region via an amino acid bridge, resulting in a single-chain polypeptide. Techniques for the assembly of functional Fv portions in E. coli can also be used (see, e.g., Skerra et al., Science 242:1038-1041 (1988), which is incorporated herein by reference in its entirety).

[0132] In some embodiments, the antigen-binding moiety or other binding agent comprises one or more scFvs. An scFv can be a fusion protein of the variable regions of an antibody's heavy chain (VH) and light chain (VL) connected by a short linker peptide, e.g., 10 to about 25 amino acids. The linker is typically glycine-rich for flexibility and serine- or threonine-rich for solubility, and can connect the N-terminus of the VH to the C-terminus of the VL, or vice versa. The protein retains the specificity of the original antibody despite the removal of the constant region and the introduction of the linker. scFv antibodies are described, for example, in Houston, J.S., Methods in Enzymol. 203 (1991) 46-96. Methods for producing scFv molecules and designing suitable peptide linkers are described, for example, in U.S. Patent No. 4,704,692; U.S. Patent No. 4,946,778; Raag and Whitlow, FASEB 9:73-80 (1995) and Bird and Walker, TIBTECH 9:132-137 (1991). scFv-Fc is described by Sokolowska-Wedzina et al., Mol. Cancer Res. 15(8):1040-1050, 2017.

[0133] In some embodiments, the antigen-binding moiety or other binding agent is a single-domain antibody, which is an antibody moiety consisting of a single monomeric variable antibody domain. Single-domain antibodies can be derived from the variable domain of an antibody heavy chain from a camelid (e.g., a nanobody or VHH moiety). Additionally, single-domain antibodies can be autonomous human heavy chain variable domains (aVH) or VNAR moieties derived from sharks (see, e.g., Hasler et al., Mol. Immunol. 75:28-37, 2016).

[0134] Techniques for producing single domain antibodies (DABs or VHHs) are known in the art, as disclosed, for example, in Cossins et al. (2006, Prot Express Purif 51:253-259) and Li et al. (Immunol. Lett. 188:89-95, 2017). Single domain antibodies can be obtained, for example, from camels, alpacas, or llamas by standard immunization techniques (see, for example, Muyldermans et al., TIBS 26:230-235, 2001; Yau et al., J Immunol Methods 281:161-75, 2003; and Maass et al., J Immunol Methods 324:13-25, 2007). VHHs can have strong antigen-binding ability and can interact with epitopes that are inaccessible to conventional VH-VL pairs (see, for example, Muyldermans et al., 2001). Alpaca serum IgG contains approximately 50% camel heavy chain IgG antibodies (HCAbs) (see, e.g., Maass et al., 2007). Alpacas can be immunized with antigens, and VHHs that bind to and neutralize the target antigen can be isolated (see, e.g., Maass et al., 2007). PCR primers that amplify alpaca VHH coding sequences have been identified and can be used to construct alpaca VHH phage display libraries, which can be used to isolate antibody fragments by standard biopanning techniques well known in the art (see, e.g., Maass et al., 2007).

[0135] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see, e.g., Milstein and Cuello, Nature 305:537 (1983); WO 93 / 08829; and Traunecker et al., EMBO J. 10:3655 (1991)), and "knobs-in-holes" engineering (see, e.g., U.S. Pat. No. 5,731,168; Carter (2001), J Immunol Methods 248, 7-15). Multispecific antibodies can also be produced by manipulating electrostatic steering effects to create antibody Fc-heterodimeric molecules (see, e.g., WO 2009 / 089004); cross-linking two or more antibodies or antigen-binding portions thereof (see, e.g., U.S. Pat. No. 4,676,980 and Brennan et al., Science, 229:81 (1985)); using leucine zippers to produce bispecific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553). (1992)); use of "diabody" technology to generate bispecific antibody portions (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and use of single-chain Fv (scFv) dimers (see, e.g., Gruber et al., J. Immunol., 152:5368 (1994)); and by preparation of trispecific antibodies as described, for example, in Tutt et al., J. Immunol. 147:60 (1991).

[0136] Engineered antibodies with three or more functional antigen-binding sites, including "octopus antibodies," can also be binding agents (see, eg, US Patent Application Publication No. 2006 / 0025576).

[0137] The binding agents (e.g., antibodies or antigen-binding portions) herein also include "dual-acting FAbs" or "DABs," which contain antigen-binding sites that bind to two different antigens (see, e.g., U.S. Patent Application Publication No. 2008 / 0069820 and Bostrom et al., 2009, Science 323:1610-14). "Crossmab" antibodies are also included herein (see, e.g., WO 2009 / 080251, WO 2009 / 080252, WO 2009 / 080253, WO 2009 / 080254, and WO 2013 / 026833).

[0138] In some embodiments, the binding agent comprises different antigen-binding sites fused to one or the other of the two subunits of the Fc domain; thus, the two subunits of the Fc domain may be comprised in two non-identical polypeptide chains. Recombinant co-expression of these polypeptides and subsequent dimerization results in several possible combinations of the two polypeptides. Therefore, to improve the yield and purity of bispecific molecules in recombinant production, it may be advantageous to introduce modifications into the Fc domain of the binding agent that promote the association of the desired polypeptides.

[0139] Generally, this method involves replacing one or more amino acid residues at the interface of the two Fc domains with charged amino acid residues, such that homodimer formation is electrostatically unfavored, but heterodimerization is electrostatically favored.

[0140] In some embodiments, the binding agent is a "bispecific T cell engager" or BiTE (see, e.g., WO 2004 / 106381, WO 2005 / 061547, WO 2007 / 042261, and WO 2008 / 119567). This approach utilizes two antibody variable domains arranged on a single polypeptide. For example, the single polypeptide chain can include two single-chain Fv (scFv) moieties, each having a variable heavy (VH) domain and a variable light (VL) domain separated by a polypeptide linker of sufficient length to allow intramolecular association between the two domains. The single polypeptide further includes a polypeptide spacer sequence between the two scFvs. Each scFv recognizes a different epitope, and these epitopes can be specific for both proteins such that different proteins are bound by the BiTE.

[0141] Because it is a single polypeptide, the bispecific T cell engager can be expressed using any prokaryotic or eukaryotic expression system known in the art, such as a CHO cell line. However, specific purification techniques (see, e.g., EP 1 691 833) may be required to separate the monomeric bispecific T cell engager from other multimeric species that may have biological activity other than the intended activity of the monomer. In one exemplary purification scheme, a solution containing the secreted polypeptide is first subjected to metal affinity chromatography, and the polypeptide is eluted using a gradient of imidazole concentration. This eluate is further purified using anion exchange chromatography, and the polypeptide is eluted using a gradient of sodium chloride concentration. Finally, this eluate is subjected to size exclusion chromatography to separate the monomer from the multimeric species. In some embodiments, the bispecific antibody binder is composed of a single polypeptide chain comprising two single-chain FV moieties (scFVs) fused to each other by a peptide linker.

[0142] In some embodiments, the binding agent is multispecific, for example, an IgG-scFv. IgG-scFv formats include IgG(H)-scFv, scFv-(H)IgG, IgG(L)-scFv, svFc-(L)IgG, 2scFV-IgG, and IgG-2scFv. These and other bispecific antibody formats and methods for making them are described, for example, in Brinkmann and Kontermann, MAbs 9(2):182-212 (2017); Wang et al., Antibodies, 2019, 8, 43; Dong et al., 2011, MAbs 3:273-88; Natsume et al., J. Biochem. 140(3):359-368, 2006; Cheal et al., Mol. Cancer Ther. 13(7):1803-1812, 2014; and Bates and Power, Antibodies, 2019, 8, 28.

[0143] Igg-like dual variable domain antibodies (DVD-Ig) have been described by Wu et al., 2007, Nat Biotechnol 25:1290-97; Hasler et al., Mol. Immunol. 75:28-37, 2016, and in WO 08 / 024188 and WO 07 / 024715. Triomabs have been described by Chelius et al., MAbs 2(3):309-319, 2010. 2-in-1-IgG has been described by Kontermann et al., Drug Discovery Today 20(7):838-847, 2015. Tanden antibodies, or TandAbs, have been described by Kontermann et al., supra. An scFv-HSA-scFv antibody has also been described by Kontermann et al. (ibid.).

[0144] Intact (e.g., whole) antibodies, their dimers, individual light and heavy chains, or antigen-binding portions thereof, and other binding agents can be recovered and purified by known techniques, such as immunoabsorption or immunoaffinity chromatography, chromatographic methods such as HPLC (high performance liquid chromatography), ammonium sulfate precipitation, gel electrophoresis, or any combination thereof. See generally, Scopes, Protein Purification (Springer-Verlag, New York, 1982). Substantially pure CD70-binding antibodies or antigen-binding portions thereof or other binding agents of at least about 90% to 95% homogeneity are advantageous, and particularly for pharmaceutical uses, those having 98% to 99% or greater homogeneity are advantageous. Once purified, partially or to the desired homogeneity, the intact CD70 antibodies or antigen-binding portions thereof or other binding agents can then be used therapeutically or in the development and implementation of assay procedures, immunofluorescence staining, and the like. See generally, Vols. I & II Immunol. Meth. (Lefkovits & Pernis, eds., Acad. Press, NY, 1979 and 1981).

[0145] Antibody-drug conjugates In some embodiments, the CD70 antibodies, antigen-binding portions, or other binding agents described herein are part of a CD70 antibody-drug conjugate (also referred to as a CD70 conjugate or CD70 ADC). In some embodiments, the CD70 antibodies, antigen-binding portions, or other binding agents are attached to at least one linker, and at least one drug is attached to each linker. As used herein, in the context of a conjugate, the term "drug" refers to cytotoxic agents (such as chemotherapeutic agents or drugs), immunomodulators, nucleic acids (including siRNAs), growth inhibitory agents, toxins (e.g., protein toxins, enzymatically active toxins of bacterial, fungal, plant, or animal origin, or fragments thereof), radioisotopes, PROTACs, and other compounds that are active against target cells when delivered to the target cells.

[0146] cytotoxic agents In some embodiments, the CD70 conjugate comprises at least one drug that is a cytotoxic agent. A "cytotoxic agent" refers to an agent that has a cytotoxic effect on a cell. A "cytotoxic effect" refers to the depletion, elimination, and / or killing of target cells. Cytotoxic agents include, for example, tubulin-disrupting agents, topoisomerase inhibitors, DNA minor groove binders, and DNA alkylating agents.

[0147] Tubulin disrupting agents include, for example, auristatins, dolastatins, tubulysins, colchicine, vinca alkaloids, taxanes, cryptophycins, maytansinoids, hemiasterins, and other tubulin disrupting agents. Auristatins are derivatives of the natural product dolastatin 10. Exemplary auristatins include MMAE (N-methylvaline-valine-dolaisoleucine-dolaproine-norephedrine), MMAF (N-methylvaline-valine-dolaisoleucine-dolaproine-phenylalanine), and AFP (see WO 2004 / 010957 and WO 2007 / 008603). Other auristatin-like compounds are disclosed, for example, in U.S. Patent Application Publication Nos. 2021 / 0008099, 2017 / 0121282, 2013 / 0309192, and 2013 / 0157960. Dolastatins include, for example, dolastatin 10 and dolastatin 15 (see, for example, Pettit et al., J. Am. Chem. Soc., 1987, 109, 6883-6885; Pettit et al., Anti-Cancer Drug Des., 1998, 13, 243-277; and U.S. Patent Application Publication No. 2001 / 0018422). Additional dolastatin derivatives contemplated for use herein are disclosed in U.S. Patent No. 9,345,785, which is incorporated herein by reference.

[0148] Tubulysins include, but are not limited to, tubulysin D, tubulysin M, tubuphenylalanine, and tubutyrosine. Tubulysin analogues, including tubulysin M, are described in WO 2017 / 096311 and WO 2016 / 040684.

[0149] Colchicines include, but are not limited to, colchicine and CA-4.

[0150] Vinca alkaloids include, but are not limited to, vinblastine (VBL), vinorelbine (VRL), vincristine (VCR) and vindesine (VOS).

[0151] Taxanes include, but are not limited to, paclitaxel and docetaxel.

[0152] Cryptophycins include, but are not limited to, cryptophycin-1 and cryptophycin-52.

[0153] Maytansinoids include, but are not limited to, maytansine, maytansinol, maytansine analogs DM1, DM3 and DM4, and ansamitocin-2. Exemplary maytansinoid drug moieties include those with modified aromatic rings such as C-19-dechloro (U.S. Pat. No. 4,256,746) (prepared by lithium aluminum hydride reduction of ansamitocin P2); C-20-hydroxy (or C-20-demethyl) + / -C-19-dechloro (U.S. Pat. Nos. 4,361,650 and 4,307,016) (prepared by demethylation using Streptomyces or Actinomyces or dechlorination using LAH); and C-20-demethoxy, C-20-acyloxy (-OCOR), + / -dechloro (U.S. Pat. No. 4,294,757) (prepared by acylation using acyl chloride), as well as those with modifications at other positions.

[0154] Maytansinoid drug moieties include C-9-SH (U.S. Pat. No. 4,424,219) (prepared by reaction of maytansinol with H2S or P2S5); C-14-alkoxymethyl (demethoxy / CH2OR) (U.S. Pat. No. 4,331,598); C-14-hydroxymethyl or acyloxymethyl (CH2OH or CHOAc) (U.S. Pat. No. 4,450,254) (prepared from Nocardia); C-15-hydroxy / acyloxy (U.S. Pat. No. 4,364,866) (prepared by conversion of maytansinol by Streptomyces); C-15-methoxy (U.S. Pat. Nos. 4,313,946 and 4,315,929) (prepared from Trewia nudiflora nudiflora); C-18-N-demethyl (U.S. Pat. Nos. 4,362,663 and 4,322,348) (prepared by demethylation of maytansinol with Streptomyces); and 4,5-deoxy (U.S. Pat. No. 4,371,533) (prepared by titanium trichloride / LAH reduction of maytansinol).

[0155] Hemiasterins include, but are not limited to, hemiasterin and HTI-286.

[0156] Other tubulin disrupting agents include taccalonolide A, taccalonolide B, taccalonolide AF, taccalonolide AJ, taccalonolide Al-epoxide, discodermolide, epothilone A, epothilone B, and laulimalide.

[0157] In some embodiments, the cytotoxic agent may be a topoisomerase inhibitor, such as camptothecin. Exemplary camptothecins include, for example, camptothecin, irinotecan (also known as CPT-11), belotecan, (7-(2-(N-isopropylamino)ethyl)camptothecin), topotecan, 10-hydroxy-CPT, SN-38, exatecan, and exatecan analog DXd (see U.S. Patent Application Publication No. 20150297748). Other camptothecins are disclosed in International Publication No. WO 1996 / 021666, International Publication No. WO 00 / 08033, U.S. Patent Application Publication No. 2016 / 0229862, and International Publication No. WO 2020 / 156189.

[0158] In some embodiments, the cytotoxic agent is a duocarmycin, including the synthetic analogs KW-2189 and CBI-TMI.

[0159] immunomodulators In some embodiments, the drug is an immunomodulatory agent. The immunomodulatory agent can be, for example, a TLR7 and / or TLR8 agonist, a STING agonist, a RIG-I agonist, or other immunomodulatory agent.

[0160] In some embodiments, the drug is an immunomodulatory agent, such as a TLR7 and / or TLR8 agonist. In some embodiments, the TLR7 agonist is selected from imidazoquinolines, imidazoquinoline amines, thiazoquinolines, aminoquinolines, aminoquinazolines, pyrido[3,2-d]pyrimidine-2,4-diamines, pyrimidine-2,4-diamines, 2-aminoimidazoles, 1-alkyl-1H-benzimidazol-2-amines, tetrahydropyridopyrimidines, heteroaromatic azides-2,2-dioxides, benzonaphthyridines, guanosine analogs, adenosine analogs, thymidine homopolymers, ssRNA, CpG-A, polyG10, and polyG3. In some embodiments, the TLR7 agonist is selected from imidazoquinolines, imidazoquinoline amines, thiazoquinolines, aminoquinolines, aminoquinazolines, pyrido[3,2-d]pyrimidine-2,4-diamines, pyrimidine-2,4-diamines, 2-aminoimidazoles, 1-alkyl-1H-benzimidazol-2-amines, tetrahydropyridopyrimidines, heteroaromatic azides-2,2-dioxides, or benzonaphthyridines. In some embodiments, the TLR7 agonist is a non-naturally occurring compound. Examples of TLR7 modulators include GS-9620, GSK-2245035, imiquimod, resiquimod, DSR-6434, DSP-3025, IMO-4200, MCT-465, MEDI-9197, 3M-051, SB-9922, 3M-052, Limtop, TMX-30X, TMX-202, RG-7863, RG-7795, as well as compounds disclosed in U.S. Patent Application Publication No. 20160168164 (Janssen), U.S. Patent Application Publication No. 20150299194 (Roche), U.S. Patent Application Publication No. 20110098248 (Gilead Sciences), U.S. Patent Application Publication No. 20100143301 (Gilead Sciences), and U.S. Patent Application Publication No. 20150299194 (Roche). Sciences) and the compounds disclosed in US Patent Application Publication No. 20090047249 (Gilead Sciences).

[0161] In some embodiments, the TLR8 agonist is selected from benzazepine, imidazoquinoline, thiazoloquinoline, aminoquinoline, aminoquinazoline, pyrido[3,2-d]pyrimidine-2,4-diamine, pyrimidine-2,4-diamine, 2-aminoimidazole, 1-alkyl-1H-benzimidazol-2-amine, tetrahydropyridopyrimidine or ssRNA. In some embodiments, the TLR8 agonist is selected from benzazepine, imidazoquinoline, thiazoloquinoline, aminoquinoline, aminoquinazoline, pyrido[3,2-d]pyrimidine-2,4-diamine, pyrimidine-2,4-diamine, 2-aminoimidazole, 1-alkyl-1H-benzimidazol-2-amine and tetrahydropyridopyrimidine. In some embodiments, the TLR8 agonist is a non-naturally occurring compound. Examples of TLR8 agonists include motolimod, resiquimod, 3M-051, 3M-052, MCT-465, IMO-4200, VTX-763, and VTX-1463.

[0162] In some embodiments, the TLR8 agonist can be any of the compounds described in WO2018 / 170179, WO2020 / 056198, and WO2020056194.

[0163] Other TLR7 and TLR8 agonists are described, for example, in WO 2016142250, WO 2017046112, WO 2007024612, WO 2011022508, WO 2011022509, WO 2012045090, WO 2012097173, WO 2012097177, WO 2017079283, U.S. Patent Application Publication No. 20160008374, U.S. Patent Application Publication No. 20160194350, U.S. Patent Application Publication No. 20160289229, U.S. Patent No. 6,043,238, U.S. Patent Application Publication No. 20180086755 (Gilead), WO 2017216054 (Roche), WO 2017190669 (Shanghai De Novo Pharmatech), WO 2017202704 (Roche), WO 2017202703 (Roche), WO 20170071944 (Gilead), U.S. Patent Application Publication No. 20140045849 (Janssen), U.S. Patent Application Publication No. 20140073642 (Janssen), WO 2014056953 (Janssen), WO 2014076221 (Janssen), WO 2014128189 (Janssen), U.S. Patent Application Publication No. 20140350031 (Janssen), WO 2014023813 (Janssen), U.S. Patent Application Publication No. 20080234251 (Array Biopharma), U.S. Patent Application Publication No. 20080306050 (Array Biopharma), U.S. Patent Application Publication No. 20100029585 (Ventirx Pharma), U.S. Patent Application Publication No. 20110092485 (Ventirx Pharma), U.S. Patent Application Publication No. 20110118235 (Ventirx Pharma), U.S. Patent Application Publication No. 20120082658 (VentirxPharma), U.S. Patent Application Publication No. 20120219615 (Ventirx Pharma), U.S. Patent Application Publication No. 20140066432 (Ventirx Pharma), U.S. Patent Application Publication No. 20140088085 (Ventirx Pharma), U.S. Patent Application Publication No. 20140275167 (Novira Therapeutics), and U.S. Patent Application Publication No. 20130251673 (Novira Therapeutics), WO 2018198091 (Novartis AG), and U.S. Patent Application Publication No. 20170131421 (Novartis AG).

[0164] In some embodiments, the immunomodulatory agent is a STING agonist.Examples of STING agonist include those disclosed in International Publication No. 2020059895, International Publication No. 2015077354, International Publication No. 2020227159, International Publication No. 2020075790, International Publication No. 2018200812 and International Publication No. 2020074004.

[0165] In some embodiments, the immunomodulatory agent is a RIG-I agonist. Examples of RIG-I agonists include KIN1148, SB-9200, KIN700, KIN600, KIN500, KIN100, KIN101, KIN400 and KIN2000.

[0166] toxin In some embodiments, the drug is an enzymatically active toxin or fragment thereof, including, but not limited to, diphtheria A chain, nonbinding active fragment of diphtheria toxin, exotoxin A chain (from Pseudomonas aeruginosa), ricin A chain, abrin A chain, modeccin A chain, α-sarcin, Aleurites fordii protein, dianthin protein, Phytolaca americana proteins (PAPI, PAPII, and PAP-S), Momordica charantia inhibitor, curcin, crotin, Sapaonaria officinalis inhibitor, gelonin, mitogenin, restrictocin, phenomycin, enomycin, and a trichothecene.

[0167] radioactive isotope In some embodiments, the drug is a radioactive atom.Various radioisotopes can be used to prepare radioconjugates.Examples include I131, I125, Y90, Re186, Re188, Sm153, Bi213, P32, Pb212 and the radioisotope of lutetium (e.g., Lu177).

[0168] PROTAC In some embodiments, the drug is a proteolysis-directing chimeric molecule (PROTAC). PROTACs are described, for example, in U.S. Patent Application Publication Nos. 20210015942, 20210015929, 20200392131, 20200216507, 20200199247, and 20190175612, the disclosures of which are incorporated herein by reference.

[0169] Linker CD70 conjugates typically include at least one linker, each linker having at least one drug attached thereto. Typically, the conjugate includes a linker between the CD70 antibody (or antigen-binding portion thereof or other binding agent) and the drug. In various embodiments, the linker is a protease-cleavable linker, an acid-cleavable linker, a disulfide linker, a disulfide-containing linker, or a disulfide-containing linker having a dimethyl group adjacent to the disulfide bond (e.g., an SPDB linker) (see, e.g., Jain et al., Pharm. Res. 32:3526-3540 (2015); Chari et al., Cancer Res. 52:127-131 (1992); U.S. Pat. No. 5,208,020), a self-stabilizing linker (see, e.g., WO 2018 / 031690 and WO 2015 / 095755 and Jain et al., Pharm. Res. 32:3526-3540 (2015)), a non-cleavable linker (see, e.g., WO 2007 / 008603), a photolabile linker, and / or a hydrophilic linker (see, e.g., WO 2015 / 123679).

[0170] In some embodiments, the linker is a cleavable linker that can be cleaved under intracellular conditions, such that cleavage of the linker releases the drug from the antibody (or antigen-binding portion thereof or other binding agent) and / or the linker in the intracellular environment. For example, in some embodiments, the linker can be cleaved by a cleaving agent present in the intracellular environment (e.g., within a lysosome, endosome, or caveolae). The linker can be, for example, a peptidyl linker that is cleaved by an intracellular peptidase or protease enzyme, including, but not limited to, a lysosomal or endosomal protease (see, e.g., WO 2004 / 010957, U.S. Patent Application Publication No. 20150297748, U.S. Patent Application Publication No. 2008 / 0166363, U.S. Patent Application Publication No. 20120328564, and U.S. Patent Application Publication No. 20200347075). Typically, the peptidyl linker is at least one amino acid long or at least two amino acids long. Intracellular cleaving agents can include cathepsins B and D and plasmin, all of which are known to hydrolyze dipeptide drug derivatives, resulting in the release of the active drug within target cells (see, e.g., Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123). The most typical peptidyl linker is cleavable by an enzyme present in target antigen-expressing cells. For example, a peptidyl linker cleavable by the thiol-dependent protease cathepsin B, which is highly expressed in cancerous tissues, can be used (e.g., Phe-Leu or Gly-Phe-Leu-Gly linker). Other such linkers are described, for example, in U.S. Pat. No. 6,214,345. In specific embodiments, the peptidyl linker cleavable by an intracellular protease is a Val-Cit linker or a Phe-Lys linker (see, e.g., U.S. Pat. No. 6,214,345, which describes the synthesis of doxorubicin using a val-cit linker), or a Gly-Gly-Phe-Gly (SEQ ID NO: 35) linker (see, e.g., U.S. Patent Application Publication No. 2015 / 0297748).One advantage of using intracellular proteolytic release of the drug is that the drug is typically attenuated when conjugated, and the serum stability of the conjugate is typically high. See also U.S. Patent No. 9,345,785.

[0171] As used herein, the terms "cleaved intracellularly" and "intracellular cleavage" refer to an intracellular metabolic process or reaction for an antibody-drug conjugate by which a covalent bond, e.g., a linker, between the drug (e.g., a cytotoxic agent) and the antibody is broken, yielding free drug dissociated from the antibody within the cell or other metabolic product of the conjugate. Thus, the cleaved portion of the conjugate is an intracellular metabolic product.

[0172] In some embodiments, the cleavable linker is pH-sensitive, i.e., sensitive to hydrolysis at a certain pH value. Typically, pH-sensitive linkers are hydrolyzable under acidic conditions. For example, acid-labile linkers (e.g., hydrazones, semicarbazones, thiosemicarbazones, cis-aconitic acid amides, orthoesters, acetals, ketals, etc.) that are hydrolyzable in lysosomes can be used (see, for example, U.S. Pat. Nos. 5,122,368; 5,824,805; and 5,622,929; Dubowchik and Walker, 1999, Pharm. Therapeutics 83:67-123; Neville et al., 1989, Biol. Chem. 264:14653-14661). Such linkers are relatively stable under neutral pH conditions, such as the pH conditions in blood, but are unstable below pH 5.5 or 5.0, which is the approximate pH of lysosomes. In certain embodiments, the hydrolyzable linker is a thioether linker, such as a thioether attached to the drug via an acylhydrazone bond (see, eg, US Pat. No. 5,622,929).

[0173] In some embodiments, the linker is cleavable under reducing conditions (eg, a disulfide linker). For example, a variety of disulfide linkers are known, including those that can be formed using SATA (N-succinimidyl-5-acetylthioacetate), SPDP (N-succinimidyl-3-(2-pyridyldithio)propionate), SPDB (N-succinimidyl-3-(2-pyridyldithio)butyrate), and SMPT (N-succinimidyl-oxycarbonyl-α-methyl-α-(2-pyridyl-dithio)toluene)-, SPDB, and SMPT (see, e.g., Thorpe et al., 1987, Cancer Res. 47:5924-5931; Wawrzynczak et al., In Immunoconjugates: Antibody Conjugates in Radioimagery and Therapy of Cancer (C.W. Vogel, ed., Oxford University Press, 1987; see also U.S. Pat. No. 4,880,935).

[0174] In some embodiments, the linker is a malonic acid linker (Johnson et al., 1995, Anticancer Res., 15:1387-93), a maleimidobenzoyl linker (Lau et al., 1995, Bioorg-Med-Chem. 3(10):1299-1304), or a 3'-N-amide analog (Lau et al., 1995, Bioorg-Med-Chem. 3(10):1305-12). In some embodiments, the linker unit is not cleavable, such as a maleimidocaproyl linker, and the drug is released by antibody degradation (see U.S. Patent Application Publication No. 2005 / 0238649).

[0175] In some embodiments, the linker is substantially insensitive to the extracellular environment. As used herein, "substantially insensitive to the extracellular environment" in the context of a linker means that about 20% or less, typically about 15% or less, more typically about 10% or less, and even more typically about 5% or less, about 3% or less, or about 1% or less of the linkers in a sample of an antibody-drug conjugate (ADC) are cleaved when the ADC is present in an extracellular environment (e.g., plasma). Whether a linker is substantially insensitive to the extracellular environment can be determined, for example, by incubating both (a) an ADC ("ADC sample") and (b) an equimolar amount of unconjugated antibody or drug ("control sample") independently with plasma for a predetermined period of time (e.g., 2, 4, 8, 16, or 24 hours), and then comparing the amount of unconjugated antibody or drug present in the ADC sample with the amount present in the control sample, as measured, for example, by high-performance liquid chromatography.

[0176] In some embodiments, the linker promotes cellular internalization. In some embodiments, the linker promotes cellular internalization when conjugated to a drug, such as a cytotoxic agent (i.e., in the context of the linker-drug moiety of an ADC described herein). In yet other embodiments, the linker promotes cellular internalization when conjugated to both a drug and a CD70 antibody (i.e., in the context of an ADC described herein).

[0177] Various linkers that can be used in the present compositions and methods are described in WO2004010957. In some embodiments, the protease-cleavable linker comprises a thiol-reactive spacer and a dipeptide. In some embodiments, the protease-cleavable linker consists of a thiol-reactive maleimidocaproyl spacer, a valine-citrulline dipeptide, and a p-aminobenzyloxycarbonyl spacer.

[0178] In some embodiments, the acid-cleavable linker is a hydrazine linker or a quaternary ammonium linker (see WO 2017 / 096311 and WO 2016 / 040684).

[0179] In some embodiments, the linker is a self-stabilizing linker comprising a maleimide group, such as those described in US Pat. No. 9,504,756.

[0180] In some embodiments, the linker is a hydrophilic linker, such as the hydrophilic peptides of WO2015 / 123679 and the sugar alcohol polymer-based linkers disclosed in WO2013 / 012961 and WO2019 / 213046.

[0181] In other embodiments, conjugates of CD70 antibodies (or antigen-binding moieties or other binding agents) and drugs may be made using a variety of bifunctional protein coupling agents, such as N-succinimidyl-3-(2-pyridyldithio)propionate (SPDP), succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC), iminothiolane (IT), bifunctional derivatives of imidoesters (such as dimethyl adipimidate HCl), active esters (such as disuccinimidyl suberate), aldehydes (such as glutaraldehyde), bis-azido compounds (such as bis(p-azidobenzoyl)hexanediamine), bis-diazonium derivatives (such as bis-(p-diazoniumbenzoyl)-ethylenediamine), diisocyanates (such as toluene 2,6-diisocyanate), and bis-active fluorine compounds (1,5-difluoro-2,4-dinitrobenzene). Chelating agents for conjugation of radionucleotides to antibodies, antigen-binding portions thereof, or other binding agents are described, for example, in WO 94 / 11026.

[0182] Conjugates of CD70 antibodies (or antigen-binding portions or other binding agents) include, but are not limited to, those commercially available (e.g., from Pierce Biotechnology, Inc., Rockford, Illinois, USA), including, but not limited to, BMPS, EMCS, GMBS, HBVS, LC-SMCC, MBS, MPBH, SBAP, SIA, SIAB, SMCC, SMPB, SMPH, sulfo-EMCS, sulfo-GMBS, sulfo-KMUS, sulfo-MBS, sulfo-SIAB, sulfo-SMCC, and sulfo-SMPB, and such conjugates prepared using crosslinkers including SVSB (succinimidyl-(4-vinylsulfone)benzoate).

[0183] In some embodiments, the linker can be attached to the end of the amino acid sequence of an antibody, antigen-binding moiety, or other binding agent, or to a side chain modification of the antibody, antigen-binding moiety, or other binding agent, such as the side chain of a lysine, serine, threonine, cysteine, tyrosine, aspartic acid, unnatural amino acid residue, glutamine, or glutamic acid residue. The bond between the antibody, antigen-binding moiety, or other binding agent and the linker or drug can be via any of several bonds, including, but not limited to, an amide bond, an ester bond, an ether bond, a carbon-nitrogen bond, a carbon-carbon single, double, or triple bond, a disulfide bond, or a thioether bond. Functional groups that can form such bonds include, for example, amino groups, carboxyl groups, aldehyde groups, azide groups, alkyne and alkene groups, ketones, carbonates, and carbonyl functional groups linked to leaving groups such as cyano and succinimidyl groups and hydroxyl groups.

[0184] In some embodiments, the linker is attached to the antibody, antigen-binding moiety, or other binding agent at an interchain disulfide. In some embodiments, the linker is attached to the antibody, antigen-binding moiety, or other binding agent at a hinge cysteine ​​residue. In some embodiments, the linker is attached to the antibody, antigen-binding moiety, or other binding agent at an engineered cysteine ​​residue. In some embodiments, the linker is attached to the antibody, antigen-binding moiety, or other binding agent at a lysine residue. In some embodiments, the linker is attached to the antibody, antigen-binding moiety, or other binding agent at an engineered glutamine residue. In some embodiments, the linker is attached to the antibody, antigen-binding moiety, or other binding agent at an engineered non-natural amino acid in the heavy chain.

[0185] In some embodiments, the linker is attached to the antibody, antigen-binding moiety, or other binding agent via a sulfhydryl group. In some embodiments, the linker is attached to the antibody, antigen-binding moiety, or other binding agent via a primary amine. In some embodiments, the linker is attached via a linkage created between an unnatural amino acid on the antibody, antigen-binding moiety, or other binding agent by reacting with an oxime bond formed by modifying a ketone group on the drug with an alkoxyamine.

[0186] In some embodiments, the linker is attached to the antibody, antigen-binding moiety, or other binding agent via a sortase A linker, which can be generated by a sortase A enzyme that fuses an LPXTG recognition motif (SEQ ID NO: 33) to an N-terminal GGG motif to regenerate a native amide bond.

[0187] Exemplary Linker-Drug Combinations In some embodiments, a drug such as a tubulin-disrupting agent, e.g., an auristatin, is attached to the linker by its C-terminal carboxyl group, which forms an amide bond with the linker (e.g., a linker unit (LU)), as described in U.S. Patent No. 9,463,252, which is incorporated herein by reference. In some embodiments, the linker comprises at least one amino acid.

[0188] In some embodiments, the linker also comprises a stretcher unit and / or an amino acid unit. Exemplary stretcher units and amino acid units are described in U.S. Patent Nos. 9,345,785 and 9,078,931, each of which is incorporated herein by reference.

[0189] In some embodiments, the antibody drug conjugate comprises an anti-CD70 antibody covalently linked to MMAE via a mc-val-cit-PAB linker.

[0190] In some embodiments, the CD70 conjugate has the following formula: [ka] or a pharmaceutically acceptable salt thereof, wherein mAb is a CD70 antibody, antigen-binding portion thereof, or other binding agent; S is a sulfur atom of the antibody, antigen-binding portion, or other binding agent; A is a Stretcher unit; and p is from about 3 to about 5, or from about 3 to about 8.

[0191] Drug loading is represented by p, the average number of drug molecules (e.g., cytotoxic agents) per antibody (or antigen-binding moiety or other binding agent) in the conjugate. For example, if p is about 4, then the average drug loading, considering all of the antibodies (or antigen-binding moieties or other binding agents) present in the composition, is about 4. In some embodiments, p is in the range of about 3 to about 5, about 3.6 to about 4.4, or about 3.8 to about 4.2. In some embodiments, p can be about 3, about 4, or about 5. In some embodiments, p is in the range of about 6 to about 8, more preferably about 7.5 to about 8.4. In some embodiments, p can be about 6, about 7, or about 8.

[0192] The average number of drugs per antibody (or antigen-binding moiety or other binding agent) in a preparation can be characterized by conventional means such as mass spectrometry, ELISA assay, and HPLC. The quantitative distribution of antibody-drug conjugates with respect to p can also be determined. In some instances, separation, purification, and characterization of homogeneous antibody-drug conjugates with a certain p value from antibody-drug conjugates with other drug loads can be achieved by means such as reverse-phase HPLC or electrophoresis.

[0193] In some embodiments, a Stretcher unit can link an antibody (or antigen-binding portion or other binding agent) to an amino acid or peptide (e.g., a valine-citrulline peptide) via a sulfhydryl group on the antibody (or antigen-binding portion or other binding agent). Sulfhydryl groups can be generated, for example, by reduction of the interchain disulfide bond of a CD70 antibody (or antigen-binding portion or other binding agent). For example, a Stretcher unit can be linked to an antibody (or antigen-binding portion or other binding agent) via the sulfur atom generated from reduction of the interchain disulfide bond of the antibody (or antigen-binding portion or other binding agent). In some embodiments, a Stretcher unit is linked to an antibody (or antigen-binding portion or other binding agent) solely via the sulfur atom generated from reduction of the interchain disulfide bond of the antibody. In some embodiments, sulfhydryl groups can be generated by reaction of amino groups on lysine moieties of a CD70 antibody (or antigen-binding portion or other binding agent) with 2-iminothiolane (Traut's reagent) or other sulfhydryl-generating reagents. In some embodiments, the CD70 antibody (or antigen-binding portion or other binding agent) is a recombinant antibody and is engineered to have one or more lysines, hi some embodiments, the recombinant CD70 antibody (or antigen-binding portion or other binding agent) is engineered to have an additional cysteine, such as an additional sulfhydryl group, e.g., an engineered cysteine.

[0194] The synthesis and structure of MMAE are described in U.S. Patent No. 6,884,869, which is incorporated herein by reference in its entirety for all purposes. The synthesis and structure of exemplary Stretcher units and methods of making antibody-drug conjugates are described, for example, in U.S. Patent Application Publication Nos. 2006 / 0074008 and 2009 / 0010945, each of which is incorporated herein by reference in its entirety.

[0195] Representative Stretcher units are set forth within the brackets of Formula IIa and Formula IIb in US Pat. No. 9,211,319, incorporated herein by reference.

[0196] In some embodiments, the CD70 conjugate comprises monomethyl auristatin E (MMAE) and a protease-cleavable linker. It is contemplated that the protease-cleavable linker comprises a thiol-reactive spacer and a dipeptide. In various embodiments, the protease-cleavable linker comprises a thiol-reactive maleimidocaproyl spacer, a valine-citrulline (val-cit) dipeptide, and a p-aminobenzyloxycarbonyl or PAB spacer.

[0197] The abbreviation "PAB" stands for self-immolating spacer: [ka] Refers to...

[0198] The abbreviation "MC" stands for stretcher maleimidocaproyl: [ka] Refers to...

[0199] In other exemplary embodiments, the conjugate has the following general formula: Ab-[L3]-[L2]-[L1] m -AA n -Drugs where Ab is a CD70 antibody (or antigen-binding moiety or other binding agent); the drug is, for example, a cytotoxic agent such as a tubulin-disrupting agent or a topoisomerase inhibitor; L3 is a component of a linker comprising an antibody coupling moiety (such as a stretcher unit) and one or more acetylene (or azide) groups; L2 comprises an optional PEG (polyethylene glycol) azide (or acetylene) at one end that is complementary to the acetylene (or azide) moiety of L3 and a reactive group such as a carboxylic acid or hydroxyl group at the other end; L1 comprises a foldable unit (e.g., a self-immolative group), or a peptidase-cleavable moiety or acid-cleavable moiety optionally attached to the foldable unit; AA is an amino acid; m is an integer having a value of 0 or 1, and n is an integer having a value of 0, 1, 2, 3, or 4. Such linkers can be assembled via click chemistry (see, e.g., U.S. Pat. Nos. 7,591,944 and 7,999,083).

[0200] In some embodiments, the drug is camptothecin or a camptothecin (CPT) analog, such as irinotecan (also known as CPT-11), belotecan, topotecan, 10-hydroxy-CPT, exatecan, DXd, or SN-38. Representative structures are shown below. [ka]

[0201] Conjugated Ab-[L3]-[L2]-[L1] m -AA n -Referring to the drug, in some embodiments, m is 0. Conjugate Formula Ab-[L3]-[L2]-[L1] m -AA nIn some embodiments, L2 is absent, referring to the drug. In such embodiments, an ester moiety is first formed between the carboxylic acid of an amino acid (AA) such as glycine, alanine, or sarcosine, or a peptide such as glycylglycine, and the hydroxyl group of a drug, such as a cytotoxic agent. In this example, the N-terminus of the amino acid or polypeptide can be protected as a Boc, Fmoc, or monomethoxytrityl (MMT) derivative and deprotected after forming an ester bond with the hydroxyl group of the cytotoxic agent. Since "monomethoxytrityl (MMT)" is removable by mild acid treatment, such as dichloroacetic acid, which does not cleave the BOC group, selective removal of the amine protecting group can be achieved in the presence of a BOC protecting group at the hydroxyl position of a cytotoxic agent containing an additional hydroxyl group by using MMT as a protecting group for the amino group of the amino acid or polypeptide involved in ester formation. After the amino group of the amino acid or polypeptide that forms the ester bond with the hydroxyl of the drug is unmasked, the amino group reacts with the activated form of the COOH group on the PEG moiety of L2 (if present) under standard amide-forming conditions. In preferred embodiments, L3 comprises a thiol-reactive group that links to a thiol group on an antibody (or antigen-binding portion or other binding agent). The thiol-reactive group is optionally maleimide or vinyl sulfone, or bromoacetamide or iodoacetamide that links to a thiol group on an antibody. In some embodiments, the reagent having a thiol-reactive group is generated from, for example, succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) or succinimidyl-(ε-maleimido)caproate, and the thiol-reactive group is a maleimide group.

[0202] In another embodiment, m is 0 and AA comprises a peptide moiety, preferably a di-, tri-, or tetrapeptide, that is cleavable by an intracellular peptidase, such as cathepsin B. Examples of cathepsin B-cleavable peptides are Phe-Lys, Val-Cit (Dubowchick, 2002), Ala-Leu, Leu-Ala-Leu, Ala-Leu-Ala-Leu (SEQ ID NO: 36) (Trouet et al., 1982), and Gly-Gly-Phe-Gly (SEQ ID NO: 35) (see, e.g., WO 2014 / 057687).

[0203] In some embodiments, L1 is comprised of an intracellularly cleavable peptide, such as a cathepsin B-cleavable peptide, connected at the C-terminus of the peptide to a foldable unit, such as p-aminobenzyl alcohol (or p-amino-benzyloxycarbonyl), with the benzyl alcohol moiety directly attached to the hydroxyl group of the cytotoxic agent in chloroformate form. In this embodiment, n is 0. Alternatively, when "n" is non-zero, the benzyl alcohol moiety of the p-amidobenzyl alcohol (or p-amino-benzyloxycarbonyl) moiety is attached to the N-terminus of the amino acid or peptide linked at the hydroxyl group of the drug (e.g., cytotoxic agent) through the activated form of p-amidobenzyl alcohol, i.e., PABOCOPNP, where PNP is p-nitrophenyl. In some embodiments, the linker comprises a thiol-reactive group that links to a thiol group of an antibody (or antigen-binding moiety or other binding agent). The thiol-reactive group is optionally maleimide or vinyl sulfone, or bromoacetamide or iodoacetamide, that links to a thiol group of an antibody. In a preferred embodiment, the component having a thiol-reactive group is generated from, for example, succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) or succinimidyl-(ε-maleimido)caproate, where the thiol-reactive group is a maleimide group.

[0204] In some embodiments, when the drug is a cytotoxic agent such as camptothecin or its analogs or derivatives having a 20-hydroxyl group, L1 is comprised of an intracellularly cleavable peptide, such as a cathepsin B-cleavable peptide, connected at the C-terminus of the peptide to the foldable linker p-aminobenzyl alcohol (or p-amino-benzyloxycarbonyl), with the benzyl alcohol moiety directly linked to CPT-20-O-chloroformate. In this embodiment, n is 0. Alternatively, when "n" is non-zero, the benzyl alcohol moiety of the p-amidobenzyl alcohol moiety is linked to the N-terminus of the amino acid or polypeptide linked at the 20-position of CPT through the activated form of p-amidobenzyl alcohol, i.e., PABOCOPNP, where PNP is p-nitrophenyl. In a preferred embodiment, the linker comprises a thiol-reactive group that links to a thiol group on an antibody (or antigen-binding moiety or other binding agent). The thiol-reactive group is optionally maleimide or vinyl sulfone, or bromoacetamide or iodoacetamide, that links to a thiol group on an antibody. In a preferred embodiment, the component having a thiol-reactive group is generated from, for example, succinimidyl-4-(N-maleimidomethyl)cyclohexane-1-carboxylate (SMCC) or succinimidyl-(ε-maleimido)caproate, where the thiol-reactive group is a maleimide group.

[0205] In some embodiments, the L2 component of the conjugate is present and contains a polyethylene glycol (PEG) spacer, which can be up to about MW 5000 in size; in preferred embodiments, the PEG is a defined PEG having 1-12 or 1-30 repeating monomer units. In some embodiments, the PEG is a defined PEG having 1-12 repeating monomer units. Introduction of PEG can involve the use of commercially available heterobifunctional PEG derivatives. Heterobifunctional PEGs typically contain azide or acetylene groups. An example of a heterobifunctional defined PEG containing 8 repeating monomer units, where "NHS" is succinimidyl, is shown below in the following formula: [ka]

[0206] In some embodiments, L3 has a plurality of acetylene (or azide) groups, ranging from 2 to 40, preferably 2 to 20, more preferably 2 to 5, and a single antibody binding moiety.

[0207] A representative conjugate in which the drug is a cytotoxic agent such as SN-38 (a CPT analog) prepared using a maleimide-containing SN-38-linker derivative, with the linkage to the antibody (referred to as MAb) represented as a succinimide, is shown below: Here, m=0, and the 20-O-AA ester attached to SN-38 is a glycinate; azide-acetylene coupling of L2 and L3 results in a triazole moiety as shown. [ka]

[0208] Another representative conjugate prepared using a maleimide-containing SN-38-linker derivative, with the linkage to the antibody (MAb) represented as the succinimide, is shown below, where n=0 in general formula 2; "L1" contains a cathepsin B-cleavable dipeptide, Phe-Lys, linked to a foldable p-aminobenzyl alcohol moiety, which is attached to SN-38 as a carbonate bond at position 20; and azide-acetylene coupling connecting the "L2" and "L3" moieties results in a triazole moiety as shown. [ka]

[0209] Another representative SN-38 conjugate, mAb-CL2-SN-38, was prepared using a maleimide-containing SN-38-linker derivative with the bond to the antibody represented as a succinimide and is shown below: Here, the 20-O-AA ester attached to SN-38 is a glycinate linked to the L1 moiety via a p-aminobenzyl alcohol moiety and a cathepsin-B cleavable dipeptide; the cathepsin-B cleavable dipeptide is linked to "L2" via an amide bond, while the "L2" and "L3" moieties are coupled via azide-acetylene "click chemistry." [ka]

[0210] In another representative example, "L1" contains a single amino acid bound to a foldable p-aminobenzyl alcohol moiety, where the p-aminobenzyl alcohol is substituted or unsubstituted (R), and can be conjugated in the general conjugate formula Ab-[L3]-[L2]-[L1] m -AA n -drug, m=1 and n=0, and the drug is exemplified by SN-38. The structure is represented below (referred to as MAb-CLX-SN-38). The single amino acid AA can be selected from any one of the following L-amino acids: alanine, arginine, asparagine, aspartic acid, cysteine, glutamine, glutamic acid, glycine, histidine, isoleucine, leucine, lysine, methionine, phenylalanine, proline, serine, threonine, tryptophan, tyrosine, and valine. The substituent R of the 4-aminobenzyl alcohol moiety is hydrogen or an alkyl group selected from C1-C10 alkyl groups. [ka]

[0211] An embodiment of mAb-CLX-SN-38 (above) (called mAb-CL2A-SN-38) where the single amino acid AA is L-lysine and R=H and the drug is a cytotoxic agent exemplified by SN-38 is shown below: [ka]

[0212] In other embodiments, the drug is a cytotoxic agent attached to a linker comprising a Stretcher unit (Z) attached to an amino acid unit (AA) attached to a Spacer unit (Y), the Stretcher unit being attached to an antibody (or antigen-binding portion thereof or other binding agent, referred to as an Ab or MAb), and the Spacer unit being attached to an amino group of the cytotoxic agent. Such linkers have the following formula: Ab-Z-AA-Y-cytotoxic agent wherein Z is -(succinimide-3-yl-N)-(CH) n 2 -C(=O)-, -CH2-C(=O)-NH-(CH2)n 3 -C(=O)-, -C(=O)-cycHex(1,4)-CH2-(N-yl-3-diminiccuS)-, or --C(=O)--(CH2)n 4 -C(=O)-, n 2 represents an integer from 2 to 8, and n 3 represents an integer from 1 to 8, and n 4 represents an integer of 1 to 8; cyc.Hex(1,4) represents a 1,4-cyclohexylene group; (N-yl-3-diminiccuS)- represents a group represented by the following formula: [ka] (having a structure represented by It has.

[0213] In some embodiments, AA is a peptide of 2 to 7 amino acids. In some embodiments, the spacer unit Y is -NH-(CH) b-(C=O)- or -NH-CH2-O-CH2-(C=O)- (wherein b is an integer of 1 to 5).

[0214] In some embodiments, the cytotoxic agent is exatecan. In some embodiments, the amino acid unit (AA) is -Gly-Gly-Phe-Gly- (SEQ ID NO: 35). In some embodiments, the spacer unit Y is -NH-CH2-O-CH2-(C=O)-.

[0215] In some embodiments, the linker-cytotoxic agent has the following structure: [ka] and the released cytotoxic agent is DXd (see US Pat. No. 9,808,537).

[0216] Conjugation of Drug-Linkers to Antibodies, Antigen-Binding Moieties, and Other Binding Agents Techniques for attaching drugs to antibodies (or antigen-binding portions thereof or other binding agents) via linkers are well known in the art. See, e.g., Alley et al., Current Opinion in Chemical See Biology 2010 14:1-9; Senter, Cancer J., 2008, 14(3):154-169. In some embodiments, a linker is first attached to a drug (e.g., a cytotoxic agent), and then a drug-linker is attached to an antibody or antigen-binding portion thereof or other binding agent. In some embodiments, a linker is first attached to an antibody or antigen-binding portion thereof or other binding agent, and then a drug is attached to the linker. In the following discussion, the term drug-linker is used to illustrate the attachment of a linker or drug-linker to an antibody or antigen-binding portion thereof or other binding agent; one of ordinary skill in the art will recognize that the attachment method selected can be determined according to the linker and the cytotoxic agent or other drug. In some embodiments, a drug is attached to an antibody or antigen-binding portion thereof or other binding agent via a linker in a manner that reduces the activity of the drug until it is released from the conjugate (e.g., by hydrolysis, proteolysis, or a cleaving agent).

[0217] In general, conjugates can be prepared by several routes employing organic chemical reactions, conditions, and reagents known to those skilled in the art, including: (1) reacting a nucleophilic group on an antibody (or antigen-binding portion thereof or other binding agent) with a bivalent linker reagent to form an antibody-linker intermediate via a covalent bond, followed by reaction with a drug (e.g., a cytotoxic agent); and (2) reacting a nucleophilic group on a drug (e.g., a cytotoxic agent) with a bivalent linker reagent to form a drug-linker via a covalent bond, followed by reaction with a nucleophilic group on an antibody or antigen-binding portion thereof or other binding agent. An exemplary method for preparing conjugates via the latter route is described in U.S. Pat. No. 7,498,298, expressly incorporated herein by reference.

[0218] Nucleophilic groups on antibodies, antigen-binding moieties, and other binding agents include, but are not limited to, (i) N-terminal amine groups, (ii) side-chain amine groups, such as lysine, (iii) side-chain thiol groups, such as cysteine, and (iv) sugar hydroxyl or amino groups when the antibody is glycosylated. Amine groups, thiol groups, and hydroxyl groups are nucleophilic and can react to form covalent bonds with electrophilic groups on linker moieties and linker reagents, including (i) active esters such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl halides and benzyl halides, such as haloacetamides; and (iii) aldehyde groups, ketone groups, carboxyl groups, and maleimide groups. Certain antibodies (antigen-binding moieties and other binding agents) have reducible interchain disulfides, i.e., cysteine ​​bridges. Antibodies (and antigen-binding moieties and other binding agents) can be made reactive for conjugation with linker reagents by treating them with a reducing agent such as DTT (dithiothreitol) or tricarbonylethylphosphine (TCEP) so that the antibody is fully or partially reduced. Thus, each cysteine ​​bridge theoretically forms two reactive thiol nucleophiles. Additional nucleophilic groups can be introduced into antibodies (and antigen-binding moieties and other binding agents) through modification of lysine residues, for example, by reacting the residue with 2-iminothiolane (Traut's reagent) to convert the amine to a thiol. Reactive thiol groups can also be introduced into antibodies (and antigen-binding moieties and other binding agents) by introducing one, two, three, four, or more cysteine ​​residues (e.g., by preparing antibodies, antigen-binding moieties, and other binding agents containing one or more non-naturally occurring cysteine ​​amino acid residues).

[0219] Conjugates can also be generated by the reaction between an electrophilic group on an antibody (or antigen-binding portion thereof or other binding agent), such as an aldehyde or ketone carbonyl group, and a nucleophilic group on a linker reagent or drug. Useful nucleophilic groups on a linker reagent include, but are not limited to, hydrazide, oxime, amino, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide. In one embodiment, an antibody (or antigen-binding portion thereof or other binding agent) is modified to introduce an electrophilic moiety that can react with a nucleophilic substituent on a linker reagent or drug. In another embodiment, the sugar of a glycosylated antibody can be oxidized, for example, with a periodate oxidation reagent, to form an aldehyde or ketone group that can react with an amine group on a linker reagent or drug moiety. The resulting imine Schiff base group can form a stable bond or can be reduced, for example, with a borohydride reagent, to form a stable amine bond. In one embodiment, reaction of the carbohydrate moiety of a glycosylated antibody with either galactose oxidase or sodium metaperiodate can result in carbonyl (aldehyde and ketone) groups in the antibody (or its antigen-binding portion or other binding agent) that can react with appropriate groups on a drug (see, e.g., Hermanson, Bioconjugate Techniques). In another embodiment, an antibody containing an N-terminal serine or threonine residue can be reacted with sodium metaperiodate to generate an aldehyde in place of the first amino acid (Geoghegan & Stroh, (1992) Bioconjugate Chem. 3:138-146; U.S. Pat. No. 5,362,852). Such aldehydes can be reacted with cytotoxic agents or linkers.

[0220] Exemplary nucleophilic groups on drugs, such as cytotoxic agents, include, but are not limited to, (i) active esters, such as NHS esters, HOBt esters, haloformates, and acid halides; (ii) alkyl halides and benzyl halides, such as haloacetamides; and (iii) amine, thiol, hydroxyl, hydrazide, oxime, hydrazine, thiosemicarbazone, hydrazine carboxylate, and arylhydrazide groups, which can react to form covalent bonds with electrophilic groups on linker moieties and linker reagents, including aldehyde, ketone, carboxyl, and maleimide groups.

[0221] Non-limiting exemplary cross-linking agents that can be used to prepare conjugates are described herein or known to those skilled in the art. Methods for linking two moieties, including an antibody (or antigen-binding portion or other binding agent) and a chemical moiety, using such cross-linking agents are known in the art. In some embodiments, a fusion protein comprising an antibody and a drug can be produced, for example, by recombinant technology or peptide synthesis. A recombinant DNA molecule can include a region encoding an antibody (or its antigen-binding portion or other binding agent) and the active portion of the conjugate (e.g., a cytotoxic moiety) adjacent to each other or separated by a region encoding a linker that does not destroy the desired properties of the conjugate.

[0222] In some embodiments, the drug-linker is attached to an interchain cysteine ​​residue of an antibody (or antigen-binding portion thereof or other binding agent). See, e.g., WO 2004 / 010957 and WO 2005 / 081711. In such embodiments, the linker typically contains a maleimide group for attachment to the cysteine ​​residue of the interchain disulfide. In some embodiments, the linker or drug-linker is attached to a cysteine ​​residue of an antibody or antigen-binding portion thereof, as described in U.S. Pat. No. 7,585,491 or U.S. Pat. No. 8,080,250. The drug loading of the resulting conjugate is typically in the range of 1 to 8.

[0223] In some embodiments, the linker or drug-linker is attached to a lysine or cysteine ​​residue of an antibody (or antigen-binding portion thereof or other binding agent), as described in WO 2005 / 037992 or WO 2010 / 141566. The drug loading of the resulting conjugate is typically in the range of 1-8.

[0224] In some embodiments, engineered cysteine ​​residues, polyhistidine sequences, glycoengineered tags, or transglutaminase recognition sequences can be used for site-specific attachment of a linker or drug-linker to an antibody or antigen-binding portion thereof or other binding agent.

[0225] In some embodiments, the drug-linker is attached to an engineered cysteine ​​residue at an Fc residue other than the interchain disulfide. ..., in accordance with EU numbering of Kabat, in the heavy chain, 118, 221, 224, 227, 228, 230, 231, 223, 233, 234, 235, 236, 237, 238, 239, 240, 241, 243, 244, 245, 247, 249, 250, 258, 262, 263, 264, 265, 266, 267, 268, 269, 270, 271, 272, 273, 275, 276, 278, 280, 281, 283, 285, 286, 287, 288, 289, 290, 300, 301, 302, 303, 304, 305, 306, 307, 308, 309, 310, 311, 312, 313, 314, 315, 316, 317, 318, 319, 320, 321, 322, 323, 324, 325, 326, 327, 328, 329, 330 and / or 428, and / or to engineered cysteines introduced into the IgG (typically IgG1) at positions 106, 108, 142 (light chain), 149 (light chain), and / or V205. An exemplary substitution for site-specific conjugation using an engineered cysteine ​​is S239C (see, e.g., U.S. Patent Application Publication No. 20100158909; numbering of the Fc region is according to the EU index).

[0226] In some embodiments, the linker or drug-linker is attached to one or more introduced cysteine ​​residues of an antibody (or antigen-binding portion thereof or other binding agent), as described in WO2006 / 034488, WO2011 / 156328, and / or WO2016040856.

[0227] In some embodiments, an exemplary substitution for site-specific conjugation using bacterial transglutaminase is N297S or N297Q in the Fc region. In some embodiments, a linker or drug-linker is attached to the glycan or modified glycan of an antibody or antigen-binding moiety or a glycoengineered antibody (or other binding agent). For example, see International Publication Nos. WO 2017 / 147542, WO 2020 / 123425, WO 2020 / 245229, WO 2014 / 072482, WO 2014 / 065661, WO 2015 / 057066 and WO 2016 / 022027, the disclosures of which are incorporated herein by reference.

[0228] Pharmaceutical preparations Another aspect of the CD70 antibodies and antigen-binding portions thereof or other binding agents, as well as conjugates of any of these, relates to compositions comprising the active ingredient (i.e., a CD70 antibody or antigen-binding portion thereof or other binding agent described herein or a conjugate thereof, or a nucleic acid encoding an antibody or antigen-binding portion thereof or other binding agent described herein). In some embodiments, the composition is a pharmaceutical composition. As used herein, the term "pharmaceutical composition" refers to an active agent in combination with a pharmaceutically acceptable carrier accepted for use in the pharmaceutical industry. The phrase "pharmaceutically acceptable" is employed herein to refer to compounds, materials, compositions and / or dosage forms that are suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response or other problem or complication, within the scope of sound medical judgment and commensurate with a reasonable benefit / risk ratio.

[0229] The preparation of pharmacological compositions containing active ingredients dissolved or dispersed therein is well understood in the art and need not be limited based on a particular formulation. Typically, such compositions are prepared as injectables, either as liquid solutions or suspensions; however, solid forms or suspensions suitable for rehydration in liquid before use can also be prepared. The preparations can also be emulsified or presented as liposomal compositions. The CD70 antibody or its antigen-binding portion or other binding agent or conjugate thereof can be mixed with an excipient that is pharmaceutically acceptable and compatible with the active ingredient, in an amount suitable for use in the therapeutic methods described herein. Suitable excipients are, for example, water, saline, dextrose, glycerol, ethanol, etc., and combinations thereof. Additionally, if desired, pharmaceutical compositions can contain minor amounts of auxiliary substances, such as wetting or emulsifying agents, pH buffering agents, and the like, which enhance or maintain the effectiveness of the active ingredient (e.g., the CD70 antibody or its antigen-binding portion or other binding agent or conjugate thereof). The pharmaceutical compositions described herein can include pharmaceutically acceptable salts of the components therein. Pharmaceutically acceptable salts include acid addition salts (formed with the free amino groups of the polypeptide) formed with inorganic acids such as, for example, hydrochloric or phosphoric acid, or organic acids such as acetic, tartaric, or mandelic acid. Salts formed with free carboxyl groups can also be derived from inorganic bases such as, for example, sodium hydroxide, potassium hydroxide, ammonium hydroxide, calcium hydroxide, or ferric hydroxide, and organic bases such as isopropylamine, trimethylamine, 2-ethylaminoethanol, histidine, or procaine. Physiologically acceptable carriers are well known in the art. An exemplary liquid carrier is a sterile aqueous solution containing the active ingredient (e.g., a CD70 antibody and / or its antigen-binding portion or other binding agent or conjugate thereof) and water, which may contain both buffers such as sodium phosphate at physiological pH values, saline, or phosphate-buffered saline.Furthermore, aqueous carriers can contain two or more buffer salts, and salts such as sodium chloride and potassium chloride, dextrose, polyethylene glycol and other solutes.Liquid compositions can also contain liquid phases in addition to water and in addition to water.Examples of such additional liquid phases are glycerin, vegetable oils such as cottonseed oil, and water-oil emulsions.The amount of active agent that will be effective in treating a particular disorder or condition depends on the nature of the disorder or condition and can be determined by standard clinical techniques.

[0230] In some embodiments, a pharmaceutical composition comprising a CD70 antibody or antigen-binding portion thereof or other binding agent conjugate described herein, or a nucleic acid encoding a CD70 antibody or antigen-binding portion thereof or other binding agent described herein, may be a lyophilizate.

[0231] In some embodiments, a syringe containing a therapeutically effective amount of a CD70 antibody or antigen-binding portion thereof, or a conjugate thereof, or a pharmaceutical composition described herein is provided.

[0232] Cancer treatment In some embodiments, the CD70 antibodies or antigen-binding portions thereof, other binding agents and conjugates described herein may be used in a method comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate described herein to a subject in need thereof, such as a subject with cancer.

[0233] In some embodiments, methods are provided for treating cancer, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively. In some embodiments, methods are provided for treating cancer, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 3 and 4, respectively. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 5 and 6, respectively. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 7 and 8, respectively. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 9 and 10, respectively.In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:11 and SEQ ID NO:12, respectively.

[0234] In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively; and wherein the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region and VL region have the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:7 and SEQ ID NO:8, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region and VL region have the amino acid sequences set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region and VL region have the amino acid sequences set forth in SEQ ID NO:11 and SEQ ID NO:12, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0235] In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively; and wherein the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:7 and SEQ ID NO:8, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:11 and SEQ ID NO:12, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0236] In some embodiments, a method of treating cancer comprises administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and wherein the VH and VL The methods are provided, wherein the CDRs have the amino acid sequences set forth in a set of amino acid sequences selected from: (i) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (ii) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (iii) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (iv) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:18, respectively; and (v) SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0237] In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0238] In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0239] In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments of treating cancer, each VH and VL region comprises a human framework region.

[0240] In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:18, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0241] In some embodiments, methods of treating cancer are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0242] In some embodiments, the subject is in need of treatment for cancer and / or malignancies. In some embodiments, the subject is in need of treatment for a CD70+ cancer or CD70+ malignancy, such as hepatocellular carcinoma, colorectal cancer, pancreatic cancer, ovarian cancer, indolent non-Hodgkin's lymphoma (indolent NHL) (e.g., follicular NHL, small lymphocytic lymphoma, lymphoplasmacytic NHL, or marginal zone NHL), non-Hodgkin's lymphoma (non-indolent), cancers of the B-cell lineage, including Burkitt's lymphoma and chronic lymphocytic leukemia, multiple myeloma, renal cell carcinoma, nasopharyngeal carcinoma, thymic carcinoma, and glioma. In some embodiments, the method is for treating a subject with a CD70+ cancer or malignancy. In some embodiments, the method is for treating hepatocellular carcinoma in a subject. In some embodiments, the method is for treating colorectal cancer in a subject. In some embodiments, the method is for treating pancreatic cancer in a subject. In some embodiments, the method is for treating ovarian cancer in a subject. In some embodiments, the method is for treating an indolent non-Hodgkin's lymphoma (indolent NHL), such as, for example, follicular NHL, small lymphocytic lymphoma, lymphoplasmacytic NHL, or marginal zone NHL, in a subject. In some embodiments, the method is for treating a non-Hodgkin's lymphoma in a subject. In some embodiments, the method is for treating a cancer of the B-cell lineage, such as, for example, Burkitt's lymphoma or chronic lymphocytic leukemia, in a subject. In some embodiments, the method is for treating multiple myeloma in a subject. In some embodiments, the method is for treating renal cell carcinoma in a subject. In some embodiments, the method is for treating nasopharyngeal carcinoma in a subject. In some embodiments, the method is for treating thymic carcinoma in a subject. In some embodiments, the method is for treating glioma in a subject.

[0243] The methods described herein include administering a therapeutically effective amount of a CD70 binding antibody or antigen-binding portion thereof, or other binding agent, or conjugate thereof, to a subject with a CD70+ cancer or malignant tumor. As used herein, the phrase "therapeutically effective amount," "effective amount," or "effective dose" refers to an amount of a CD70 antibody or antigen-binding portion thereof, or other binding agent or conjugate described herein, that provides a therapeutic benefit in the treatment, management, or prevention of recurrence of a cancer or malignant tumor, e.g., an amount that provides a statistically significant reduction in at least one symptom, sign, or marker of a tumor or malignant tumor. Determining a therapeutically effective amount is well within the capabilities of one of ordinary skill in the art. Generally, a therapeutically effective amount may vary depending on the subject's medical history, age, condition, sex, and the severity and type of the subject's medical condition, as well as the administration of other pharmaceutically active agents.

[0244] The terms "cancer" and "malignant tumor" refer to the uncontrolled growth of cells that interferes with the normal function of bodily organs and systems. Cancer or malignant tumors may be primary or metastatic, i.e., invasive, seeding tumor growth in tissues distant from the original tumor site. A "tumor" refers to the uncontrolled growth of cells that interferes with the normal function of bodily organs and systems. A subject with cancer is one who has objectively measurable cancer cells present within the subject's body. This definition includes benign tumors and malignant cancers, as well as latent dormant tumors and micrometastases. Cancers that migrate from their original location and seed other vital organs can ultimately lead to the subject's death through the functional decline of the affected organ. Hematologic malignancies (hematopoietic cancers), such as leukemia and lymphoma, can, for example, overwhelm a subject's normal hematopoietic compartment, thereby resulting in hematopoietic failure (in the form of anemia, thrombocytopenia, and neutropenia) and ultimately death.

[0245] Examples of cancer include, but are not limited to, carcinoma, lymphoma, blastoma, sarcoma, and leukemia. More specific examples of such cancers include, but are not limited to, basal cell carcinoma, biliary tract cancer, bladder cancer, bone cancer, brain and CNS cancer, breast cancer (e.g., triple-negative breast cancer), peritoneal cancer, cervical cancer, bile duct cancer, choriocarcinoma, chondrosarcoma, colon and rectal cancer (colorectal cancer), connective tissue cancer, cancer of the digestive system, endometrial cancer, esophageal cancer, eye cancer, head and neck cancer, gastric cancer (including gastrointestinal cancer and gastric cancer), glioblastoma (GBM). , liver cancer, hepatoma, intraepithelial neoplasia, kidney or renal cancer (e.g., clear cell carcinoma), laryngeal cancer, leukemia, liver cancer, lung cancer (e.g., small cell lung cancer, non-small cell lung cancer, lung adenocarcinoma, and lung squamous cell carcinoma), lymphoma including Hodgkin's lymphoma and non-Hodgkin's lymphoma, melanoma, mesothelioma, myeloma, neuroblastoma, oral cancer (e.g., lip, tongue, mouth, and pharynx), ovarian cancer, pancreatic cancer, prostate cancer, retinoblastoma, rhabdomyosarcoma, respiratory system cancer , salivary gland cancer, sarcoma, skin cancer, squamous cell carcinoma, testicular cancer, thyroid cancer, uterine or endometrial cancer, uterine serous carcinoma, urinary system cancer, vulvar cancer; and other carcinomas and sarcomas, as well as B-cell lymphomas (low-grade / follicular non-Hodgkin's lymphoma (NHL), small lymphocytic (SL) NHL, intermediate-grade / follicular NHL, intermediate-grade diffuse NHL, high-grade immunoblastic NHL, high-grade lymphoblastic NHL, high-grade small non-cleaved nucleus NHL, These include: bladder NHL, bulky lesion NHL, mantle cell lymphoma, AIDS-related lymphoma, and Waldenstrom's macroglobulinemia), chronic lymphocytic leukemia (CLL), acute lymphoblastic leukemia (ALL), hairy cell leukemia, chronic myeloblastic leukemia, and post-transplant lymphoproliferative disorder (PTLD), as well as abnormal blood vessel proliferation associated with phacomatosis, edema (such as that associated with brain tumors), and Meigs syndrome.

[0246] In some embodiments, the cancer is a solid tumor. In some embodiments, the cancer is selected from solid tumors, including but not limited to, hepatocellular carcinoma, colorectal cancer, renal cell carcinoma, pancreatic cancer, ovarian cancer, nasopharyngeal carcinoma, thymic carcinoma, and glioma. In some embodiments, the cancer is selected from blood cancers, also known as hematologic malignancies. In some embodiments, the cancer is selected from blood cancers, such as low-grade non-Hodgkin's lymphoma (low-grade NHL) (e.g., follicular NHL, small lymphocytic lymphoma, lymphoplasmacytic NHL, or marginal zone NHL), non-Hodgkin's lymphoma (non-low-grade), such as NS cancers of B-cell lineage, including Burkitt's lymphoma and chronic lymphocytic leukemia. In some embodiments, the cancer or malignant tumor is CD70 positive (CD70+). As used herein, the term "CD70 positive" or "CD70+" is used to describe cancer cells, clusters of cancer cells, tumor masses, or metastatic cells that express CD70 on the cell surface (membrane-bound CD70). Some non-limiting examples of CD70-positive cancers include hepatocellular carcinoma, colorectal cancer, pancreatic cancer, ovarian cancer, low-grade non-Hodgkin's lymphoma (low-grade NHL) (e.g., follicular NHL, small lymphocytic lymphoma, lymphoplasmacytic NHL, or marginal zone NHL), non-Hodgkin's lymphoma, B-cell lineage cancer including Burkitt's lymphoma and chronic lymphocytic leukemia, multiple myeloma, renal cell carcinoma, nasopharyngeal carcinoma, thymic carcinoma, and glioma.

[0247] It is contemplated that the methods herein reduce tumor size or tumor burden in a subject and / or reduce metastasis in a subject. In various embodiments, the subject's tumor size is reduced by about 25-50%, about 40-70%, or about 50-90% or more. In various embodiments, the method reduces tumor size by 10%, 20%, 30% or more. In various embodiments, the method reduces tumor size by 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 100%.

[0248] As used herein, "subject" refers to a human or an animal. Typically, an animal is a vertebrate, such as a primate, a rodent, a domestic animal, or a game animal. Primates include chimpanzees, cynomolgus monkeys, spider monkeys, and macaques, such as rhesus monkeys. Rodents include mice, rats, woodchucks, ferrets, rabbits, and hamsters. Domestic and game animals include cattle, horses, pigs, deer, bison, buffalo, feline species, such as domestic cats, canine species, such as dogs, foxes, wolves, avian species, such as chickens, emus, ostriches, and fish, such as trout, catfish, and salmon. In certain embodiments, the subject is a mammal, such as a primate, for example, a human. The terms "patient," "individual," and "subject" are used interchangeably herein.

[0249] Preferably, the subject is a mammal. The mammal can be, but is not limited to, a human, a non-human primate, a mouse, a rat, a dog, a cat, a horse, or a cow. Non-human mammals can be advantageously used as subjects to represent animal models of, for example, various cancers. Furthermore, the methods described herein can be used to treat domestic animals and / or pets. The subject can be male or female. In certain embodiments, the subject is a human.

[0250] In some embodiments, the subject may be a subject who has previously been diagnosed with or identified as having a CD70+ cancer and is in need of treatment, but need not have already been treated for the CD70+ cancer. In some embodiments, the subject may also be a subject who has not previously been diagnosed with a CD70+ cancer in need of treatment. In some embodiments, the subject may be a subject who exhibits one or more risk factors for a condition or one or more complications associated with a CD70+ cancer, or a subject who does not exhibit risk factors. A subject "in need" of treatment for a CD70+ cancer may specifically be a subject who has the condition or has been diagnosed with the condition. In other embodiments, a subject "at risk of developing" a condition refers to a subject who has been diagnosed with a condition (e.g., a CD70+ cancer) at risk of developing the condition or at risk of re-experiencing the condition.

[0251] As used herein, the terms "treat," "treatment," "treating," or "amelioration," when used in reference to a disease, disorder, or medical condition, refer to therapeutic treatment of a condition with the goal of reversing, alleviating, ameliorating, inhibiting, slowing, or halting the progression or severity of the symptom or condition. The term "treating" includes reducing or alleviating at least one adverse effect or symptom of the condition. Treatment is generally "effective" if one or more symptoms or clinical markers are reduced. Alternatively, treatment is "effective" if the progression of the condition is reduced or halted. That is, "treatment" includes not only the improvement of symptoms or markers, but also the cessation of symptoms or at least a delay in progression or worsening that would be expected in the absence of treatment. Beneficial or desired clinical results include, but are not limited to, a reduction in CD70+ cancer cells in a subject, alleviation of one or more symptoms, a reduction in the degree of the defect, a stabilized (i.e., non-worsening) state of cancer or malignancy, a delay or slowing of tumor growth and / or metastasis, and an increase in lifespan compared to that expected in the absence of treatment. As used herein, the term "administering" refers to providing a CD70 binding antibody or antigen-binding portion thereof or other binding agent or conjugate described herein, or a nucleic acid encoding a CD70 antibody or antigen-binding portion thereof or other binding agent described herein, to a subject by a method or route that results in binding of the CD70 binding antibody or antigen-binding portion thereof or other binding agent or conjugate to CD70+ cancer or malignant cells. Similarly, a pharmaceutical composition comprising a CD70 binding antibody or antigen-binding portion thereof or other binding agent or conjugate described herein, or a nucleic acid encoding a CD70 antibody or antigen-binding portion thereof or other binding agent disclosed herein, can be administered by any suitable route that results in effective treatment in the subject.

[0252] The dosage range for a CD70-binding antibody or antigen-binding portion thereof or binding agent or conjugate depends on potency and includes an amount large enough to produce the desired effect, such as slowing tumor growth or reducing tumor size. The dosage should not be so large as to cause unacceptable adverse side effects. Generally, dosages vary depending on the age, condition, and sex of the subject and can be determined by one of ordinary skill in the art. Dosages may also be adjusted by an individual physician in the event of any complications. In some embodiments, dosages range from 0.1 mg / kg to 10 mg / kg body weight. In some embodiments, dosages range from 0.5 mg / kg to 15 mg / kg body weight. In some embodiments, dosages range from 0.5 mg / kg to 5 mg / kg body weight. Alternatively, dosages can be titrated to maintain serum levels between 1 μg / mL and 1000 μg / mL. For systemic administration, a subject can be administered a therapeutic amount, such as, for example, 0.1 mg / kg, 0.5 mg / kg, 1.0 mg / kg, 2.0 mg / kg, 2.5 mg / kg, 5 mg / kg, 10 mg / kg, 12 mg / kg or more.

[0253] The administration of the doses listed above can be repeated.In a preferred embodiment, the doses listed above are administered every week, every other week, every 3 weeks or every month for several weeks or months.The duration of treatment depends on the clinical progress of the patient and the responsiveness to treatment.

[0254] In some embodiments, the dose may be about 0.1 mg / kg to about 100 mg / kg. In some embodiments, the dose may be about 0.1 mg / kg to about 25 mg / kg. In some embodiments, the dose may be about 0.1 mg / kg to about 20 mg / kg. In some embodiments, the dose may be about 0.1 mg / kg to about 15 mg / kg. In some embodiments, the dose may be about 0.1 mg / kg to about 12 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 100 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 25 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 20 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 15 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 12 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 10 mg / kg.

[0255] In some embodiments, the dose may be administered intravenously. In some embodiments, the intravenous administration may be an infusion administered over a period of about 10 minutes to about 4 hours. In some embodiments, the intravenous administration may be an infusion administered over a period of about 30 minutes to about 90 minutes.

[0256] In some embodiments, the dose may be administered weekly. In some embodiments, the dose may be administered every other week. In some embodiments, the dose may be administered about every two weeks. In some embodiments, the dose may be administered about every three weeks. In some embodiments, the dose may be administered every four weeks.

[0257] In some embodiments, a total of about 2 to about 10 doses are administered to the subject. In some embodiments, a total of 4 doses are administered. In some embodiments, a total of 5 doses are administered. In some embodiments, a total of 6 doses are administered. In some embodiments, a total of 7 doses are administered. In some embodiments, a total of 8 doses are administered. In some embodiments, a total of 9 doses are administered. In some embodiments, a total of 10 doses are administered. In some embodiments, more than 10 doses are administered.

[0258] Pharmaceutical compositions containing a CD70 binding antibody or antigen-binding portion thereof, or other CD70-binding agent or CD70 conjugate thereof can be administered in unit doses. The term "dose unit," when used in reference to pharmaceutical compositions, refers to physically discrete units suitable as unitary dosages for subjects, each unit containing a predetermined quantity of active material (e.g., a CD70 binding antibody or antigen-binding portion thereof, or other binding agent or conjugate thereof) calculated to produce a desired therapeutic effect, together with the required physiologically acceptable diluent, i.e., carrier or vehicle.

[0259] In some embodiments, the CD70 binding antibody or its antigen-binding portion or other binding agent or its conjugate, or any of these pharmaceutical compositions, is administered together with immunotherapy.As used herein, "immunotherapy" refers to a therapeutic strategy designed to induce or enhance the subject's own immune system to fight cancer or malignant tumors.Examples of immunotherapy include, but are not limited to, antibodies such as checkpoint inhibitors.

[0260] In some embodiments, immunotherapy involves administration of a checkpoint inhibitor. In some embodiments, immune checkpoint inhibitors include agents that inhibit CTLA-4, PD-1, PD-L1, etc. Suitable anti-CTLA-4 inhibitors include, for example, ipilimumab, tremelimumab, antibodies disclosed in PCT Publication No. WO 2001 / 014424, antibodies disclosed in PCT Publication No. WO 2004 / 035607, antibodies disclosed in U.S. Patent Application Publication No. 2005 / 0201994, and antibodies disclosed in granted European Patent No. 1212422. Additional anti-CTLA-4 antibodies are described in U.S. Patent Nos. 5,811,097, 5,855,887, 6,051,227, and 6,984,720; PCT Publication Nos. WO 01 / 14424 and WO 00 / 37504; and U.S. Patent Application Publication Nos. 2002 / 0039581 and 2002 / 086014. Other anti-CTLA-4 antibodies that can be used in the methods of the invention include those disclosed, for example, in WO 98 / 42752; U.S. Pat. Nos. 6,682,736 and 6,207,156; Hurwitz et al., Proc. Natl. Acad. Sci. USA, 95(17):10067-10071 (1998); Camacho et al., J. Clin. Oncology, 22(145):Abstract No. 2505 (2004) (antibody CP-675206); Mokyr et al., Cancer Res, 58:5301-5304 (1998), U.S. Pat. Nos. 5,977,318, 6,682,736, 7,109,003, and 7,132,281.

[0261] Suitable anti-PD-1 inhibitors include, for example, nivolumab, pembrolizumab, pidilizumab, MEDI0680, and combinations thereof. In other specific embodiments, anti-PD-L1 therapeutic agents include atezolizumab, BMS-936559, MEDI4736, MSB0010718C, and combinations thereof.

[0262] Suitable anti-PD-1 inhibitors include, for example, those described in Topalian et al., Immune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy, Cancer Cell 27:450-61 (April 13, 2015), which is incorporated herein by reference in its entirety.

[0263] In some embodiments, the checkpoint inhibitor is ipilimumab (Yervoy), nivolumab (Opdivo), pembrolizumab (Keytruda), atezolizumab (Tecentriq), avelumab (Bavencio), or durvalumab (Imfinzi).

[0264] In some embodiments, methods are provided for improving therapeutic outcomes in subjects receiving immunotherapy. The methods generally include administering an effective amount of immunotherapy to a subject with cancer; and administering to the subject a therapeutically effective amount of a CD70 antibody, antigen-binding portion, other binding agent, or conjugate thereof, or a pharmaceutical composition thereof, wherein the CD70 antibody, antigen-binding portion, other binding agent, or conjugate thereof specifically binds to CD70+ cancer cells; and improving the subject's therapeutic outcome compared to administration of immunotherapy alone. In some embodiments, the CD70 antibody, antigen-binding portion, other binding agent, or conjugate thereof comprises any of the embodiments of the CD70 antibody, antigen-binding portion, other binding agent, or conjugate thereof described herein.

[0265] In some embodiments, the improved outcome is an objective response selected from stable disease, partial response, or complete response as determined by standard medical criteria for the cancer being treated. In some embodiments, the improved outcome is a reduction in tumor burden. In some embodiments, the improved outcome is progression-free survival or disease-free survival.

[0266] Treatment of autoimmune diseases In some embodiments, the CD70 antibodies or antigen-binding portions thereof, other binding agents and conjugates described herein may be used in a method comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate described herein to a subject in need thereof, such as a subject with an autoimmune disease.

[0267] In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively. In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 3 and 4, respectively. In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 5 and 6, respectively. In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 7 and 8, respectively. In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NOs: 9 and 10, respectively.In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:11 and SEQ ID NO:12, respectively.

[0268] In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively; and wherein the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:7 and SEQ ID NO:8, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:11 and SEQ ID NO:12, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with 1 to 8, 1 to 6, 1 to 4, or 1 to 2 conservative amino acid substitutions within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0269] In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in a pair of amino acid sequences selected from SEQ ID NOs: 3 and 4, respectively; SEQ ID NOs: 5 and 6, respectively; SEQ ID NOs: 7 and 8, respectively; SEQ ID NOs: 9 and 10, respectively; and SEQ ID NOs: 11 and 12, respectively; and wherein the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:3 and SEQ ID NO:4, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:5 and SEQ ID NO:6, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:7 and SEQ ID NO:8, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods are provided for treating an autoimmune disease, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:9 and SEQ ID NO:10, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified. In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH and VL regions have the amino acid sequences set forth in SEQ ID NO:11 and SEQ ID NO:12, respectively; the heavy chain variable framework region and the light chain variable framework region are optionally modified with substitution, deletion, or insertion of 1 to 8, 1 to 6, 1 to 4, or 1 to 2 amino acids within the framework regions, and wherein the CDRs of the heavy chain variable region or the light chain variable region are unmodified.

[0270] In some embodiments, a method of treating an autoimmune disease comprises administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and wherein the VH and VL The methods are provided, wherein the CDRs have the amino acid sequences set forth in a set of amino acid sequences selected from: (i) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (ii) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (iii) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively; (iv) SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:18, respectively; and (v) SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0271] In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0272] In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0273] In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0274] In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25, and SEQ ID NO:18, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0275] In some embodiments, methods of treating an autoimmune disease are provided, comprising administering a CD70 antibody or antigen-binding portion thereof or other binding agent or conjugate thereof comprising a heavy chain variable region (VH) and a light chain variable region (VL), wherein the VH region comprises complementarity-determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, and the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs have the amino acid sequences set forth in SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, and SEQ ID NO: 26, respectively. In some embodiments, each VH and VL region comprises a humanized framework region. In some embodiments, each VH and VL region comprises a human framework region.

[0276] In some embodiments, a subject is in need of treatment for an autoimmune disease. The methods described herein include administering a therapeutically effective amount of a CD70 binding antibody or antigen-binding portion thereof, or other binding agent, or conjugate thereof, to a subject with an autoimmune disease. As used herein, the phrases "therapeutically effective amount," "effective amount," or "effective dose" refer to an amount of a CD70 antibody or antigen-binding portion thereof, or other binding agent or conjugate described herein, that provides a therapeutic benefit in the treatment, management, or prevention of recurrence of an autoimmune disease, e.g., an amount that provides a statistically significant reduction in at least one symptom, sign, or marker of an autoimmune disease. Determining a therapeutically effective amount is well within the capabilities of one skilled in the art. Generally, a therapeutically effective amount may vary depending on the subject's medical history, age, condition, sex, and the severity and type of the subject's medical condition, as well as the administration of other pharmaceutically active agents.

[0277] The term "autoimmune disease" refers to an immunological disorder characterized by the expression of CD70 due to inappropriate activation of immune cells (e.g., lymphocytes or dendritic cells), which interferes with the normal function of the body's organs and systems. Examples of autoimmune diseases include, but are not limited to, rheumatoid arthritis, psoriatic arthritis, autoimmune demyelinating diseases (e.g., multiple sclerosis, allergic encephalomyelitis), endocrine eye disorders, uveitis, systemic lupus erythematosus, myasthenia gravis, Graves' disease, glomerulonephritis, autoimmune liver disorders, inflammatory bowel diseases (e.g., Crohn's disease), anaphylaxis, allergic reactions, Sjogren's syndrome, type 1 diabetes, primary biliary cirrhosis, Wegener's granulomatosis, fibromyalgia, polymyositis, dermatomyositis, polyendocrine deficiency, schwannosis gravis, and schwannosis gravis. Mitt's syndrome, autoimmune uveitis, Addison's disease, adrenalitis, thyroiditis, Hashimoto's thyroiditis, autoimmune thyroid disease, pernicious anemia, gastric atrophy, chronic hepatitis, lupoid hepatitis, atherosclerosis, subacute cutaneous lupus erythematosus, hypoparathyroidism, Dressler's syndrome, autoimmune thrombocytopenia, idiopathic thrombocytopenic purpura, hemolytic anemia, pemphigus vulgaris, pemphigus folliculorum, dermatitis herpetiformis, alopecia areata, pemphigoid, scleroderma, progressive systemic sclerosis, CREST syndrome (calcinosis, Raynaud's phenomenon, esophageal hypoperistalsis, sclerodactyly, and Telangiectasia), male and female autoimmune infertility, ankylosing spondylitis, ulcerative colitis, mixed connective tissue disease, polyarteritis nodosa, systemic necrotizing vasculitis, atopic dermatitis, atopic rhinitis, Goodpasture's syndrome, Chagas' disease, sarcoidosis, rheumatic fever, asthma, recurrent miscarriage, antiphospholipid syndrome, farmer's lung, erythema multiforme, postcardiotomy syndrome, Cushing's syndrome, autoimmune chronic active hepatitis, bird fancier's disease, toxic epidermal necrolysis, Alport's syndrome, alveolitis, allergic alveolitis, fibrosing alveolitis, interstitial lung disease , erythema nodosum, pyoderma gangrenosum, transfusion reactions, Takayasu's arteritis, polymyalgia rheumatica, temporal arteritis, schistosomiasis, giant cell arteritis, ascariasis, aspergillosis, Samter's syndrome, eczema, lymphomatoid granulomatosis, Behçet's disease, Kaplan's syndrome, Kawasaki disease, dengue fever, encephalomyelitis, endocarditis, endomyocardial fibrosis, endophthalmitis, erythema elevata, psoriasis, erythroblastosis fetalis, eosinophilic fasciitis, Shulman's syndrome, Felty's syndrome, filariasis, cyclitis, chronic cyclitis, heterochromatic cyclitis, Fuchs' cyclitis, IgA nephropathy,These include Henoch-Schönlein purpura, graft-versus-host disease, transplant rejection, cardiomyopathy, Eaton-Lambert syndrome, relapsing polychondritis, cryoglobulinemia, Waldenström macroglobulinemia, Evans syndrome, and autoimmune hypogonadism.

[0278] In some embodiments, the methods described herein encompass treatment of disorders of B lymphocytes (e.g., systemic lupus erythematosus, Goodpasture's syndrome, rheumatoid arthritis, and type I diabetes), Th1 lymphocytes (e.g., rheumatoid arthritis, multiple sclerosis, psoriasis, Sjogren's syndrome, Hashimoto's thyroiditis, Graves' disease, primary biliary cirrhosis, Wegener's granulomatosis, tuberculosis, or graft-versus-host disease), or Th2 lymphocytes (e.g., atopic dermatitis, systemic lupus erythematosus, atopic asthma, rhinoconjunctivitis, allergic rhinitis, Omenn's syndrome, systemic sclerosis, or chronic graft-versus-host disease). Generally, disorders involving dendritic cells involve disorders of Th1 lymphocytes or Th2 lymphocytes.

[0279] In some embodiments, the immunological disorder is a T cell-mediated immunological disorder, such as a T cell disorder in which activated T cells associated with the disorder express CD70. CD70 antibodies, antigen-binding portions, other binding agents, and conjugates can be administered to deplete such CD70-expressing activated T cells. In specific embodiments, administration of CD70 antibody antigen-binding portions, other binding agents, and conjugates can deplete CD70-expressing activated T cells, but resting T cells are not substantially depleted by the anti-CD70 antigen-binding portions, other binding agents, and conjugates. In this context, "not substantially depleted" means that less than about 60%, or less than about 70%, or less than about 80% of resting T cells are not depleted.

[0280] As used herein, "subject" refers to a human or an animal. Typically, an animal is a vertebrate, such as a primate, a rodent, a domestic animal, or a game animal. Primates include chimpanzees, cynomolgus monkeys, spider monkeys, and macaques, such as rhesus monkeys. Rodents include mice, rats, woodchucks, ferrets, rabbits, and hamsters. Domestic and game animals include cattle, horses, pigs, deer, bison, buffalo, feline species, such as domestic cats, canine species, such as dogs, foxes, wolves, avian species, such as chickens, emus, ostriches, and fish, such as trout, catfish, and salmon. In certain embodiments, the subject is a mammal, such as a primate, for example, a human. The terms "patient," "individual," and "subject" are used interchangeably herein.

[0281] Preferably, the subject is a mammal. The mammal may be, but is not limited to, a human, a non-human primate, a mouse, a rat, a dog, a cat, a horse, or a cow. Non-human mammals can be advantageously used as subjects that represent animal models of, for example, various autoimmune diseases. Furthermore, the methods described herein can be used to treat domestic animals and / or pets. The subject may be male or female. In certain embodiments, the subject is a human.

[0282] In some embodiments, the subject may be a subject who has previously been diagnosed with an autoimmune disease or who has been identified as suffering from an autoimmune disease and who is in need of treatment, but who does not necessarily have already received treatment for the autoimmune disease. In some embodiments, the subject may also be a subject who has not previously been diagnosed with an autoimmune disease in need of treatment. In some embodiments, the subject may be a subject who exhibits one or more risk factors for a condition or one or more complications associated with an autoimmune disease, or a subject who does not exhibit risk factors. A subject "in need" of treatment for an autoimmune disease may specifically be a subject who has the condition or has been diagnosed with the condition. In other embodiments, a subject "at risk of developing" a condition refers to a subject who has been diagnosed with an autoimmune disease (e.g., an autoimmune disease) who is at risk of developing the condition or at risk of re-experiencing the condition.

[0283] As used herein, the terms "treat," "treatment," "treating," or "amelioration," when used in reference to a disease, disorder, or medical condition, refer to therapeutic treatment of a condition with the goal of reversing, alleviating, ameliorating, inhibiting, slowing, or halting the progression or severity of the symptom or condition. The term "treating" includes reducing or alleviating at least one adverse effect or symptom of the condition. Treatment is generally "effective" if one or more symptoms or clinical markers are reduced. Alternatively, treatment is "effective" if the progression of the condition is reduced or halted. That is, "treatment" includes not only the improvement of symptoms or markers, but also the cessation of symptoms or at least a delay in the progression or worsening of symptoms that would be expected in the absence of treatment. Beneficial or desired clinical results include, but are not limited to, a decrease in a subject's CD70+ autoimmune cells, a reduction in one or more symptoms, a decrease in the degree of deficiency, a stabilized (i.e., non-worsening) state of the autoimmune disease, a delay or slowing of the progression of the autoimmune disease, and an increase in lifespan compared to that expected in the absence of treatment. As used herein, the term "administering" refers to providing a CD70 binding antibody or antigen-binding portion thereof, or other binding agent or conjugate described herein, or a nucleic acid encoding a CD70 antibody or antigen-binding portion thereof, or other binding agent described herein, to a subject by a method or route that results in binding of the CD70 binding antibody or antigen-binding portion thereof, or other binding agent or conjugate to CD70+ autoimmune cells. Similarly, a pharmaceutical composition comprising a CD70 binding antibody or antigen-binding portion thereof, or other binding agent or conjugate described herein, or a nucleic acid encoding a CD70 antibody or antigen-binding portion thereof, or other binding agent disclosed herein, can be administered by any suitable route that results in effective treatment in the subject.

[0284] The dosage range for a CD70-binding antibody or antigen-binding portion thereof or binding agent or conjugate depends on potency and includes an amount large enough to produce the desired effect, e.g., slowing the progression of an autoimmune disease or reducing symptoms. The dosage should not be so large as to cause unacceptable adverse side effects. Generally, dosages vary depending on the age, condition, and sex of the subject and can be determined by one of ordinary skill in the art. Dosages may also be adjusted by an individual physician in the event of any complications. In some embodiments, dosages range from 0.1 mg / kg to 10 mg / kg body weight. In some embodiments, dosages range from 0.5 mg / kg to 15 mg / kg body weight. In some embodiments, dosages range from 0.5 mg / kg to 5 mg / kg body weight. Alternatively, dosages can be titrated to maintain serum levels between 1 μg / mL and 1000 μg / mL. For systemic administration, a subject can be administered a therapeutic amount, such as, for example, 0.1 mg / kg, 0.5 mg / kg, 1.0 mg / kg, 2.0 mg / kg, 2.5 mg / kg, 5 mg / kg, 10 mg / kg, 12 mg / kg or more.

[0285] The administration of the doses listed above can be repeated.In a preferred embodiment, the doses listed above are administered every week, every other week, every 3 weeks or every month for several weeks or months.The duration of treatment depends on the clinical progress of the patient and the responsiveness to treatment.

[0286] In some embodiments, the dose may be about 0.1 mg / kg to about 100 mg / kg. In some embodiments, the dose may be about 0.1 mg / kg to about 25 mg / kg. In some embodiments, the dose may be about 0.1 mg / kg to about 20 mg / kg. In some embodiments, the dose may be about 0.1 mg / kg to about 15 mg / kg. In some embodiments, the dose may be about 0.1 mg / kg to about 12 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 100 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 25 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 20 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 15 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 12 mg / kg. In some embodiments, the dose may be about 1 mg / kg to about 10 mg / kg.

[0287] In some embodiments, the dose may be administered intravenously. In some embodiments, the intravenous administration may be an infusion administered over a period of about 10 minutes to about 4 hours. In some embodiments, the intravenous administration may be an infusion administered over a period of about 30 minutes to about 90 minutes.

[0288] In some embodiments, the dose may be administered weekly. In some embodiments, the dose may be administered every other week. In some embodiments, the dose may be administered about every two weeks. In some embodiments, the dose may be administered about every three weeks. In some embodiments, the dose may be administered every four weeks.

[0289] In some embodiments, a total of about 2 to about 10 doses are administered to the subject. In some embodiments, a total of 4 doses are administered. In some embodiments, a total of 5 doses are administered. In some embodiments, a total of 6 doses are administered. In some embodiments, a total of 7 doses are administered. In some embodiments, a total of 8 doses are administered. In some embodiments, a total of 9 doses are administered. In some embodiments, a total of 10 doses are administered. In some embodiments, more than 10 doses are administered.

[0290] Pharmaceutical compositions containing a CD70 binding antibody or antigen-binding portion thereof, or other CD70-binding agent or CD70 conjugate thereof can be administered in unit doses. The term "dose unit," when used in reference to pharmaceutical compositions, refers to physically discrete units suitable as unitary dosages for subjects, each unit containing a predetermined quantity of active material (e.g., a CD70 binding antibody or antigen-binding portion thereof, or other binding agent or conjugate thereof) calculated to produce a desired therapeutic effect, together with the required physiologically acceptable diluent, i.e., carrier or vehicle.

[0291] In some embodiments, the CD70 binding antibody or antigen-binding portion thereof, other binding agent, or conjugate thereof, or pharmaceutical composition of any of these, is administered in conjunction with immunosuppressive therapy. In some embodiments, a method for improving therapeutic outcome in a subject receiving immunosuppressive therapy is provided. The method generally comprises administering an effective amount of immunosuppressive therapy to a subject with an autoimmune disorder; and administering to the subject a therapeutically effective amount of a CD70 antibody, antigen-binding portion, other binding agent, or conjugate thereof, or pharmaceutical composition thereof, wherein the CD70 antibody, antigen-binding portion, other binding agent, or conjugate thereof specifically binds to CD70+ autoimmune cells; and the subject's therapeutic outcome is improved compared to administration of immunotherapy alone. In some embodiments, the CD70 antibody, antigen-binding portion, other binding agent, or conjugate thereof comprises any of the embodiments of the CD70 antibody, antigen-binding portion, other binding agent, or conjugate thereof described herein. In some embodiments, the improved therapeutic outcome is a reduction in disease progression, alleviation of one or more symptoms, etc.

[0292] The present invention is further illustrated by the following embodiments, which should not be construed as limiting. 1. Heavy chain variable (VH) region and light chain variable (VL) region A binder comprising The VH region comprises complementarity determining regions HCDR1, HCDR2, and HCDR3 arranged in heavy chain variable region framework regions, the VL region comprises LCDR1, LCDR2, and LCDR3 arranged in light chain variable region framework regions, and the VH and VL CDRs are SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:13, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, respectively; SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:14, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, respectively; SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:15, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:26, respectively; SEQ ID NO:21, SEQ ID NO:22, SEQ ID NO:23, SEQ ID NO:24, SEQ ID NO:25 and SEQ ID NO:18, respectively; and SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26, respectively A binding agent having an amino acid sequence selected from the set of amino acid sequences set forth in the group consisting of: 2. The VH region and the VL region are each SEQ ID NO:3 and SEQ ID NO:4; SEQ ID NO:5 and SEQ ID NO:6; SEQ ID NO:7 and SEQ ID NO:8; SEQ ID NO: 9 and SEQ ID NO: 10; and SEQ ID NO: 11 and SEQ ID NO: 12 2. The binding agent of embodiment 1, having an amino acid sequence selected from the pair of amino acid sequences set forth in the group consisting of: 3. The VH region and the VL region are each SEQ ID NO:3 and SEQ ID NO:4; SEQ ID NO:5 and SEQ ID NO:6; SEQ ID NO:7 and SEQ ID NO:8; SEQ ID NO: 9 and SEQ ID NO: 10; and SEQ ID NO: 11 and SEQ ID NO: 12 and having an amino acid sequence selected from the pair of amino acid sequences shown in the group consisting of: 2. The binding agent of embodiment 1, wherein the heavy chain framework regions and the light chain framework regions are optionally modified by substitution, deletion or insertion of 1 to 8 amino acids within the framework regions. 4. The binding agent according to any one of embodiments 1 to 3, wherein HCDR1, HCDR2 and HCDR3 and LCDR1, LCDR2 and LCDR3 have the amino acid sequences set forth in SEQ ID NO: 21, SEQ ID NO: 22 and SEQ ID NO: 15, and SEQ ID NO: 24, SEQ ID NO: 25 and SEQ ID NO: 26, respectively. 5. The binding agent of embodiment 1, wherein the framework regions are human framework regions. 6. The binding agent of any one of embodiments 1 to 5, which is an antibody or an antigen-binding portion thereof. 7. The binding agent of any one of embodiments 1 to 6, which is a monoclonal antibody, Fab, Fab', F(ab'), Fv, disulfide-linked Fc, scFv, single domain antibody, diabody, bispecific antibody, or multispecific antibody. 8. The binding agent of any one of embodiments 1 to 7, wherein the heavy chain variable region further comprises a heavy chain constant region. 9. The binding agent of embodiment 8, wherein the heavy chain constant region is of the IgG isotype. 10. The binding agent of embodiment 9, wherein the heavy chain constant region is an IgG1 constant region. 11. The binding agent of embodiment 8, wherein the heavy chain constant region is an IgG4 constant region. 12. The binding agent of embodiment 10, wherein the IgG1 constant region has the amino acid sequence set forth in SEQ ID NO: 28. 13. The binding agent of any one of embodiments 1 to 12, wherein the light chain variable region further comprises a light chain constant region. 14. The binding agent of embodiment 13, wherein the light chain constant region is of the kappa isotype. 15. The binding agent of embodiment 14, wherein the light chain constant region has the amino acid sequence set forth in SEQ ID NO: 29. 16. The binding agent of any one of embodiments 8 to 18, wherein the heavy chain constant region further comprises an amino acid modification that reduces binding affinity to at least human Fc gamma RIII. 17. The binding agent of any one of embodiments 1 to 16, which is monospecific. 18. The binding agent of any one of embodiments 1 to 17, which is bivalent. 19. The binding agent of any one of embodiments 1 to 17, which is bispecific. 20. A pharmaceutical composition comprising the binding agent of any one of embodiments 1 to 19 and a pharmaceutically acceptable carrier. 21. A nucleic acid encoding a binding agent according to any one of embodiments 1 to 19. 22. A vector comprising the nucleic acid of embodiment 21. 23. A cell line comprising the vector of embodiment 22. 24. A binder according to any one of embodiments 1 to 19, at least one linker attached to the binding agent; at least one drug attached to each linker; A conjugate comprising: 25. The conjugate of embodiment 24, wherein each drug is selected from a cytotoxic agent, an immunomodulator, a nucleic acid, a growth inhibitory agent, a PROTAC, a toxin, and a radioisotope. 26. The conjugate of any one of embodiments 24 to 25, wherein each linker is attached to the binder via an interchain disulfide residue, a lysine residue, an engineered cysteine ​​residue, a glycan, a modified glycan, the N-terminal residue of the binder, or a polyhistidine residue attached to the binder. 27. The conjugate of any one of embodiments 24 to 26, wherein the average drug loading of the conjugate is about 1 to about 8, about 2, about 4, about 6, about 8, about 10, about 12, about 14, about 16, about 3 to about 5, about 6 to about 8, or about 8 to about 16. 28. The conjugate of any one of embodiments 24 to 27, wherein the drug is a cytotoxic agent. 29. The conjugate of embodiment 28, wherein the cytotoxic agent is selected from the group consisting of an auristatin, a maytansinoid, a camptothecin, a duocarmycin, or a calicheamicin. 30. The conjugate of embodiment 29, wherein the cytotoxic agent is an auristatin. 31. The conjugate of embodiment 30, wherein the cytotoxic agent is MMAE or MMAF. 32. The conjugate of embodiment 29, wherein the cytotoxic agent is camptothecin. 33. The conjugate of embodiment 32, wherein the cytotoxic agent is exatecan. 34. The conjugate of embodiment 32, wherein the cytotoxic agent is SN-38. 35. The conjugate of embodiment 29, wherein the cytotoxic agent is calicheamicin. 36. The conjugate of embodiment 29, wherein the cytotoxic agent is a maytansinoid. 37. The conjugate of embodiment 36, wherein the maytansinoid is maytansine, maytansinol or the maytansine analogues DM1, DM3 and DM4, and ansamitocin-2. 38. The conjugate according to any one of embodiments 24 to 37, wherein the linker is a cleavable linker. 39. The conjugate of embodiment 38, wherein the linker comprises mc-VC-PAB, CL2, CL2A, or (succinimide-3-yl-N)-(CH2)nC(=O)-Gly-Gly-Phe-Gly-NH-CH2-O-CH2-(C=O)- (wherein n=1 to 5). 40. The conjugate of embodiment 39, wherein the linker comprises mc-VC-PAB. 41. The conjugate of embodiment 39, wherein the linker comprises CL2A. 42. The conjugate according to embodiment 39, wherein the linker comprises CL2. 43. The conjugate of embodiment 39, wherein the linker comprises (succinimide-3-yl-N)—(CH2)nC(═O)-Gly-Gly-Phe-Gly-NH-CH2-O—CH2-(C═O)—. 44. The conjugate according to embodiment 43, wherein the linker is attached to at least one molecule of exatecan. 45. The conjugate of any one of embodiments 24 to 27, wherein the drug is an immunomodulator. 46. ​​The conjugate of embodiment 45, wherein the immunomodulatory agent is selected from the group consisting of a TRL7 agonist, a TLR8 agonist, a STING agonist, or a RIG-I agonist. 47. The conjugate of embodiment 46, wherein the immunomodulatory agent is a TLR7 agonist. 48. The conjugate of embodiment 46, wherein the TLR7 agonist is imidazoquinoline, imidazoquinoline amine, thiazoquinoline, aminoquinoline, aminoquinazoline, pyrido[3,2-d]pyrimidine-2,4-diamine, pyrimidine-2,4-diamine, 2-aminoimidazole, 1-alkyl-1H-benzimidazol-2-amine, tetrahydropyridopyrimidine, heteroaromatic azide-2,2-dioxide, benzonaphthyridine, guanosine analogue, adenosine analogue, thymidine homopolymer, ssRNA, CpG-A, polyG10, and polyG3. 49. The conjugate of embodiment 45, wherein the immunomodulatory agent is a TLR8 agonist. 50. The conjugate of embodiment 49, wherein the TLR8 agonist is selected from imidazoquinolines, thiazoloquinolines, aminoquinolines, aminoquinazolines, pyrido[3,2-d]pyrimidine-2,4-diamines, pyrimidine-2,4-diamines, 2-aminoimidazoles, 1-alkyl-1H-benzimidazol-2-amines, tetrahydropyridopyrimidines or ssRNA. 51. The conjugate of embodiment 45, wherein the immunomodulatory agent is a STING agonist. 52. The conjugate of embodiment 45, wherein the immunomodulatory agent is a RIG-I agonist. 53. The conjugate of embodiment 52, wherein the RIG-I agonist is selected from KIN1148, SB-9200, KIN700, KIN600, KIN500, KIN100, KIN101, KIN400 and KIN2000. 54. The conjugate of any one of embodiments 45 to 53, wherein the linker is selected from the group consisting of mc-VC-PAB, CL2, CL2A and (succinimide-3-yl-N)-(CH2)nC(=O)-Gly-Gly-Phe-Gly-NH-CH2-O-CH2-(C=O)- (wherein n=1 to 5). 55. A pharmaceutical composition comprising a conjugate according to any one of embodiments 24 to 54 and a pharmaceutically acceptable carrier. 56. A method for treating CD70+ cancer, comprising administering to a subject in need thereof a therapeutically effective amount of a binding agent according to any one of embodiments 1 to 19, a conjugate according to any one of embodiments 24 to 54, or a pharmaceutical composition according to embodiment 20 or 55. 57. The method of embodiment 56, wherein the CD70+ cancer is a solid tumor or a hematological malignancy. 58. The method of embodiment 57, wherein the CD70+ cancer is selected from hepatocellular carcinoma, colorectal cancer, pancreatic cancer, ovarian cancer, low-grade non-Hodgkin's lymphoma, non-Hodgkin's lymphoma, cancer of the B-cell lineage, multiple myeloma, renal cell carcinoma, nasopharyngeal carcinoma, thymic carcinoma, and glioma. 59. The method of embodiment 57, wherein the CD70 cancer is a solid tumor. 60. The method of any one of embodiments 56 to 59, further comprising administering immunotherapy to the subject. 61. The method of embodiment 60, wherein the immunotherapy comprises a checkpoint inhibitor. 62. The method of embodiment 61, wherein the checkpoint inhibitor is selected from an antibody that specifically binds to human PD-1, human PD-L1, or human CTLA4. 63. The method of embodiment 62, wherein the checkpoint inhibitor is pembrolizumab, nivolumab, cemiplimab, or ipilimumab. 64. The method of any one of embodiments 56 to 63, further comprising administering chemotherapy to the subject. 65. The method according to any one of embodiments 56 to 64, comprising administering a conjugate according to any one of embodiments 25 to 53 or a pharmaceutical composition according to claim 55. 66. The method of any one of embodiments 56 to 65, wherein the binding agent, conjugate or pharmaceutical composition is administered intravenously. 67. The method of embodiment 66, wherein the binding agent, conjugate or pharmaceutical composition is administered at a dose of about 0.1 mg / kg to about 12 mg / kg. 68. The method of any one of embodiments 56 to 67, wherein the subject's outcome is improved. 69. The method of embodiment 68, wherein the improved treatment outcome is an objective response selected from stable disease, partial response, or complete response. 70. The method of embodiment 68, wherein the improved outcome is a reduction in tumor burden. 71. The method of embodiment 68, wherein the improved outcome is progression-free survival or disease-free survival. 72. Use of a binding agent according to any one of embodiments 1 to 19 or a pharmaceutical composition according to embodiment 20 for treating a CD70+ cancer in a subject. 73. Use of a conjugate according to any one of embodiments 24 to 54 or a pharmaceutical composition according to embodiment 55 for treating a CD70+ cancer in a subject. 74. A method for treating an autoimmune disease, comprising administering a therapeutically effective amount of the binding agent of any one of embodiments 1 to 19, the conjugate of any one of embodiments 24 to 54, or the pharmaceutical composition of embodiment 20 or 55 to a subject in need thereof. 75. The method of embodiment 74, wherein the autoimmune disease is rheumatoid arthritis, multiple sclerosis or systemic lupus erythematosus. 76. The method of any one of embodiments 74 to 75, further comprising administering immunosuppressive therapy to the subject. 77. The method according to any one of embodiments 74 to 76, comprising administering a conjugate according to any one of embodiments 24 to 54 or a pharmaceutical composition according to claim 55. 78. The method of any one of embodiments 74 to 77, wherein the binding agent, conjugate or pharmaceutical composition is administered intravenously. 79. The method of embodiment 78, wherein the binding agent, conjugate or pharmaceutical composition is administered at a dose of about 0.1 mg / kg to about 12 mg / kg. 80. The method of any one of embodiments 74 to 79, wherein the subject's outcome is improved. 81. The method of embodiment 80, wherein the improved outcome is a reduction in disease progression or a reduction in disease severity. 82. Use of a binding agent according to any one of embodiments 1 to 19 or a pharmaceutical composition according to embodiment 20 for treating an autoimmune disease in a subject. 83. Use of a conjugate according to any one of embodiments 24 to 54 or a pharmaceutical composition according to embodiment 55 for treating an autoimmune disease in a subject.

[0293] The description of the embodiments of the present disclosure is not intended to be exhaustive or to limit the disclosure to the precise form disclosed. Specific embodiments and examples of the present disclosure are described herein for illustrative purposes, but those skilled in the art will recognize that various equivalent modifications are possible within the scope of the present disclosure. The teachings of the disclosure provided herein can be applied to other procedures or methods, as appropriate. The various embodiments described herein can be combined to provide further embodiments. Aspects of the present disclosure can be modified, as appropriate, to adopt the compositions, functions, and concepts of the above references and applications to provide still further embodiments of the present disclosure. These and other changes can be made to the present disclosure in light of the detailed description.

[0294] Specific elements of any of the foregoing embodiments may be combined with or substituted for elements of other embodiments. Furthermore, although advantages associated with certain embodiments of the present disclosure have been described in the context of those embodiments, other embodiments may also exhibit such advantages, and not all embodiments necessarily need to exhibit such advantages to fall within the scope of the present disclosure.

[0295] All identified patents and other publications are expressly incorporated herein by reference for the purpose of describing and disclosing, for example, the methodology described in such publications that might be used in connection with the present invention. These publications are provided solely for their disclosure prior to the filing date of the present application. Nothing in this regard should be construed as an admission that the inventors are not entitled to antedate such disclosure by prior invention or for any other reason. All statements as to the date or representation as to the contents of these documents are based on the information available to the applicant and do not constitute any admission as to the accuracy of the dates or contents of these documents.

[0296] Example Example 1: Generation of human antibodies against human CD70 An anti-CD70 antibody with higher affinity and better properties was generated by random mutation of the CDR regions of the antibody heavy and light chains of the parent antibody 69A7 (see U.S. Patent No. 8,124,738). The amino acid sequences of the heavy and light chain variable regions of 69A7 are shown in SEQ ID NOs: 1 and 2, respectively. The HCDR and LCDR amino acid sequences are shown in SEQ ID NOs: 21 to 26.

[0297] CDR scan library construction Random mutations were introduced into each of the six CDRs (3 HCDRs + 3 LCDRs) (Chothia numbering convention) of the parent antibody 69A7 by PCR-based mutagenesis using degenerate primers. The spliced ​​PCR products were used for library construction according to standard protocols.

[0298] The CDR library size was approximately 2 billion (2 × 10) based on serial dilution titration. 9 ) Random colonies were picked for sequencing. Alignment of some random sequences from the unselected library results showed that the random mutation library had good sequence diversity (data not shown). The phagemid library was rescued and used in the following panning procedure.

[0299] Panning and screening The following standard protocol was followed for library panning. Immunotubes were coated with 0.5 ml of CD70 antigen at the indicated concentration (see panning summary, Table 1) and placed in the refrigerator overnight. The tubes were washed once with PBS, blocked with 1% BSA / PBS, and placed at room temperature for 1 hour. The tubes were incubated with the indicated amount of library phage sample (CFU, see panning summary, Table 1) at room temperature for 1 hour. The tubes were washed 10 times with PBST buffer. To elute bound phage, 0.5 ml of 100 mM TEA (triethylamine) was added and incubated at room temperature for 2 minutes. The eluate was then transferred to a new tube and immediately neutralized by adding 0.25 ml of 1.0 M Tris-HCl (pH 8.0) and mixing. The eluate (0.75 ml) was added to 10 ml of logarithmic-phase E. coli TG1 (OD600 ~ 0.5), mixed thoroughly, and incubated at 37°C (water bath) for 30 min without shaking. Ten-fold dilutions of the culture were made in 2xTY medium, and 10 μL of each dilution was plated onto TYE / amp / glu plates and incubated overnight at 30°C. The following day, the number of colonies for each dilution was counted, and the CFU (colony-forming units) of the panning output were calculated. The remaining culture was centrifuged at 2,800 g for 15 min, resuspended in 0.5 ml of 2xTY medium, plated onto two 150 mm TYE / amp / glu plates, and incubated overnight at 30°C. The following day, 3 ml of 2xTY / amp / glu medium was added to each plate, and the bacteria were scraped off the plates with a cell spreader. Glycerol stocks were made by mixing 1.5 ml of bacteria with 0.5 ml of 80% glycerol and the stocks were placed at -80°C.

[0300] To prepare phage particles for the next round of selection, the glycerol stock was inoculated into 40 ml of 2xTY / amp / glu medium, starting at an OD600 of approximately 0.01-0.05. The culture was grown at 37°C with shaking (300 rpm) until the OD600 reached 0.4-0.6. The culture was infected by adding helper phage CM13 to the culture at a helper phage:bacteria ratio of 5-10:1. The bacterial culture was incubated at 37°C for 30 minutes stationary in a water bath with occasional mixing, followed by 30 minutes of shaking at 37°C. The bacterial culture was centrifuged at 3,000 rpm for 20 minutes, and the supernatant was removed. The pellet was resuspended in 100 ml of 2xTY / amp / glu medium and grown overnight at 30°C with shaking. The culture was then harvested by centrifugation at 6,000 g for 30 minutes. A ⅕ volume of PEG solution was added to the supernatant, followed by incubation on ice for 1 hour. Phage particles were then precipitated by centrifugation at 4,000 g for 20 minutes at 4°C. The supernatant was completely removed. The phage pellet was resuspended in 1–2 ml of cold PBS. Residual bacteria were removed by microcentrifugation at maximum speed for 5 minutes at 4°C. The prepared phage was used immediately for selection or stored at −80°C in aliquots containing 10% glycerol. The titer of the phage preparation was determined by infecting 100 μL of logarithmic-phase E. coli TG1 with a 10-fold dilution of the phage solution (2xTY, up to 10). The selection steps were repeated, starting from step 1, for a total of three rounds.

[0301] Three rounds of panning were performed as described above. The concentration of the washing buffer PBS-Tween 20 in the second and third rounds was gradually increased to 0.2% and 0.3%, respectively, and the coating antigen in the second and third rounds was gradually decreased to 4 μg and 2 μg, respectively. After three rounds of screening, the target-positive enrichment rate was 6.9 × 10 as shown in Table 1. 5( 690,000), which was significantly different from the blank control.

[0302] ELISA assay on purified phage samples. A sterile 96-well round-bottom microtiter plate was filled with 100 μl / well of 2xYT-2% glucose. A single TG1 colony was picked from the selection plate from the third (final) enrichment round using a sterile pipette tip and used to inoculate one well per colony. The plate was sealed with a breathable membrane and incubated overnight at 30°C with shaking. This plate served as the master plate. The next day, an aliquot of the culture was transferred to a new deep-well induction plate containing 400 μl / well of 2xYT-0.1% glucose. Using a multichannel pipette, approximately 10 μl / well was pipetted from the master plate to the new induction plate. The induction plate was incubated in a phage orbital shaker (37°C, 200 rpm) for approximately 2–4 hours until the bacteria reached logarithmic phase. IPTG was added to each well to a final concentration of 0.2 mM, and the plate was grown overnight at 30°C with shaking at 200 rpm. The next day, the induction plates were spun at 3,500 rpm for 10 minutes, and the supernatants were used in the following scFv ELISA (plates were optionally placed at 4°C for temporary storage; supernatants could be used within 2 weeks).

[0303] Phage binding to the CD70 antigen was tested by phage ELISA. Briefly, the antigen CD70 (ACRO, CDL-H 5246) was diluted to 5 μg / ml and coated onto a microtiter plate overnight using 100 μL / well. The next day, the plate was washed twice with PBST (0.1% Tween 20 in PBS) using 200 μL / well. Blocking buffer (2% milk in PBST) was added using 200 μL / well. The plate was incubated at RT for 1 hour. The plate was washed twice with PBST. IPTG-induced culture supernatant was added to each well using 50 μL / well and incubated at RT for 1 hour. The plate was washed 3-4 times with PBST. Anti-human HRP was diluted 1:5,000 in PBST using 50 μL / well. The plate was incubated at RT for 20 minutes. The plate was then washed again five times with PBST. Fresh development solution (10 ml development buffer, 13.3 μL Amplex Red (5 mg / ml in DMSO), 3.3 μL HO) was prepared and added using 50 μL / well and developed for 1-60 minutes at RT. Plates were read at Ex=530 nm, Em=590 nm, and cutoff=570 nm.

[0304] [Table 1]

[0305] Using the scFv Elisa procedure described above, two 96-well plates of single colonies were picked, cultured, and induced for scFv expression. The scFv supernatants were used in the screening assay.

[0306] Twenty clones with positive signals were sequenced. The sequences of five selected clones are shown in Table 2. The HCDRs and LCDRs within each variable region are marked in bold. These clones have at least two or more amino acid substitutions in HCDR3 / LCDR3 (SEQ ID NO: 13 to SEQ ID NO: 18) for each candidate antibody compared to the parent antibody 69A7. Five unique sequences, 2A4, 1H8, 2E7, 2D2, and 1A4, were selected for further analysis. One new VH / VL combination was prepared; the VH / VL pair 2A4P0L1 was derived from the VH of 2A4 and the VL of 2D2.

[0307] [Table 2]

[0308] Example 2: Characterization of scFV leads To rank the leads from Example 1 by binding affinity, scFv expression levels were measured using ProbeLife and specific binding was titrated by ELISA for five lead candidates, 2A4, 1H8, 2E7, 2D2 and 1A4, based on scFv concentration.

[0309] ScFv quantification was performed as follows: Expression levels in culture supernatants were measured using the Gator system (ProbeLife). After prewetting the anti-His sensor in Q buffer (ProbeLife), the sensor was immersed in the scFv supernatant well for 2 minutes. Expression titers were calculated by the system based on the standard curve of the anti-His sensor. The ELISA assay used is described above.

[0310] The results are shown in Table 3 and Figure 1. Most of the lead antibodies (except 2E7) had expression levels similar to or lower than the parent antibody, 69A7. However, all leads had significantly improved binding compared to the parent 69A7 scFv clone.

[0311] [Table 3]

[0312] Example 3: Characterization of anti-human CD70 antibodies To further rank the leads based on binding affinity and internalization, the scFvs were converted to full IgG antibodies and full IgG expression levels were measured. Based on antibody concentration, specific binding was titrated by ELISA or FACS.

[0313] Anti-CD70 antibody production: Full IgG anti-CD70 lead antibodies (1A4, 2A4, 1H8, 2D2, 2E7, and 2A4P0L1), a reference parent antibody (69A7), and another reference antibody, 1F6 (borsetuzumab, see U.S. Patent No. 7,491,390), were constructed from six leads and two controls, with their human heavy and light variable regions connected to human IgG1 and kappa constant regions, respectively. (The VH and VL sequences of the 1F6 antibody are shown in SEQ ID NOs: 19 and 20, respectively.) Briefly, for efficient translation and antibody secretion, the Kozak consensus sequence "GCCGCCACC" (SEQ ID NO: 31) and signal peptide "MGWSCIILFLVATATGVHS" (SEQ ID NO: 32) were inserted at the 5' end of the gene construct. The final DNA coding sequences of the heavy and light chains were optimized, synthesized, and assembled into the vector pcDNA3.4.

[0314] The resulting plasmids were transiently transfected into ExpiCHO-S cells using the ExpiCHO™ Expression System (Thermo, ExpiFectamine™ CHO Transfection Kit, Cat. No. A29129) based on the standard ExpiFectamine CHO Transfection procedure (Gibco, A29129) in spinner flasks. The transient transfection suspension was incubated for 10 days, and then the clarified supernatant was purified using a Protein A column.

[0315] Antibodies were purified from clarified cell culture supernatants using Protein A chromatography (Protein A resin slurry, 4.5 mL, Bogen, catalog no. 18-0010-02). Briefly, the supernatant was prepared for affinity chromatography, loaded onto a column, and allowed to completely drain through the resin. The column was washed with binding buffer containing 0.15 M NaCl and 0.2 M PB, pH 7.0. The antibodies were eluted with elution buffer containing 0.15 M NaCl, 0.1 M glycine, and 0.2 M PB, pH 3.0. Fractions were collected and neutralized by adding 1 / 10 volume of 1 M Tris, pH 9.0. Fractions were dialyzed against 1x PBS for 2 hours. Purified antibodies were quantified by absorbance at A280. Samples from each step of Protein A chromatography were applied to a 12% SDS-PAGE gel for reducing and non-reducing electrophoresis. Hydrophobicity was assessed by hydrophobic interaction chromatography (HIC) on 4.6 × 100 mm TSK gel Butyl-NPR (Tosoh Corporation) using a Waters HPLC 2695 system.

[0316] The expression levels after purification are shown in Table 4. Antibody clone 2A4 had a higher expression level; clones 1A4, 2D2 and 2E7 had intermediate expression levels, and clones 2A4P0L1 and 1H8 had lower expression levels.

[0317] The hydrophobicity analysis is shown in Table 5. Clones 2D2 and 2A4 have similar hydrophobicity to the parent antibody 69A7; clones 2A4P0L1, 1H8 and 2E7 are slightly more hydrophobic than the parent antibody 69A7.

[0318] [Table 4]

[0319] [Table 5]

[0320] Antibody binding specificity assessment by ELISA The binding specificity of the CD70 antibody was tested by ELISA according to standard protocols. Briefly, 96-well microplates were coated with 2 μg / ml human or cynomolgus monkey CD70 recombinant protein in PBS at 100 μl / well and incubated overnight at 4°C. The plates were washed twice with TBS + 0.5% Tween 20. 200 μL of blocking buffer (2% BSA in PBS) was added to each well, and the plates were incubated at 37°C for 2 hours. The plates were washed using the above washing buffer. Serially diluted antibodies were added to the ELISA plate at 100 μl / well, and the plates were incubated at room temperature for 1 hour. The plates were then washed three times. HRP-conjugated anti-human Fc antibody solution (Sigma, I 18885-2ML, diluted with blocking buffer) was added to the plate at 100 μl / well. The plates were incubated at room temperature for 1 hour and then washed three times. TMB solution was then added to the plate using 100 μl / well, and the plate was left at RT for 5-15 minutes. Stop solution (2M H2SO4) was then added using 50 μl / well. Absorbance was measured at A450 and A630.

[0321] The results are shown in Figures 2 and 3. The half effective concentration (EC 50 ) values ​​are the half effective concentrations (EC 50 ) value. Antibodies 2E7, 1H8 and 2D2, like h1F6, had better cross-binding activity for the cynomolgus antigen than antibody 69A7.

[0322] Determination of antibody binding affinity by flow cytometry The lead antibody was tested for binding to renal carcinoma and glioblastoma cells expressing CD70 on the cell surface by flow cytometry. Cell lines 786-O (ATCC® CRL-1932™, provided by COBIOER), Caki-1 (ATCC® HTB-46™, provided by COBIOER), U251, and DBTRG-05MG (ATCC® CRL-2020™, provided by COBIOER) were tested for antibody binding, respectively. 786-O cells were cultured in RPMI 1640 medium (Gibco, catalog number 11875093) containing 10% FBS (Gibco, catalog number 10099141), and Caki-1 cells were cultured in McCoy's 5a modified medium (Gibco, catalog number 16600082) containing 10% FBS. U251 cells were cultured in MEM medium containing 10% FBS and 1% NEAA + 1 mM sodium pyruvate. DBTRG-05MG cells were cultured in DMEM medium (Gibco, Cat. No. C11995500BT) containing 10% FBS. Each of the lead antibodies and controls was incubated with a 100 μl FACS buffer (1×PBS containing 0.1% BSA) containing 3×10 of a different cell line (3×10 ). 5 The cells were incubated with 100 μl of 1:200 diluted PE-conjugated anti-human Fc (Abcam, Ab98596) in FACS buffer for 30 minutes at 4° C. The cells were then pelleted, washed, and incubated with 100 μl of 1:200 diluted PE-conjugated anti-human Fc (Abcam, Ab98596) in FACS buffer for 30 minutes at 4° C. The cells were pelleted again, washed with PBS, resuspended in FACS buffer, and analyzed by flow cytometer (Beckman, CytoFLEX).

[0323] The EC50 values ​​of anti-CD70 antibodies for different cell lines are shown in Table 6 and Figures 4-7. Flow cytometry analysis confirmed that the anti-CD70 antibodies bound to renal cell lines 786-O and Caki-1 cells and to glioblastoma U251 and DBTRG-05MG cells. The EC50 values ​​of antibody 2E7 were 1.8-3.5 times higher than those of antibody 69A7, and the EC50 values ​​of antibody 2A4P0L1 were 1.7-2.2 times higher than those of antibody 69A7. Antibodies 2H8 and 2D2 had slightly higher binding capacities to the cell lines than antibody 69A7.

[0324] [Table 6]

[0325] Example 4: Internalization of anti-CD70 antibodies The lead antibody and controls were tested for their ability to be internalized into CD70-expressing renal carcinoma cells 786-O and Caki-1 cells using a FACS immunofluorescence staining assay.

[0326] In short, 2 x 10 5 Cells were harvested from tissue culture flasks by treatment with 0.25% trypsin / EDTA and then incubated with 10 μg / ml of lead or control antibody in FACS buffer (1×PBS containing 0.1% BSA) at 4°C for 30 minutes. Cells were washed at 4°C to remove unbound antibody and either kept on ice or transferred to 37°C. At set time points (0, 4, and 24 hours), cells were incubated with PE-conjugated anti-human Fc (Abcam, Ab98596) for 30 minutes at 4°C and then analyzed by flow cytometry. The internalization ratio was calculated by subtracting the MFI at 37°C from the MFI at 4°C and then compared to the MFI at 4°C.

[0327] The results are shown in Table 7 and Figures 8 and 9. The results demonstrate the change in surface levels of anti-CD70 antibodies in 786-O and Caki-1 cell lines maintained at 4°C or 37°C over the course of a 4-hour study. Surface levels of antibody were significantly reduced in cells shifted to 37°C over the course of the assay. Based on cell binding affinity, the results demonstrate that anti-CD70 antibodies 1H8, 2D2, and 2E7 resulted in higher absolute amounts of antibody internalized into cells than the parent antibody 69A7.

[0328] [Table 7]

[0329] Example 5: Determining affinity binding of CD70 antibodies to CD70 Immobilization of CD70 antigen onto a CM5 sensor chip. Immobilization of the antigen CD70 ECD was performed at 25°C using HBS-EP as the running buffer. The sensor chip surfaces of flow cells 1 and 4 were activated with freshly mixed 50 mmol / L N-hydroxysuccinimide (NHS) and 200 mmol / L 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC) for 420 seconds (10 μL / min). Then, 10 mmol / L CD70 antigen diluted in NaAC (pH 4.5) was injected into flow cell 4 to achieve conjugation of an appropriate response unit, and flow cell 1 was set as a blank. After the amine coupling reaction, the remaining active coupling sites on the chip surface were blocked by a 420-second injection of 1 mol / L ethanolamine hydrochloride.

[0330] Affinity measurement of CD70 antibodies binding to CD70 ECD. The assay was performed at 25°C, with HBS-EP as the running buffer. Diluted antibody was injected over the surfaces of flow cells 1 and 4 during the association phase, followed by injection of running buffer for the dissociation phase. All data were processed using Biacore T200 Evaluation software version 3.1. Blank injections of flow cell 1 and buffer in each cycle were used as double references for response unit subtraction. Kinetic data of the interaction between the antibody and the CD70 antigen were obtained through affinity measurements.

[0331] The data are summarized in Table 8. Antibody 2E7 has a 22-fold higher affinity for the CD70 antigen than the parent antibody 69A7 and a 2- to 3-fold higher affinity for the CD70 antigen than the reference antibody h1F6. The affinity of the other antibodies, 1H8, 2D2, 2A4, and 2A4P0L1, for the CD70 antigen was improved by 3 to 8 fold compared to the affinity of the parent antibody 69A7.

[0332] [Table 8]

[0333] Example 6: Evaluation of cell killing by anti-CD70 antibodies conjugated to cytotoxins in renal cell carcinoma cell lines Anti-CD70 antibodies conjugated to cytotoxins were tested for their ability to kill CD70+ renal cell carcinoma cell lines in a cell proliferation assay.

[0334] The anti-CD70 conjugate was prepared as follows: The pH of the CD70 antibody solution was adjusted to within the pH 7.0-7.5 range by adding 0.5 M disodium phosphate. 0.5 M EDTA was added to achieve a final EDTA concentration of 5 mM in the antibody solution. 10 mM TCEP (tris(2-chloroethyl) phosphate) solution was added to achieve the desired TCEP / mAb molar ratio. The reduction was maintained at RT for 90 min. DMSO was then added to achieve a 10% v / v concentration. The drug conjugate Mc-VC-PAB-MMAE (maleimidylcaproyl-valine-citrulline-para-aminobenzoyl MMAE) was dissolved in DMSO to achieve a final concentration of 10 mM and added to the reaction solution at a 30-50% molar excess compared to the moles of available cysteine ​​thiol. The conjugation reaction was left at RT for 30 min. To quench the reaction, NAC (N-acetyl-L-cysteine) stock solution was added to achieve a NAC / Mc-VC-PAB-MMAE molar ratio of 5. The quenched reaction was left at RT for 15 min. Purification was performed on a PD10 column.

[0335] Cytotoxicity against renal tumor cells Renal carcinoma cancer cell line 786-O was seeded at 400 cells / well for 24 hours. Antibody conjugates prepared as described above were added to the wells in 3-fold serial dilutions at a starting concentration of 30 μg / ml. Plates were allowed to incubate for 96 hours. After 90 hours, 40 μl of CTG (Promega, catalog number G7572) was added per well to the plate, and luciferase readings were taken 5 minutes later. Percent growth inhibition relative to untreated cells was calculated.

[0336] The results are shown in Figure 10. The results demonstrate that the anti-CD70 conjugates 1H8-ADC, 2D2-ADC, and 2E7-ADC were cytotoxic to renal carcinoma cancer cells. The IC50 values ​​of the antibody conjugates show that 2E7-ADC had much better cell growth inhibition (more than 10-fold) than the parent antibody conjugate (69A7-ADC).

[0337] The present invention is not limited in scope by the specific embodiments described herein. Indeed, various modifications of the invention in addition to those described herein will become apparent to those skilled in the art from the foregoing description and the accompanying drawings. Such modifications are intended to fall within the scope of the appended claims.

[0338] Various publications, including patents, patent application publications, and scientific literature, are cited herein, the disclosures of which are incorporated by reference in their entireties for all purposes.

[0339] Example 7: Affinity data of 2E7 / 69A7 for species CD70 tested by Biolayer Interferometry (BLI) Recombinant proteins consisting of human, rat, or mouse CD70 extracellular domain (ECD) linked to a His tag were purchased from ACRO Systems. 69A7 and 2E7 (20 nM) were immobilized on an anti-human IgG Fc biosensor chip (ForteBio). Binding assays using a concentration of recombinant protein in solution (100 nM) were performed using Octet RED (ForteBio). The association time was set to 180 s, and the dissociation time was set to 300 s. Binding affinities were calculated using ForteBio Data Acquisition 6.3 software. Affinity was derived by fitting the kinetic data to a 1:1 Langmuir binding model using a global fitting algorithm. 69A7 and 2E7 demonstrated high binding affinity for human CD70, with equilibrium dissociation constants (KD) of 2.9 and 0.97 nM, respectively. 69A7 and 2E7 showed no cross-reactivity with rat or mouse CD70 (Table 9). Binding assays of 2E7 using multiple dilutions of recombinant CD70 ECD protein in solution (from 200 nM to 3.13 nM) were also performed using the same method. 2E7 exhibited high binding affinity to human and cynomolgus CD70, with KDs of 0.81 nM and 0.39 nM, respectively. 2E7 had no cross-reactivity with rat or mouse CD70 (Table 10).

[0340] [Table 9]

[0341] [Table 10A] [Table 10B]

[0342] Example 8: Binding of 2E7 to cells, Raji and MCF-7 The binding activity of 2E7 or isotype control with target cell lines (Raji) or cell lines (MCF-7) with negligible levels of CD70 expression was assessed by flow cytometry (Beckman, Cytoflex). 5 Cells / well were seeded into 96-well V-bottom plates and incubated with 100 μl of 2E7 in serial dilutions. After 30 min of incubation at 4°C, the cells were washed twice with PBS and stained with 100 μl of 1:200 diluted PE-conjugated anti-human Fc in FACS buffer (1×PBS containing 1% BSA), followed by 30 min of incubation at 4°C. The cells were finally washed twice with PBS and analyzed by flow cytometry. 2E7 exhibited strong binding activity to the human CD70-expressing cell line, Raji, with an EC50 of approximately 19 nM (Figure 11), but showed no binding to the CD70-negative cell line, MCF-7 (Figure 12), demonstrating the specificity of the interaction.

[0343] Example 9: 2E7 internalization using additional cell lines (Raji, MCF7) over time Four cell lines (786-), Caki-1, Raji, and MCF-7, were used for the internalization assay. Target (CD70) copy number was determined via the QIFIKIT (DAKO, K 0078). Briefly, cells were labeled with a primary mouse monoclonal antibody against CD70. Then, cells, setup beads, and calibration beads (from the kit) were labeled in parallel with a fluorescein-conjugated anti-mouse secondary antibody. Fluorescence correlates with the number of bound primary antibody molecules on the cells and beads. Samples were then analyzed by flow cytometer, and copy number was determined based on a calibration curve (Table 11). For the internalization assay, 3 × 10 5 Cells were incubated with 10 μg / ml 2E7 in FACS buffer (1x PBS containing 0.1% BSA) at 4°C for 30 minutes. Cells were washed at 4°C to remove unbound material and either kept on ice or transferred to 37°C for different periods. At progressive time points (1, 0.5, 1, 2, 3, and 4 hours), cells were stained with PE-conjugated anti-human Fc for 30 minutes at 4°C and analyzed by flow cytometry. The internalization rate was calculated by subtracting the mean fluorescence intensity (MFI) of cell surface-bound antibody at 37°C at each time point from the MFI of cell surface-bound antibody at 4°C at time 0, and then dividing by the MFI of cell surface-bound antibody at 4°C at time 0. 2E7 showed rapid internalization in CD70-expressing cell lines (786-O, Caki-1, and Raji) but not in a CD70-negative cell line (MCF-7) (Figure 13).

[0344] [Table 11]

[0345] Example 10: 2E7 Rat PK 2E7 was administered to male Sprague Dawley rats at 3 mg / kg via intravenous infusion (n=3 per group). Orbital blood was sampled from each rat at various time points after administration. Circulating concentrations of 2E7 were analyzed by ELISA assay (ProfoundBio) and calculated using GraphPad Prism 6 software. 2E7 exhibited stable plasma PK in rats, characteristic of an IgG1 antibody (FIG. 14).

[0346] Example 11: 2E7 conjugates: in vitro cytotoxicity Two 2E7 conjugates were utilized in the study (Table 12). For the preparation of 2E7-deruxtecan: 2 mL of antibody (10 mg / mL) in 50 mM sodium phosphate buffer containing 5 mM EDTA (pH = 6.9) was added to an aqueous solution of 10 mM TCEP HCl (tris(2-carboxyethyl)phosphine HCl) at a molar ratio of 8.0 (TCEP to mAb). The reduction reaction proceeded for 2 hours at 25°C. Deruxtecan (dissolved in DMSO at a concentration of 20 mg / mL) was added to the reduced antibody at a molar ratio of 12 (deruxtecan / mAb). The coupling reaction was stirred for 8 hours at 25°C. Excess deruxtecan and impurities were removed by ultrafiltration using 50 mM sodium phosphate buffer. The ADC was stored in 20 mM histidine buffer containing 6% sucrose and 0.02% (w / V) Tween 20 by UFDF. The purity determined by SEC-HPLC was 97.2%, and the DAR value determined by LC-MS was 7.5. For the preparation of 2E7-vedotin, 2 mL of antibody (10 mg / mL) in 50 mM sodium phosphate buffer containing 5 mM EDTA (pH = 6.9) was added to an aqueous solution of 10 mM TCEP HCl (tris(2-carboxyethyl)phosphine HCl) at a molar ratio of 2.2 (TCEP to mAb). The reduction reaction was allowed to proceed for 2 h at 25 °C. Vedotin (dissolved in DMSO at a concentration of 20 mg / mL) was added to the reduced antibody at a molar ratio of 5.0 (vedotin / mAb). The coupling reaction was stirred for 2 h at 25 °C. Excess vedotin and impurities were removed by ultrafiltration using 50 mM sodium phosphate buffer. The ADC was stored in 20 mM histidine buffer containing 6% sucrose and 0.02% (w / V) Tween 20 by UFDF. The purity was 97.4% as determined by SEC-HPLC, and the DAR value was 3.9 as determined by HIC-HPLC. For in vitro cytotoxicity testing, cells were harvested and plated into 96-well solid white flat-bottom plates one day before adding the 2E7 conjugate. The following day, cells were exposed to test articles at concentrations ranging from 670 nM to 0.00067 nM. Plates were incubated at 37°C for 96 hours.Then, 40 μl of Cell-tire Glo (CTG) was added to the plate per well, and luciferase readings were collected after 5 minutes of incubation and analyzed using a Microplate reader. All readings were normalized as a percentage of viable cells in untreated control wells, and IC50 values ​​were calculated using Prism software. 2E7-deruxtecan and 2E7-vedotin, but not 2E7, produced cytotoxic effects against all four cell lines tested (Figures 15-18).

[0347] [Table 12]

[0348] Example 12: 2E7 conjugate: in vivo efficacy in a cell line-derived xenograft (CDX) model The antitumor activity of 2E7 in benchmarking linker-drug conjugates (Table 12) was evaluated in the CDX model. Female BALB / c nude mice were inoculated into the right flank with Caki-1 cells (ATCC, HTB-46, 3 x 10 cells in 0.2 mL cell suspension) for tumor development. 6 ) or Raji cells (Betapharma, 5 × 10 in 0.1 mL cell suspension) 6 ) was subcutaneously inoculated. Five to eight days after tumor inoculation, the average tumor size was 120 to 130 mm. 3 Mice were selected and assigned to treatment groups for each model using stratified randomization based on tumor volume (n = 9-10 mice per group). Treatment began 1 day after randomization (randomization day defined as D0) and consisted of either a single-dose (day 1) or multiple-dose (days 1 / 4 / 8 / 11) regimen via intravenous infusion of 5 mg / kg of 2E7 conjugate. Tumor size and body weight were measured twice weekly in two dimensions using calipers, and volume was calculated using the formula: V = 0.5a × b 2( where a and b are the long and short diameters of the tumor, respectively) 3 Expressed as 2000mm 3Tumor volume exceeding 100 μg / kg was defined as the endpoint. Animal weight was monitored as an indirect measure of toxicity. No mice in any of the test groups showed significant weight loss. There was no morbidity or mortality during the treatment period. Compared with the vehicle control group, treatment with 2E7-deruxtecan (8) resulted in significant inhibition of tumor growth in multiple-dose or single-dose models using Caki-1 or Raji cells; 2E7-vedotin (4) exerted low to moderate antitumor activity in these models (Figures 19-22). [Sequence table] SEQ ID NO: 1-69A7 VH amino acid sequence QVQLQESGPG LVKPSETLSL TCTVSGGSV S SDYYYWS WIR QPPGKGLEWL G YIYYSGSTN YNPSLKS RVT ISVDTSKNQF SLKLRSVTTA DTAVYYCAR G D GDYGGNCFD Y WGQGTLVTV SS SEQ ID NO: 2-69A7 VL amino acid sequence EIVLTQSPAT LSLSPGERAT LSC RASQSVS SYLA WYQQKP GQAPRLLIF D ASNRAT GIPA RFSGSGSGTD FTLTISSLEP EDFAVYYC QQ RSNWPLT FGG GTKVEIK SEQ ID NO: 3-2A4 VH amino acid sequence QVQLQESGPG LVKPSETLSL TCTVSGGS VS SDYYYWS WIR QPPGKGLEWL G YIYYSGSTN YNPSLKS RVT ISVDTSKNQF SLKLRSVTTA DTAVYYCAR G DGDYGGNVFP Y WGQGTLVTV SS SEQ ID NO: 4-2A4 VL amino acid sequence EIVLTQSPAT LSLSPGERAT LSC RASQSVS SYLA WYQQKP GQAPRLLIF D ASNRAT GIPA RFSGSGSGTD FTLTISSLEP EDFAVYYC QQ RSNWPLT FGG GTKVEIK SEQ ID NO: 5 1H8 VH amino acid sequence QVQLQESGPG LVKPSETLSL TCTVSGGSV S SDYYYWS WIR QPPGKGLEWL G YIYYSGSTN YNPSLKS RVT ISVDTSKNQF SLKLRSVTTA DTAVYYCAR G DGDFMGVCFD Y WGQGTLVTV SS SEQ ID NO: 6 1H8 VL amino acid sequence EIVLTQSPAT LSLSPGERAT LSC RASQSVS SYLA WYQQKP GQAPRLLIF D ASNRAT GIPA RFSGSGSGTD FTLTISSLEP EDFAVYYC QQ RSNWPLT FGG GTKVEIK SEQ ID NO: 7 2E7 VH amino acid sequence QVQLQESGPG LVKPSETLSL TCTVSGGSV S SDYYYWS WIR QPPGKGLEWL G YIYYSGSTN YNPSLKS RVT ISV...

Claims

1. Heavy chain variable (VH) region and light chain variable (VL) region A binder containing, The VH region includes complementarity determination regions HCDR1, HCDR2, and HCDR3 located in the heavy chain variable region framework region, the VL region includes LCDR1, LCDR2, and LCDR3 located in the light chain variable region framework region, and the VH and VL CDRs are a. Sequence IDs 21, 22, 13, 24, 25, and 26, respectively; b. Sequence IDs 21, 22, 14, 24, 25, and 26, respectively; c. Sequence IDs 21, 22, 23, 24, 25, and 18, respectively; and d. Sequence IDs 16, 17, 23, 24, 25, and 26, respectively. A binder having an amino acid sequence selected from a set of amino acid sequences represented by the group consisting of the following.

2. The VH region and the VL region are, respectively, a. Sequence IDs 3 and 4; b. Sequence IDs 5 and 6; c. Sequence IDs 9 and 10; and d. Sequence IDs 11 and 12 The binder according to claim 1, having an amino acid sequence selected from a pair of amino acid sequences represented by the group consisting of the following.

3. The VH region and the VL region are, respectively, a. Sequence IDs 3 and 4; b. Sequence IDs 5 and 6; c. Sequence IDs 9 and 10; and d. Sequence IDs 11 and 12 Having an amino acid sequence selected from the amino acid sequence pairs shown in the group consisting of, The binder according to claim 1, wherein the heavy chain framework region and the light chain framework region are optionally modified by substitution, deletion or insertion of 1 to 8 amino acids within the framework region.

4. The binder according to claim 1, wherein the framework region is a human framework region.

5. The binder according to claim 1, wherein the antibody or its antigen-binding portion.

6. The binder according to claim 5, wherein the heavy chain variable region further comprises a heavy chain steady region.

7. The binder according to claim 6, wherein the heavy chain constant region is an IgG1 constant region having the amino acid sequence shown in SEQ ID NO:

28.

8. The binder according to claim 5, wherein the light chain variable region further comprises a light chain steady region.

9. The binder according to claim 8, wherein the constant light chain region is a kappa isotype having the amino acid sequence shown in SEQ ID NO:

29.

10. The binder according to claim 6, wherein the heavy chain constant region further comprises at least one amino acid modification that reduces the binding affinity to human Fc gamma RIII.

11. The binder according to claim 5, which is monospecific, divalent, or bispecific.

12. A pharmaceutical composition comprising a binder according to any one of claims 1 to 11 and a pharmaceutically acceptable carrier.

13. A nucleic acid encoding the binder according to any one of claims 1 to 11.

14. A vector comprising the nucleic acid described in claim 13.

15. A cell line comprising the vector described in claim 14.

16. A cell line comprising the nucleic acid described in Claim 13.

17. A binder according to any one of claims 1 to 11, At least one linker bonded to the binder, Each linker has at least one drug bound to it. A conjugate that includes this.

18. The conjugate according to claim 17, wherein the drug is a cytotoxic agent.

19. The conjugate according to claim 18, wherein the cytotoxic agent is selected from the group consisting of auristatin, meitansinoid, camptothecin, duocalmycin, or calicheamycin.

20. The conjugate according to claim 19, wherein the auristatin is MMAE or MMAF.

21. The conjugate according to claim 19, wherein the camptothecin is exatecan.

22. A pharmaceutical composition comprising the conjugate described in claim 17 and a pharmaceutically acceptable carrier.

23. The pharmaceutical composition according to claim 12 for treating CD70+ cancer.

24. The pharmaceutical composition according to claim 22 for treating CD70+ cancer.

25. The pharmaceutical composition according to claim 23, used in combination with a checkpoint inhibitor.

26. The pharmaceutical composition according to claim 24, which is used in combination with a checkpoint inhibitor.

27. A pharmaceutical composition according to claim 12 for treating an autoimmune disease.

28. The pharmaceutical composition according to claim 22 for treating an autoimmune disease.

Images